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”In solving a problem of this sort,
the grand thing is to be able to reason backwards.
That is a very useful accomplishment, and a very easy one,
but people do not practice it much.”
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A Study in Scarlet

Contents 5
Contents
1 Introduction 7
1.1 The Radiotracer Principle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.2 Positron Emission Tomography (PET) . . . . . . . . . . . . . . . . . . . . . . . 7
1.2.1 PET radionuclides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.2.2 Fluorine-18 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.3 Radiolabeling with fluorine-18 . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.3.1 Electrophilic substitution . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.3.2 Nucleophilic substitution . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.3.3 18F-fluorination via prosthetic groups . . . . . . . . . . . . . . . . . . . . 14
1.4 Stability of radiotracers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
1.4.1 Basic considerations of drug metabolism . . . . . . . . . . . . . . . . . 15
1.4.2 Metabolism of PET radiotracers . . . . . . . . . . . . . . . . . . . . . . 17
1.4.3 Countermeasures for radiotracer metabolism . . . . . . . . . . . . . . . 21
1.4.4 Metabolic stability of compounds with cycloalkyl rings . . . . . . . . . . . 22
1.4.5 Cycloalkyl rings in radiopharmaceuticals . . . . . . . . . . . . . . . . . . 24
2 Aims and Scope 29
3 Results and Discussion 33
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.2 Proposed model test system . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.3 Retrosynthetic considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
3.3.1 Retrosynthetic approach of radiochemical syntheses . . . . . . . . . . . 35
3.3.2 Retrosynthetic approach of organic syntheses . . . . . . . . . . . . . . . 37
3.4 Organic syntheses of precursors for indirect radiolabeling and its reference
compound . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.4.1 Synthesis of labeling precursor cis-cyclobutane-1,3-diyl bis(4-methyl-
benzenesulfonate) (20) . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.4.2 Preparation of labeling precursor trans-cyclobutane-1,3-diyl bis(4-methyl-
benzenesulfonate) (29) . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
3.4.3 Syntheses of other bis-cyclobutyl alkyl- (21, 23) and arylsulfonyl precur-
sors (22, 33) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.4.4 Synthesis of reference compound trans-3-fluorocyclobutyl 4-methylbenzene-
sulfonate (34) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.5 Organic syntheses of reference compounds L- and D-3FCBT (4, 47) . . . . . . 51
3.5.1 Synthesis of O-(3-fluorocyclobutyl)-L-tyrosine (4) . . . . . . . . . . . . . 51
3.5.2 Synthesis of O-(3-fluorocyclobutyl)-D-tyrosine (47) . . . . . . . . . . . . 55
3.6 Organic syntheses of precursors for direct radiolabeling . . . . . . . . . . . . . 57
3.6.1 Preparation of methyl N-(tert-butoxycarbonyl)-O-[trans-3-(4-methylbenz-
enesulfonyloxy)cyclobutyl]-L-tyrosine (48) . . . . . . . . . . . . . . . . . 57
3.6.2 Synthesis of methyl N-(tert-butoxycarbonyl)-O-[cis-3-(4-methylbenzene-
sulfonyloxy)cyclobutyl]-L-tyrosine (49) . . . . . . . . . . . . . . . . . . . 58
3.6.3 Preparation of tert-butoxy N-(tert-butoxycarbonyl)-O-[trans-3-(4-methyl-
benzenesulfonyloxy)cyclobutyl]-L-tyrosine (54) . . . . . . . . . . . . . . 61
3.6.4 Syntheses of the N-trityl protected precursors . . . . . . . . . . . . . . . 62
6 Contents
3.7 Radiosyntheses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
3.7.1 Radiosynthesis of n.c.a. [18F]fluorocyclobutyl tyrosine via indirect radio-
labeling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
3.7.2 Radiosynthesis of n.c.a. [18F]fluorocyclobutyl tyrosine via direct radio-
labeling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
3.8 Physicochemical and biological characterization of 3[18F]FCBT . . . . . . . . . 93
3.8.1 Determination of the lipophilicity of the non-radioactive L-3FCBT . . . . . 93
3.8.2 In vitro cell uptake assay of L-3[18F]FCBT . . . . . . . . . . . . . . . . . 94
3.8.3 Biodistribution in A549 tumor bearing mice . . . . . . . . . . . . . . . . 95
3.8.4 Animal PET/CT imaging of D- and L-3[18F]FCBT . . . . . . . . . . . . . 97
3.8.5 Investigation of the in vitro and in vivo stability . . . . . . . . . . . . . . . 100
4 Summary and Outlook 105
5 Experimental 115
5.1 Material and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
5.1.1 Radioananalytical methods . . . . . . . . . . . . . . . . . . . . . . . . . 116
5.2 Organic syntheses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
5.2.1 Syntheses of precursors for indirect labeling and reference compound . . 118
5.2.2 Synthesis of reference compounds O-(cis-3-fluorocyclobutyl)-DL-tyrosine 125
5.2.3 Syntheses of precursors for direct labeling . . . . . . . . . . . . . . . . . 131
5.3 Radiosyntheses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
5.3.1 Production of no-carrier-added (n.c.a.) [18F]fluoride . . . . . . . . . . . . 140
5.3.2 Preparation of the n.c.a. [18F]fluoride-cryptate complex . . . . . . . . . . 140
5.3.3 Radiosynthesis of n.c.a. O-(cis-3-[18F]fluorocyclobutyl)-L-tyrosine ([18F]4)
via indirect radiolabeling . . . . . . . . . . . . . . . . . . . . . . . . . . 140
5.3.4 Radiosynthesis of n.c.a. O-(cis-3-[18F]fluorocyclobutyl)-L-tyrosine ([18F]4)
via direct radiolabeling . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
5.3.5 Preparation of O-(3-[18F]fluoroethyl)-L-tyrosine ([18F]FET) . . . . . . . . 147
5.4 Physicochemical and biological characterization . . . . . . . . . . . . . . . . . 147
5.4.1 Determination of the lipophilicity of the non-radioactive L-3FCBT . . . . . 147
5.4.2 In vitro cell uptake assay of L-3[18F]FCBT . . . . . . . . . . . . . . . . . 148
5.4.3 Biodistribution in A549 tumor bearing mice . . . . . . . . . . . . . . . . 148
5.4.4 PET/CT imaging of L-3[18F]FCBT . . . . . . . . . . . . . . . . . . . . . 148
5.4.5 Determination of in vitro metabolic stability in rat hepatocytes . . . . . . 149
5.4.6 Determination of in vitro plasma stability . . . . . . . . . . . . . . . . . . 149
5.4.7 Determination of in vivo stability in mice . . . . . . . . . . . . . . . . . . 149
Bibliography 150
A List of Abbreviation 167
B Publications 171
C Danksagung 173
D Erklärung und Versicherung 175
1 INTRODUCTION

1 INTRODUCTION 9
1 Introduction
An effective personalized patient management requires powerful diagnostic tools for an early
detection of diseases, early therapy response assessment and therapy monitoring. Such di-
agnostic tools have improved significantly over the recent decades [1]. For use in biomedical
research and clinical applications, the list of these imaging systems include, among many oth-
ers, conventional imaging technologies such as X-ray techniques, computed tomography (CT),
ultrasound (US), and magnetic resonance imaging (MRI) and are complemented with highly
sensitive molecular imaging modalities such as single photon emission computed tomography
(SPECT) and positron emission tomography (PET) [1]. In particular, the development of fused
PET-CT machines (and more recently fused PET-MRI) plus the incentive from reimbursement
for PET procedures and effective diagnosis of various diseases triggered a boost in diagnostic
accuracy and the application of molecular imaging, especially in the diagnosis of cancer [2–
4]. The combination of high spatial resolution morphology imaging (CT, MRI) with the in vivo
detection of cellular and molecular alterations led to a new level of disease detection and
therapeutic interventions.
1.1 The Radiotracer Principle
George Charles de Hevesy established the application of a radioactive targeting probe, the
so called radiotracer principle, to follow metabolic processes in plants and animals in the
1900s and received the Nobel Prize in Chemistry in 1943 [2, 5]. The application of a ra-
diotracer followed by specific target recognition and detection of the emitted γ-rays offers a
unique opportunity for non-invasive disease detection. A prerequisite for an ideal radiotracer
is the application of a very low amount of substance (nano- to sub-nanomolar) to avoid any
interference with the target processes and to ensure a favorable toxicological profile of such
compounds enabling for a rapid approval process.
A typical radiotracer consists of a targeting moiety combined with a radioactive signal source.
Targeting vectors are usually small molecules, peptides, oligonucleotides or antibodies [6]. A
wide variety of radionuclides for SPECT, PET and systemic radiotherapy have been used to
radiolabel those targeting vectors [7, 8]. A whole variety of such radiotracers are now routinely
used to detect diseases non-invasively in the clinical practice [9].
1.2 Positron Emission Tomography (PET)
Positron emission tomography (PET) is a molecular imaging method using radiolabeled tar-
geting vectors with positron emitting radionuclides for detection of physiologic or pathologic
processes [10]. Positron emitters are neutron deficient radionuclides decaying by the conver-
sion of a proton to a neutron and the concomitant emission of a positron (β+) and a neutrino
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(ν) [11]. The emitted positron annihilates immediately after collision with an electron within
the surrounding matter, triggering the emission of two diametrally oriented γ-rays of a char-
acteristic energy of 511 keV [3]. A schematic outline of the principle is provided in Figure 1.
Figure 1: Illustration of annihilation of a positron (β+) and an electron (e−) where two photons (γ)
are emitted in opposite directions (180◦) and detected by the photon detection ring (two
detectors highlighted in red) [3, 9].
The PET camera usually consists of scintillation detectors in a circular arrangement. The two
released diametral photons are detected in coincidence mode and it is inferred that these two
γ-rays must have resulted from the same decay event in a very short time interval. Thus, the
location of the originating decay must have taken place somewhere along the line segment
connecting the two particular detectors [1, 12]. In contrast to the currently most used imaging
modality SPECT, the PET technology allows for the detection of smaller lesions (higher sen-
sitivity) and a more accurate quantification of the tracer uptake or target binding.
Fusion of the PET technology with the morphological information derived from a multi-slice
CT scan offers a unique opportunity for the detection of disease and therapeutic intervention
planning in modern oncology (Figure 2).
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Figure 2: PET-CT image of a patient metastasized mastocarcinoma. (a) CT image, (b) fused PET-CT
image and (c) [18F]FDG PET image [13].
The most widely used PET tracer for cancer imaging is the glucose analog 2-[18F]fluoro-2-
desoxy-D-glucose ([18F]FDG). [18F]FDG enters the cell via the cell membrane glucose trans-
porter and is phosphorylated to 2-[18F]fluoro-2-desoxy-D-glucose-6-phosphate as shown in
Scheme 1. The next step of the glycolysis does not take place due to the missing oxygen
atom in C-2 position, hence, 2-[18F]fluoro-2-desoxy-D-glucose-6-phosphate is trapped intra-
cellularly. As many tumor cells have upregulated glucose transport and glycolysis, [18F]FDG
accumulates in tumor cells rather than in healthy tissues [14, 15]. [18F]FDG has been used
as a tracer of many human malignancies including lung cancer, breast cancer, lymphoma,
colorectal cancer and melanoma [16].
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Scheme 1: Structure and glycolytic pathway of 2-[18F]fluoro-2-desoxy-D-glucose ([18F]FDG).
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1.2.1 PET radionuclides
A number of PET radionuclides are preferably used to label biological active molecules. For
PET imaging selected radionuclides have half-lifes comparable to the half-life of the process
being imaged. As mentioned earlier, the primary decay mode should be of positron emission.
The most commonly used radionuclides for PET imaging with their half-life and production
reactions are listed in Table 1.
Table 1: Most commonly used PET radionuclides with their half-life times and production details [8, 9].
Nuclide Half-life Nuclear reaction Decay product Eβ+,max
[min] [keV]
11C 20 14N(p,α)11C 11B 960
13N 10 16O(p,α)13N 13C 1190
15O 2 15N(d,n)15O 15N 1720
18F 110 20Ne(d,α)18F 18O 635
18O(p,n)18F
68Ga 68 68Ge-68Ga generator* 68Zn 1900
* = production of 68Ga: 69Ga(p,2n)68Ge, generator: 68Ge (T 1
2
= 271 d)→ 68Ga
The limiting factor of these PET radionuclides are the short half-life times reaching from 2
minutes (15O) to 110 minutes (18F). Molecular probes for PET imaging are mainly labeled with
11C or 18F. The main advantage of 11C-PET over SPECT is that the radiolabeled tracer is
identical to the non-radioactive analog, such as replacing a carbon-12 by a carbon-11. The
short half-life time of 11C (20 min) is disadvantageous and rarely allows multistep syntheses
in the preparation of 11C-imaging agents.
1.2.2 Fluorine-18
Fluorine-18 with longer half-life time (110 min) can be uses as a substituent of a hydrogen
atom or a hydroxyl group (bioisosteric replacement) [16]. The similarity in size of fluorine
(1.47 Å), hydrogen (1.20 Å) and oxygen (1.52 Å) induces only a slight steric perturbation
(Table 2) [17]. The bond length of fluorine to carbon is similar to the C-O and C-H bond length
which allows F-18 to the isoelectric replacement of a OH group in a molecule [18]. The fluorine
atom has the most electronegativity, therefore, biological aspects have to be considered and
can be of advantage in radiotracer design. Another favorable feature of fluorine is the strong
C-F bond which unlikely leads to the loss of the radionuclide due to metabolism [17].
Table 2: Van der Waals radii, electronegativity and aliphatic C-X bond length of selected atoms [17].
Element van der Waals radius Electronegativity Bond length of C-X
(X) [Å] (Pauling scale) [Å]
H 1.20 2.1 1.09
O 1.52 3.5 1.43
F 1.47 4.0 1.35
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The production of fluorine-18 can be achieved by several methods [19] but nearly all fluorine-
18 used in radiochemistry now stems from the production methods below:
• 20Ne(d,α)18F→ [18F]F2 (electrophilic fluorine)
• 18O(p,n)18F→ [18F]F2 (electrophilic fluorine)
• 18O(p,n)18F→ [18F]F− (nucleophilic fluoride)
The 20Ne(d,α)18F and 18O(p,n)18F reactions are mainly applied to prepare carrier-added (c.a.)
molecular [18F]fluorine and no-carrier-added (n.c.a.) [18F]fluoride for electrophilic and nucle-
ophilic fluorination reactions.
The proton irradiation of enriched 18O-water (> 97%) via the nuclear reaction 18O(p,n)18F is
preferred due to high yields at low proton energies (< 16 MeV). After irradiation, a solution of
n.c.a. [18F]HF in the target water is obtained. The term "no-carrier-added" refers to the fact
that during the 18F-production process no non-radioactive fluorine was added which gives 18F
with very high specific activity (ratio of [18F]fluoride ion activity to its mass of fluoride ion (car-
rier)). Most radiotracer require high specific radioactivity, especially when targeting receptors
or inhibitors (or substrates of enzymes) [20].
In contrast, non-radioactive F2-gas is used as carrier in the production of [18F]F2 which usually
results in low specific activity values (see Section 1.3.1).
1.3 Radiolabeling with fluorine-18
Based on the 18F-production method, the chemical form of the received fluorine-18 deter-
mines the radiochemical reaction: n.c.a. nucleophilic [18F]fluoride and carrier-added (c.a.)
electrophilic [18F]F2. Both species allow substitution reactions but elemental fluorine is only
used for electrophilic fluorination reactions. An eminent example of such a reaction is the
original radiosynthesis of [18F]FDG [21]. Over the years a nucleophilic fluorination method
was developed [22] and is now widespread applied in clinic routine production (Section 1.3.2).
Nowadays, the nucleophilic reaction dominates the fluorine-18 radiochemistry field. In gen-
eral, the 18F-labeling methods can be divided in electrophilic substitution and addition, nucle-
ophilic substitution and 18F-fluorination via prosthetic groups.
1.3.1 Electrophilic substitution
The 18F-fluorination using electrophilic substitution (SE ) or electrophilic aromatic substitution
(SEAr) is an easy access for introducing a 18F into alkyl or aryl systems. C.a. [18F]F2 is directly
available from the cyclotron via the nuclear reaction 20Ne(d,α)18F as well as from 18O(p,n)18F
via the so-called "double-shoot" method [23]. Alternative electrophilic 18F-fluorination reagents
such as acetylhypofluorite ([18]FCH3COOF) [24] or xenon difluoride ([18]XeF2) [25] can be
used but are less reactive and have to be prepared. Recently, the group of Ritter reported
an electrophilic fluorine source originating from nucleophilic fluoride via palladium-mediated
fluorination [26].
However, radiolabeling with [18F]F2-gas has drawbacks. The electrophilic aromatic substi-
tution allows a maximum specific activity of about 0.6 MBq/µmol [27] or recently up to 16
GBq/µmol ("double-shoot" method) [28]. The radiochemical yield is limited to 50% due to the
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fact that a [18F]F2 can only carry one 18F-fluoro atom.
The electrophilic methods require a high purification effort due to sideproduct formation of the
very reactive 18F-fluorination agents. To decrease the byproducts and reduce the purification
effort, demetallation reaction of organometallic compounds can be used [29].
A good example for this reaction is the synthesis of 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine
(6-[18F]fluoro-L-DOPA). This brain radiotracer measures the activity of the aromatic L-amino
acid decarboxylase and is widely and routinely used to study striatal changes in Parkinson’s
disease patiens [30].
In the electrophilic c.a. radiofluorination of 6-[18F]fluoro-L-DOPA, the leaving group in combi-
nation with protecting groups can increase the selectivity of the fluorination. The product was
isolated after HPLC purification in a maximum radiochemical yield of 25% (Scheme 2) [31, 32],
where direct electrophilic labeling resulted in a mixture of aromatic fluoroamino acids [33].
18F
HO
OH
CO2H
NH2
SnMe3
BocO
OBoc
CO2Et
NHCHO
1. [18F]F2
2. HBr
Scheme 2: Synthesis of 6-[18F]fluoro-L-DOPA by electrophilic substitution using a leaving group and
protecting groups for selective fluorination [31].
1.3.2 Nucleophilic substitution
The direct nucleophilic substitution is the most effective approach to introduce a fluorine-18
into an aryl system. The n.c.a. [18F]HF is produced by a cyclotron using 18O enriched water
and results in high specific activity (theoretical 6.3 x 104 GBq/µmol) [34]. Owing to the high
electronegativity, the [18F]fluoride ion is strongly hydrated and inactive for nucleophilic reac-
tions. In order to use the [18F]fluoride ion for radiofluorination reactions, a separation from
the [18O]water is required, usually achieved by adsorption of the [18F]fluoride ion onto an ion
exchange resin, followed by elution with a small amount of a weak base (e.g. potassium car-
bonate) [35] and a cryptate (e.g. aminopolyether 2.2.2 [K2.2.2]). The cryptate solubilizes the
[18F]fluoride in the polar aprotic solvent (ideally of dipolar character, i.e. acetonitrile) during
the drying process. The azeotropic drying steps ensure water-free labeling conditions to avoid
low yields and byproduct formation.
The direct nucleophilic 18F-fluorination takes places according to an SN2-mechanism. Those
reactions require a suitable leaving group. Preferred leaving groups are halogens or sulfonic
acid esters (i.e. mesylate, tosylate, triflate). For aromatic nucleophilic substitutions, the aro-
matic ring needs to be activated by an electron-withdrawing substituent in order to facilitate
the reaction. The leaving group for such aromatic systems are for example -NO2, -N+Me3 or
halogens.
Triflates (trifluoromethanesulfonates) are the most reactive aliphatic leaving groups represent-
ing the perfect candidates for the use in these [18F]fluorination reactions [36, 37]. Today, the
most popular PET radiotracer 2-[18F]fluoro-2-desoxy-D-glucose ([18F]FDG) is synthesized via
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the direct nucleophilic substitution of the triflate with [18F]fluoride (aqueous) of the acetylated
mannose precursor in acetonitrile (Scheme 3). The simple hydrolysis step of the protecting
groups gives the stereospecific product in high purity and a high uncorrected radiochemical
yield (> 50%) [22, 38].
O
OAc
OAc
O
OAc
OAc
18F
O
OH
OH
18F
[18F]F-
K2.2.2, K2CO3
ACN
AcO AcO HO
OAc OH
OAc
O
Tf
NaOH
Scheme 3: Nucleophilic radiosynthesis of [18F]FDG from acetylated mannose precursor.
Aromatic nucleophilic substitution
The 18F-labeling of non-activated aromatic compounds is possible when the deactivated arene
is transformed to an activated species by introducing an electron-withdrawing group (EWG)
such as a carbonyl group, followed by classically labeling with 18F (Figure 3) [39]. This proce-
dure requires a time consuming multistep synthesis.
NO2
R
NO2
R EWG
18F
R EWGprecursor
synthesis labeling
18F
R
Figure 3: 18F-labeling method of an deactivated aromatic compound.
Heteroarenes, especially pyridines, can be labeled with fluorine-18 by nucleophilic substitu-
tion reaction to give stable n.c.a. 18F-labeled compounds without additional activation of the
aromatic ring [40]. 2-[18F]fluoropyridine can be synthesized via nucleophilic substitution using
different leaving groups such as NMe3+, Br− [41]. Relatively harsh conditions are still required
and the radiolabeling takes place in up to 85% yield [41]. The 18F-labeling of pyridines in the 2-
position have been of interests in number of PET tracers. Examples for such 18F-radiolabeled
hetereoarenes are the norchloro-fluoro-homoepibatidine [18F]NCFHEB (targeting the nicotinic
acetylcholine receptors [nAChR]) [42] and 6-pyridinyl-[18F]fluoro-WAY 100635 (targeting the
5-hydroxytryptamine receptors [5-HT]) [40, 43], as outlined in Figure 4.
The nucleophilic substituation can also occur in the 4-position. Other experiments showed
that a second substituent on the pyridinyl ring is accepted. Only fluorination on the 3-position
needs activation by an electron-withdrawing group [44].
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MeO
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N
O
N18F
6-pyridinyl-[18F]fluoro-WAY 100635[18F]NCFHEB
Figure 4: Structures of [18F]NCFHEB and 6-pyridinyl-[18F]fluoro-WAY 100635.
Aliphatic nucleophilic substitution
The most widely used 18F-labeling method is the highly efficient aliphatic nucleophilic substi-
tution with [18F]fluoride. As mentioned before, the leaving groups typically used are sulfonates
and halogens. These reactions are usually performed in mainly polar aprotic solvents (i.e.
acetonitrile, dimethylsulfoxide or N,N-dimethylformamide). Usually acetonitrile is the solvent
of choice due to its favorable characteristic during the azeotropic drying of the [18F]fluoride
to remove water and the low boiling point (82◦C). Recently, tert-butyl alcohols were reported
as a polar protic solvent increasing the nucleophilic character of the fluoride ion and can in-
crease radiochemical yield remarkably [45]. In an example, the radiosynthesis of [18F]FP-CIT,
a radiotracer for the dopamine transporter (DAT), was prepared using standard fluorination
methods with low yields (1%) [46]. Using the new tert-butyl alcohol [18F]fluorination method
[18F]FP-CIT was prepared in 36% yield (Scheme 4) [45].
N
I
CO2CH3
MsO
N
I
CO2CH3
18F
[18F]fluoride
TBAOH
110°C, 20 min
t-BuOH
Scheme 4: Optimized radiosynthesis of [18F]FP-CIT using alcohol solvent system.
1.3.3 18F-fluorination via prosthetic groups
An additional useful strategy to introduce fluorine-18 is via the radiolabeling of a prosthetic
group which is then introduced into a molecule. Therefore, in the first step a reactive species
is 18F-radiolabeled and in a second step coupled to the targeting molecule of any size via 18F-
fluoroalkylation, 18F-fluoroacylation or 18F-fluoroamidation [47–49]. Such labeling agents can
be aliphatic or aromatic. Numerous prosthetic groups have been developed for this special
purpose. The acylation approach using N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB) is
one of the most used 18F-labeling methods for peptides and proteins [48, 50, 51]. Usually,
these reagents are intended to react under mild conditions to maintain the activity of the
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biologically active molecule or macromolecule, e.g. peptides or proteins [6]. Examples of
prosthetic groups for the 18F-labeling of peptides and proteins are shown in Figure 5.
However, these syntheses are multistep reactions and overall radiochemical yields of up to
60% can be achieved [50].
O
O
18F
18F
N
H
O
NH2
18F
a)
b)
c)
N
O
O
N
H
O
Br
Figure 5: Examples of prosthetic groups for 18F-labeling of peptides and proteins; (a) amine-, (b)
carboxylate- and (c) thiol reactive [6].
1.4 Stability of radiotracers
Radiotracers, and all other drugs, meet enormous challenges to maintain their stability in vivo
implicating a high requirement on the structure of the radiotracer. For example, a biologically
active molecule found to be good in vitro but may not be useful in human due to an increased
metabolism. Many pharmacologically and biologically interesting compounds fail for further
application due to their lack of stability.
1.4.1 Basic considerations of drug metabolism
A radiotracer has to meet different criteria to be delivered to the target area of interest, these
contains the lipophilicity, selectivity, sufficient bioavailability and metabolic stability. Most im-
portant in the development of a new radiopharmaceutical is the development of a metabolically
stable tracer to meet the desired requirements and characteristics as mentioned above [52].
Metabolism, besides sustaining life (nutrients), is the inactivation or detoxification tool used by
the human body to eliminate for example pharmaceutical drugs. The metabolic process itself
can have dramatic consequences in toxicity. For example, Thalidomide was used to control
morning sickness and its use in pregnant women had terrible consequences due to the terato-
genic nature of the drug [53]. PET tracers are typically injected intravenously as thus the main
major organs involved in the metabolism process are the kidneys and liver (Figure 6) [52].
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Figure 6: Schematic diagram of drug metabolism in vivo (modified [52]).
In the body a radiotracer can undergo metabolism, also referred to as biotransformation.
These metabolic reactions have been divided into two phases. In Phase I reactions, the
molecular structures are modified (functionalization reactions) via oxidation or dealkylation re-
actions. In Phase II reactions, polar groups are added (conjugation reactions) to the molecular
structure. An overview of the Phase I and Phase II reactions are given in Table 3. Sometimes
the biotransformation can occur sequential, such as
i) addition of an polar group (i.e. hydroxyl) and
ii) the addition of a large polar moiety (i.e. glucuronic acid) [54].
However, a Phase I reaction is not always required before a Phase II reaction, thus, com-
pounds with a functional group undergo Phase II reaction (conjugation reaction) directly.
Table 3: Overview of Phase I and Phase II metabolism [55].
Phase I Phase II
Oxidation Glucuronidation/glucosidation
Reduction Sulfation
Hydrolysis Methylation
Hydration Acetylation
Dethioacetylation Amino acid conjugation
Isomerisation Glutatione conjugation
Fatty acid conjugation
Condensation
Both Phase I and Phase II reactions give more polar metabolites which possesses a higher
aqueous solubility, and the inactivated metabolites can be excreted via urine or gall bladder
(feces). The metabolism is responsible for increasing the drug’s clearance and reduction of
the exposure which decreases the bioavailability.
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1.4.1.1 Phase I metabolism
The Phase I reaction process can be considered as a preparation of pharmaceuticals for the
Phase II reactions and modifies the compound’s structure [55]. These include oxidation and
reduction reactions. In Phase I, oxidation is the most common type of biotransformation and
is catalyzed by several different enzyme families. The monooxygenase family, including Cy-
tochrome P450, plays an important role in these processes [53, 56]. Monooxygenases are
located on the endoplasmic reticulum (ER) inside cells and are mainly found in hepatocytes.
In mammals, Cytochrome P450 enzymes are distributed in liver, kidney, lung, intestine, colon
and brain [57]. The hydroxylation of aliphatic and aromatic carbon atoms is the most common
metabolism observed. In case of aliphatic hydroxyl groups, they can be converted to aldehy-
des and carboxylic acid. It is known that the biotransformation can turn non-active compound
into toxic metabolites [57].
1.4.1.2 Phase II metabolism
In Phase II a polar moiety is added to the molecule via a conjugation reaction and diverse
enzymes are involved in this process. The most important conjugation reaction is the glu-
curonidation (conjugation of glucuronic acid) [55]. Glucuronic acid, a glucose oxidation prod-
uct, can be added to aromatic or aliphatic hydroxyl group (Figure 7) which produces a highly
polar and water-soluble compound and results in inactivation and excretion via urine and gall
bladder (feces).
HO
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Figure 7: Modification with glucoronic acid as a representative example of Phase II metabolism.
Another conjugation pathway represents the sulfate conjugation (sulfation) and often occurs
in parallel with the glucuronidation. Sulfation occurs by interaction of the drug and 3’-phospho-
adenosine-5’-phosphosulfate (PAPS, Figure 8) in presence of the enzyme sulfotransferase [58].
The phenol-, alcohol- and arylamine sulfotransferase are mostly unspecific and will metabolize
a wide range of drugs and xenobiotics. In contrast the steroid sulfotransferases are specific
for a particular type of steroids [59].
Besides the glucuronidation and sulfation, conjugation with glutathione or amino acids are
possible in the Phase II biotransformation. Glutathione, an atypical tripeptide, is present at
highest concentration in the liver [57].
1.4.2 Metabolism of PET radiotracers
Directly after injection, radiotracers are exposed to metabolism in the blood and tissues. The
biotransformation may happen within minutes and the radiometabolites are generally less lipo-
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Figure 8: The structure of 3’-phosphoadenosine-5’-phosphosulfate (PAPS).
philic than the radiotracer itself. In the literature, many different radiotracers were investigated
and reported for metabolism. Figure 9 shows a selection of 11C- and 18F-radiotracers where
metabolism is reported.
Metabolism of 11C-radiotracers
11C-labeled PET tracers are typically synthesized via a simple 11C-methylation at heteroatoms
such as O, N or S [60]. These radiotracers are often metabolized via demethylation which
leads to small polar radiometabolites such as [11C]formaldehyde or [11C]carbon dioxide [61].
However, the dopamine transporter (DAT) radiotracer [11C]PE2I (Figure 9) is metabolized by
hydroxylation in rats which gives brain-penetrating radiometabolites [62] which bind to DAT
and decreases the brain PET image accuracy dramatically. [11C]WAY 100635 (Figure 9) was
observed to be metabolized in monkeys and humans [63] and failed to achieve quantification in
human PET due to radiometabolites in the brain [64]. In the example of the translocator protein
(TSPO) radiotracer [11C]PBR28 (Figure 9), metabolism via demethylation was expected but
surprisingly the major metabolism was found to be debenzylation [65]. Similar metabolism
was found for the fluorine-18 TSPO radiotracer [18F]DAA1106 (Figure 9).
Metabolism of [18F]fluoroethyl-substituted radiotracers
In this thesis, the interests focuses on the metabolism of 18F-tracers in particularly [18F]fluoro-
alkyl chains attached to hetereoatoms such as O, N and S. For these 18F-radiotracers similar
metabolism pathways are occuring as described previously (Section 1.4.2). Biotransformation
of these radiotracers can lead to the radiolabeled metabolites beeing further metabolized and
can ultimately lead to defluorination. The released [18F]fluoride ion is incorporated into bones.
This again can lead to a dramatic decrease of the PET image accuracy due to the high im-
age background. Radiotracers labeled with an N- or O-[18F]fluoroethyl group can be prone to
dealkylation through enzymatic reactions e.g. by the Cytochrome P450 enzyme to give polar
radiometabolites.
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Figure 9: Examples of 11C- and 18F-radiotracers with reported metabolism.
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Selected examples of metabolic unstable 18F-radiotracers are presented below:
[18F]FECNT: In the example of the DAT radiotracer [18F]FECNT (Figure 9), metabolites were
observed in rats, monkeys and humans [66]. A strong evidence for a 18F-labeled metabolite
containing two carbons, presumably [18F]fluoroacetaldehyde, was found to enter the brain in
a high degree. This radiometabolite also showed a nonspecific distribution and accumulation
of the metabolite over time, as clearly demonstrated in Figure 10.
Figure 10: Biodistribution of [18F]FECNT in a monkey at 3, 7 and 220 min after injection [67].
[18F]FEOBV: The vesicular acetylcholine transporter ligand [18F]FEOBV (Figure 9) showed
in rodents a polar metabolite within minutes after injection and accumulated at a slow rate
in bones [68]. Further investigation suggested the metabolite was not [18F]fluoride as ini-
tially hypothesized. Testing [18F]FEOBV in monkey showed high background due to the ra-
diometabolite as well as accumulation in the skull which implied [18F]fluoride formation due to
defluorination (Figure 11) [69].
Figure 11: PET image of [18F]FEOBV uptake into rhesus monkey brain (transaxial image at 90-120
min) with high background and 18F-uptake in skull due to radiometabolites [69].
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[18F]PD 156707: The recent developed 18F-derivate of the non-peptide endothelin type A
(ETA) receptor antagonist (Figure 9) proved to be rapidly converted to polar radiometabolites,
presumably [18F]fluoroethanol, which increased over time [70], as clearly visible in the radio-
HPLC in Figure 12.
Figure 12: Radio-HPLC analysis of rat plasma after 20 minutes p.i [70].
[18F]FET: A further example for an application of an O-alkylated [18F]fluoroethyl group is the
clinically used amino acid tracer O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET), shown in Fig-
ure 9, which is metabolized to a moderate extent in humans [71].
All radiometabolites originating from N- or O-[18F]fluoroethyl radiotracers respectively, are
the consequence of the Phase I biotransformation by the Cytochrome P450 and are believed
to be [18F]fluoroethanol [66, 72]. Detailed investigation in the fluoroalcohol metabolism re-
vealed that 2-fluoroethanol is further oxidized to fluoroacetate [73]. Later, it was confirmed by
metabolites of an imaging agent that [18F]fluoroethanol undergoes further biotransformation
to the aldehyde [18F]fluoroethanal and further oxidized to [18F]fluoroacetic acid 13 [66, 74], as
shown in Scheme.
X
18FR
H
O
18F
HO
18F
HO
O
18F
2-[18F]fluoroethanol 2-[18F]fluoroethanal 2-[18F]fluoroacetic acid
Figure 13: Examples of radiolabeled imaging agents with reported metabolism.
The radiometabolite [18F]fluoroacetate can be further metabolized, mainly in the liver, which
releases [18F]fluoride and accumulates in bone, skull and joints [75]. Metabolic stable radio-
tracers would alleviate these problems.
1.4.3 Countermeasures for radiotracer metabolism
The metabolic stability of a compound can be achieved by changing the chemical structure to
lower the possible attack site from enzymes. However, the challenge is to retain the biological
activity. For radiotracers, a change of the labeling position can increase the metabolic stability
of the compound. For example [11C]WAY 100635 (Figure 9), the compound was labeled in
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O-methyl position instead. In human PET imaging it was discovered that the tracer’s kinetic
in the brain has changed [76]. Thus, the careful choice of the radiolabeling position is very
helpful to avoid disturbing radiometabolites in the development of radiotracers.
A possibility to improve metabolic stability is the deuteration of the radiotracer. In a previous
work the norepinephrine transporter tracer [18F]FMeNER (Figure 14) was deuterated which
retarded the unwanted defluorination [77].
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Figure 14: Structure of [18F]FMeNER and deuterated [18F]FMeNER-D2.
In some examples variation of the tracer’s structure resulted in change of the biological action.
Premedication can alter the metabolism of the radiotracer without changing the molecule’s
structure [78]. The clinically used 5-HT1A receptor radiotracer [18F]FCWAY (Figure 9, imaging
panic disorders and epilepsy) showed extensive defluorination due to a metabolic dealkyla-
tion by the enzyme Cytochrome P450 in Phase I [79]. Pre-administration of a Cytochrome
P450 inhibitor (Miconazole) before application of [18F]FCWAY PET imaging agent, resulted
in almost no defluorination in rodents and therefore, a tremendous improvement of the PET
image accuracy was achieved [79]. In radiopharmacy, this approach has been used only in a
few applications. To perform such a study, great effort is needed
i) to find the appropriate inhibitor to decrease metabolism and
ii) fulfill the regulatory affairs (e.g. toxicity level) when testing in humans.
Changing the radiotracer’s structure or altering the labeling position is still a favorable way to
increase metabolic stability of radiotracers.
1.4.4 Metabolic stability of compounds with cycloalkyl rings
Changing the structure of a drug may result in an increase of metabolic stability. In the lit-
erature it has been reported that replacing an alkyl chain by a cycloalkyl ring resulted in
more metabolically stable compounds. For example, the Serotonin 5-HT1A agonist (Figure 15)
showed decreased stability in human liver microsomes when the cyclopropyl group (5-HT1A-2)
was replaced by a slightly longer or bulkier alkyl groups (5-HT1A-1) [80].
In the example of an β1-adrenoceptor antagonist (Figure 16), a resistance to metabolism was
found when the alkyl chain (Metoprolol) was substituted with a cycloalkyl group (Betaxolol)
and in addition, an increase of biological half-life could be observed [81].
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Figure 15: Structures of a Serotonin 5-HT1A agonist with the alkyl group (5-HT1A-1) substituted with
an cyclopropyl group (5-HT1A-2).
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Figure 16: Structures of β1-adrenoceptor antagonists Metoprolol and Betaxolol.
Another example shows the 11-β-hydroxysteroid dehydrogenase (HSD) inhibitors (Figure 17)
where methyl groups were replaced by a cycloalkyl group which resulted in an increase of
metabolic stability in mouse liver microsomes [82].
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Figure 17: Structure of 11-β-HSD inhibitors with substituted alkyl chains (HSD inhibitor-1) and with
substituted cycloalkyl group (HSD inhibitor-2).
In the example of a neurokinin 1 (NK1) receptor antagonist (Figure 18) the metabolic stability
was increased by replacing the piperidine with a substituted cyclobutane and retained good
binding affinity and had similar lipophilicity [83].
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Figure 18: Structures of NK1 receptor antagonists.
Conclusion
In conclusion, in a number of different examples the use of cycloalkyl groups was shown
to increase the metabolic stability and even in one example, the biological half-life of the
compound was prolongated. However, in radiopharmacy the cycloalkyl rings are not often
applied and only a small number of examples can be found in literature.
1.4.5 Cycloalkyl rings in radiopharmaceuticals
Within the field of radiopharmacy only a few reports exist on PET radiotracers containing
cycloalkyl rings. One example is a potential radiotracer for assessing myocardial fatty acid
metabolism, [18F]FCPHA (Figure 19), containing a cyclopropyl moiety which allows trapping
of the tracer in the cells [84].
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Figure 19: Radiolabeled [18F]FCPHA for imaging heart diseases.
Well-known examples for cycloalkyl rings in radipharmacy are the unnatural α-cyclic amino
acids and described in the literature [85, 86]. A selection of these tracers is shown in Figure 20.
H2N 11CO2H H2N 11CO2H
18F
H2N CO2H
18F
H2N CO2H
[11C]ACBC [11C]ACPC [18F]synFACBC [18F]antiFACBC
Figure 20: Selection of unnatural cyclic amino acids labeled with 11C or 18F.
The aminocyclopentanecarboxylic acid (ACPC) was described as a possibly therapeutic for
tumor growth inhibition in the 1960s [86]. Autoradiographic experiments demonstrated a se-
lective uptake of the unnatural amino acid ACPC in tumor tissue [87]. Hayes et al. [88] con-
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firmed this finding via 11C-labeling of ACPC. In his continuative work, Washburn et al. [89, 90]
concluded that [11C]ACBC (Figure 20) appears to have good potential as tumor PET imaging
agent and found better accumulation in the tumor than with [11C]ACPC (Figure 20). The ma-
jor limitation of 11C-labeled tracers is the short half-life (20 min), therefore, Shoup et al. [91]
developed the [18F]antiFACBC (Figure 20) which showed a high tumor uptake in rats and
showed encouraging results in human PET imaging. To support this promising PET brain tu-
mor imaging agent, Yu et al. [92] found that the newly developed [18F]synFACBC (Figure 20)
is comparable to [18F]antiFACBC. However, the cyclic unnatural amino acids, such as ACBC
and ACPC are not metabolized [92, 93].

2 AIMS AND SCOPE
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2 Aims and Scope
In the introduction (Chapter 1), different examples of metabolic unstable PET tracers were
described. The metabolic stability of these tracers is, in addition to its affinity and selectivity,
an important factor for a successful disease diagnosis. PET tracers and all other drugs are
subject to biotransformation which can form metabolites as a part of the inactivation or detox-
ification process of the human body. These metabolites may result in a higher background
which has a detrimental influence on the PET image quality or can even make imaging impos-
sible.
In general, the introduction of the F-18 label into a biologically active molecule is often achieved
via a fluoroalkyl group which can be sensitive to Cytochrome P450 or other enzyme attack.
In the literature, examples of metabolism of the fluoroethoxy group attached to heteroatoms
can be found: For example, the radiotracer for the dopamine transporter (DAT) [18F]FECNT
showed an increased accumulation of radioactivity in the bone over time in monkey [67],
thus, demonstrating clear evidence for metabolism of the tracer. The radiometabolite is a N-
dealkylation product of the Cytochrome P450 enzyme, presumably [18F]fluoroacetaldehyde,
according to Zoghbi et al. [66]. This metabolite is further oxidized to [18F]fluoroacetic acid
which is known to further metabolism to free fluoride with accumulation in the bone [75].
To date, so far, attempts to improve the metabolic stability of radiotracers are seldouly stud-
ied in detail and were performed by introducing or replacing functional groups within the
molecules. This usually results in a change of the binding properties and lipophilicity.
The aim of this work was to investigate whether [18F]fluorocyclobutyl rings can be introduced
into biologically active small molecules to improve metabolic stability of the PET tracer while
maintaining or improving the binding affinity and lipophilicity.
As model compound, no-carrier-added O-(3-[18F]fluorocyclobutyl)-L-tyrosine (L-3[18F]FCBT)
should be used since many references, especially for the synthesis of the tyrosine derivate O-
(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET), have been cited. As a first approach a reliable syn-
thesis route for the preparation of the targeting molecule L-3[18F]FCBT had to be evaluated.
The relatively straight-forward synthesis via the approach for indirect labeling was preferred
because tyrosine could be alkylated with leaving groups substituted cyclobutane-1,3-diol. This
eliminated a complex organic chemistry for the precursor syntheses. The indirect radiolabel-
ing approach could be also used to evaluate other interesting biologically active molecules.
A precursor for direct radiolabeling was needed to achieve enough radiolabeled compound
with appropriate radioactivity level for biologically tests. This also reduces the radiation dose
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of the operator during manufacturing process of L-3[18F]FCBT.
For the radioanalytics, suitable methods and conditions for radio thin layer chromatography
(radio-TLC) and radio high performance chromatography (radio-HPLC) were evaluated for
identification and quantification the 18F-labeled targeting molecule. To cope with this, refer-
ence compounds were necessary to be synthesized. Finally, the 18F-labeled cyclobutyl model
compound was investigated by radiopharmacological methods.
3 RESULTS AND DISCUSSION
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3 Results and Discussion
3.1 Introduction
The main aim of this work was to investigate the potential of radiofluorinated cycloalkyl rings
as metabolically stable surrogates for fluorinated alkyl chains attached to a heteoatom, e.g.
oxygen or nitrogen. The incorporation of this cycloalkyl ring should ideally maintain the radio-
pharmacological properties and additionally have increased metabolic stability in comparison
to its corresponding fluoroalkyl analog (Section 1.4.4).
This hypothesis is outlined generally in Figure 21, with the substituent R representing a bio-
logically active molecule that binds specifically to receptors or transporters; and X represents
a heteroatom, namely oxygen (O) and nitrogen (N), which are known to be a potential site for
metabolic attack, as discussed earlier in Section 1.4.2.
X 18F
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n
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Figure 21: Hypothesis: increase of metabolic stability by replacing alkyl 1 by a cyclobutyl group 2.
3.2 Proposed model test system
Radiolabeled amino acids are often used for tumor imaging in positron emission tomography
(PET) [94, 95]. Their increased uptake into malignant cells is a result of the high amino acid
need due to increased proliferation [4, 96].
The model system chosen to test the hypothesis were O-alkylated tyrosines, as they are
known to be transported into cells via the large amino acid transporter (LAT) which is well char-
acterized and extensively documented in literature [97–100]. Several O-alkylated derivates of
tyrosine labeled with PET- and SPECT radionuclides are reported, for example 3-[123I]iodo-
α-methyl-L-tyrosine ([123I]IMT) [101], O-([18F]fluoromethyl)-L-tyrosine ([18F]FMT) [102], O-(2-
[18F]fluoroethyl)-L-tyrosine ([18F]FET) [103] or O-(3-[18F]fluoropropyl)-L-tyrosine ([18F]FPT) [104]
and are illustrated in Figure 22. A number of these tyrosine derivates have progressed past
preclinical investigations and are being evaluated in a number of human clinical trials, e.g.
FET [105, 106] and IMT [101, 107].
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Figure 22: A selection of unnatural amino acid based tracers in clinic.
Basic design of the fluorocyclobuty radiotracer
Taking into consideration the experience with tyrosine based radiotracers and the increased
stability of cyclobutyl derivates, the basic target structure O-(3-[18F]fluorocyclobutyl)-tyrosine
[18F]3 (Figure 23) was choosen to explore the hypothesis.
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Figure 23: Basic target structure [18F]3.
The basic target structure [18F]3 possesses D- and L- as well as cis- and trans-isomers which
can have an important effect on the behavior of the tracer in vitro and in vivo. A very interest-
ing study was reported by Tsukuda et al. [104] wherein the D- and L-isomers of fluoromethyl-,
fluoroethyl- and fluoropropyl tyrosine analogs were studied in tumor bearing mice. The D-
isomers, however, revealed a faster elimination rate than their L-isomers indicating for D-
[18F]FMT and D-[18F]FET an improved tumor-to-liver ratio compared to their L-analogs. D-
[18F]FPT showed the highest tumor-to-pancreas ratio.
The cis/trans effect was investigated in the example of [18F]fluoro-L-proline ([18F]FPro) and
demonstrated that cis- and trans-configuration can alter the tumor uptake [108, 109]. The
structure is shown in Figure 24.
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Figure 24: Structure of [18F]fluoro-L-proline ([18F]FPro).
In preclinical trials, cis-[18F]FPro showed higher tumor uptake (11.8% ID/g) in mice as for
trans-[18F]FPro (7.1% ID/g). In addition, trans-[18F]FPro proved a fast clearance and no accu-
mulation in the pancreas. This data were confirmed by whole human body PET investigations.
While cis-[18F]FPro showed a retention in renal cortex, liver and pancreas, trans-[18F]FPro
was retaining particularly in muscles [110].
3.3 Retrosynthetic considerations
The target structure [18F]3 as drawn in Figure 23 can either be the D- or L-isomer of the amino
acid and the cyclobutyl moiety can be either the cis- or trans-isomer. In the majority of amino
acid based PET tracers, the L-isomer is used due to the natural occurrence in the human body,
therefore, the L-tyrosine backbone was chosen. Cis-configuration was selected because it
seemed to be easier accessible in organic chemistry. The structure of the suggested O-(3-
[18F]fluorocyclobutyl)-L-tyrosine (L-[18F]FCBT) [18F]4 is shown in Figure 25.
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Figure 25: Target structure L-[18F]FCBT [18F]4.
3.3.1 Retrosynthetic approach of radiochemical syntheses
The radiolabeled fluorocyclobutyl tyrosine [18F]4 could potentially be synthesized via indirect
or direct radiolabeling methods. The approach using indirect labeling takes advantages of
a radiolabeled intermediate which can be conjugated in a single step to any (phenolic) tar-
geting molecule [111] and gives fast access to a variety of different radiotracers. Today, the
[18F]fluoroethyl 4-methylbenzenesulfonate is a widely used prosthetic group for such alkyla-
tions due to the easy organic preparation and high stability of the precursor and the reactivity
with numerous nucleophiles [112–115].
The indirect approach is an attractive method for the radiosynthesis of the proposed O-(3-
[18F]fluorocyclobutyl)-L-tyrosine [18F]4, as it offers fast access to the desired tracer via an
intermediate prosthetic group 5, which could be synthesized by radiofluorination of the pre-
cursor 6 and coupled to tyrosine via a simple alkylation reaction (Scheme 5). Noticeable is
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the Walden inversion in the radiofluorination step (Scheme 5, compound 6→ 5: cis→ trans).
The disadvantages of an indirect method is that the overall yields of the desired radiotracer
can be low, multiple purification steps are possibly required and therefore, can be relatively
time-consuming.
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Scheme 5: Proposed retrosynthesis of the 18F-fluorinated cyclobutyl tyrosine [18F]4 via the approach
using indirect labeling (LG = leaving group).
Despite the attractiveness of indirect radiolabeling methods for fast access to the desired
tracer [18F]4, the low yields can have an influence on studies where high specific activities
are needed, e.g. receptor binding studies, or where high activity concentrations are needed,
e.g. for metabolism studies. A method using direct radiolabeling would alleviate these prob-
lems and have the additional bonus that the radiosyntheses are easier to be transferred to
an automated synthesis module, thus, reducing the radiation burden to those carrying out
the radiosynthesis. The general route is illustrated in Scheme 6. The main disadvantage of
precursors for direct labeling is the very time-consuming multiple step organic syntheses.
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Scheme 6: Proposed retrosynthesis of the 18F-fluorinated cyclobutyl tyrosine [18F]4 via the direct ap-
proach (LG = leaving group, PG1 and PG2 = protecting group).
In this direct approach the 18F-fluorination of the precursor for direct labeling 7 would be the
first step, followed by a subsequent hydrolysis step to remove the protecting groups to give
the targeting molecule [18F]4.
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3.3.2 Retrosynthetic approach of organic syntheses
3.3.2.1 Precursor for indirect radiolabeling (6)
A possible synthesis path of the indirect cyclic bis-sulfonate precursor 6 is shown in Scheme 7.
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Scheme 7: Proposed retrosynthesis of the precursor 6 for indirect radiolabeling (LG = leaving group).
In the synthesis of the precursor for indirect labeling 6, the first step would be the epoxide ring-
opening of 8 with in situ bromination to give the dibromopropane derivative 9 as described by
Avram et al. [116]. Cyclization of the dibromopropane demonstrated by Ogura et al. [117]
and McConathy et al. [118] would be followed by a stereoselective reduction of 10 to give
the cyclobutyl alcohol 11. Next would be the introduction of the sulfonyl leaving group using
standard organic synthesis methodology to give 12, followed by removal of the benzyl group
by catalytic hydrogenation to result in 13 and the repetition of the sulfonate formation should
give the desired bis-sulfonyl precursor 6.
3.3.2.2 Precursor for direct radiolabeling (7)
The precursor for direct radiolabeling 7 could be synthesized as outlined in Scheme 8 and has
the synergistic effect that the precursor for indirect labeling 6 (see Section 3.3.2.1) would be a
key compound in this synthesis.
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Scheme 8: A basic retrosynthetic route to synthesize the precursor for direct radiolabeling 7 (LG =
leaving group, PG1 and PG2 = protecting group).
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The precursor for direct radiolabeling 7 could be synthesized via an alkylation reaction of the
protected tyrosine 14 containing a free phenolic group with the cyclic bis-sulfonate precursor 6
to give the precursor for direct labeling 7. The selection of the leaving groups of the precursors
6 and 7 as well as the different protecting groups of the tyrosine have to be evaluated and will
be discussed in more detail later (Section 3.4.3 and 3.6).
3.3.2.3 Reference retrosynthesis
In organic synthesis, direct alkylation of phenols typically give excellent yields whereas direct
alkylation of unprotected tyrosines are challenging with low yields for simple alkyl chains [119].
Unprotected tyrosine however, have relatively low solubility in most of organic solvents and can
undergo side reactions, therefore, only low coupling yields are achieved [120]. Examples of
alkylation of phenoles with a primary alkyl chains are documented [102, 121–123], however,
the alkylation of unprotected tyrosine with secondary alkyl chains are not well-documented,
as demonstrated in Scheme 9.
16
LG
F
O
CO2HH2N
4
F
LG
LG
6
Scheme 9: Possible retrosynthesis of the fluorinated reference compound 4 (LG = leaving group).
Therefore, this simple route to synthesize the reference compound 4 was not pursued due to
the low chance of success.
Next, the direct alkylation of protected tyrosine was considered using fluorinated cyclobutyl
sulfonate 16 which could be synthesized via nucleophilic substitution reaction of the cyclic
bis-sulfonate 6 or fluorination of the alcohol with fluorination agents such as diethylaminosulfur
trifluoride (DAST), as outlined in Scheme 10.
16
LG
LG
LG
F
6
O
CO2HH2N
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O
CO2PG2N
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17
F
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LG
OH
13
Scheme 10: Retrosynthesis of the fluorinated reference compound 4 (LG = leaving group, PG1 and
PG2 = protecting group).
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For the synthesis of the intermediate 16, a number of fluorination methods are currently used
and described in detail in literature [124, 125] comprising the fluorination of primary and sec-
ondary alcohols [126, 127]. These fluorination methods include converting a leaving group or
an alcohol into the fluorinated analog. Similar methods were considered feasible for the cyclo-
butyl derivatives by either converting the precursor 6 to the compound 16 or the cyclobutyl
alcohol 13 to 16. The additional leaving group could results into unwanted side reactions such
as elimination or bis-fluorination.
Additional alternative methods for the synthesis of 4 were considered. The longer, time-
consuming multistep synthesis approach of the reference compound 4 would be seen by
coupling cyclobutanol 11 to protected tyrosine 14, as illustrated in Scheme 11.
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Scheme 11: Retrosynthetic approach of reference compound 4 by coupling the cyclobutyl alcohol 11
to protected tyrosine (PG1 and PG2 = protecting group).
The first step would be the Mitsunobu reaction of cis-3-(benzyloxy)cyclobutanol 11 with pro-
tected tyrosine 14, followed by removal of benzyl group by catalytic hydrogenation to give the
alcohol 18. In the next step the alcohol could be fluorinated with a fluorination agent such
as diethylaminosulfur trifluoride (DAST) involving the Walden inversion to give 17. Next the
protecting groups could be removed to achieve the desired reference compound 4.
Considering this proposed retrosynthesis, the cis-3-(benzyloxy)cyclobutanol 11 plays an im-
portant role in the syntheses of a number of precursor and reference compounds. The com-
pound 11 can be easily converted to cyclic bis-sulfonates and could serve as important start-
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ing material in the synthetic approaches of precursors for indirect or direct radiolabeling.
In the literature different leaving groups for radiofluorination and alkylation reactions are de-
scribed [36]. The leaving groups tosylate (Ts), mesylate (Ms), nosylate (Ns) and triflate (Tf)
are known and successfully applied in organic chemistry and evaluated for the syntheses of
the cyclic bis-sulfonates, as outlined in Figure 26.
TsO OTs MsO OMs
NsO ONs TfO OTf
20 21
22 23
SO2Ts =
H3C SO2Ms =
Ns =
Tf =
O2N SO2
F3C SO2
Figure 26: Examples of various cyclobutane-bis-sulfonates.
In 18F-radiochemisty the tosyl leaving group is typically used due to the usually high stability
of the tosyl precursor and its easy synthesis [115], therefore, the first step of the proposed
routes was the preparation of cis-cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) 20.
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3.4 Organic syntheses of precursors for indirect radiolabeling and its
reference compound
3.4.1 Synthesis of labeling precursor cis-cyclobutane-1,3-diyl
bis(4-methylbenzenesulfonate) (20)
The precursor fo the the indirect radiolabeling cis-cyclobutane-1,3-diyl bis(4-methylbenze-
nesulfonate) 20 (see Figure 26) was prepared in a multistep synthesis starting from epi-
bromohydrin 8 and benzyl bromide. The first 3 steps are known in the literature to give 3-
(benzyloxy)cyclobutanone 10 [116–118]. In the next step the ketone 10 was reduced to give
the intermediate cis-3-(benzyloxy)cyclobutanol 11, as shown in Scheme 12.
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Scheme 12: Reaction scheme of the key intermediate synthesis cis-3-(benzyloxy)cyclobutanol 11.
The first step was the epoxide ring-opening reaction of epibromohydrin 8 with benzyl bro-
mide in the presence of mercury (I) chloride at 160◦C [116] and the product 2-benzyloxy-1,3-
dibromopropane 9 was isolated in 39% yield after distillation (0.06 mbar, 220◦C). Monoalky-
lation of methyl methylthiomethyl sulfoxide (CH3S(O)CH2SCH3) with n-butyllithium (n-BuLi)
and 2-benzyloxy-1,3-dibromopropane 9 in tetrahydrofuran (THF) at -70◦C [117] gave the de-
sired product 24 in 40% yield after silica purification. Hydrolysis of 24 with 6 M hydrochlo-
ric acid (HCl) in THF at 0◦C [117] followed by silica purification resulted in the desired 3-
(benzyloxy)cyclobutanone 10 in 23% yield. The reduction of 10 with sodium borohydride
(NaBH4) at 0◦C and subsequent treatment with 1 M HCl in methanol (MeOH) [92] gave the
cis-alcohol 11 in 86% yield after silica purification. In the 1H NMR spectrum the signals could
be assigned to each proton and the structure confirmed (Figure 27 a).
However, the NMR data do not give information about the cis/trans-stereoisomerism, there-
fore, a Nuclear Overhauser Effect (NOE) experiment was performed to determine the cis- and
trans-configuation. Saturation of the Hy signal at δ ≈ 3.91 ppm (ν2) led to a positive NOE of
the Hx signal at δ ≈ 3.64 ppm, as well as at δ ≈ 2.73 ppm (Ha) and δ ≈ 1.95 ppm (Hb). This
is clearly visible in the NOE difference spectrum (Figure 27 b). The second NOE targeting Hx
showed an enhancement of the Hy signal (δ ≈ 3.91 ppm) and again Ha and Hb signals at δ ≈
2.73 ppm and 1.95 ppm (Figure 27 c).
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Figure 27: (a) Assigned 400 MHz 1H NMR spectrum of cis-3-(benzyloxy)cyclobutanol 11 in chloroform-
d. (b) NOE difference spectrum of 11 with irradiation of Hy (δ ≈ 3.91 ppm) and (c) irradiation
of the Hx (δ ≈ 3.63 ppm).
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The NOE difference spectrum clearly showed three signal enhancements which verifies the
cis-isomer of compound 11. In comparison, the trans-isomer would not give an enhancement
in NOE difference spectrum. In Figure 28 the two possible attack sides of the nucleophile are
shown.
H
BnO
H
H
H
H
O
axial attack
equatorial attack
Figure 28: Axial or equatorial attack of a nucleophile leads to the cis- respectively trans-isomer.
The observed stereoselective reduction with NaBH4 as reducing agent suggests an axial at-
tack of the nucleophile. This finding conforms with the literature that small nucleophiles (e.g.
LiAlH4 and NaBH4) tend to attack in an axial fashion (Felkin model) [128]. Traces of the trans-
11-isomer in the 1H NMR spectrum at 4.55 ppm, 4.30 ppm, 2.35 ppm and 2.20 ppm (Figure 27
a) provided evidence that the reducing agent can also attack to marginal degree in equatorial
fashion. The signals were estimated by chemical shifts and by comparison of the cis- and
trans-tosyl compound (see Figure 29).
Higher temperature during reduction (> 10◦C instead of 0◦C) increased the formation of trans-
11 and therefore, reduced the yield significantly. However, large nucleophiles such as lithium
tri-sec-butylborohydride (L-Selectride) tend to attack in equatorial fashion since they are hin-
dered by the axial hydrogen (see Figure 28, highlighted in green) [129].
In the synthesis of cis-cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) 20, the next steps
were tosylation of the cyclobutyl alcohol 11 followed by removal of the benzyl group by cat-
alytic hydrogenation to give the sulfonate 26. The final step was the repetition of the tosylation
to give the desired product 20 (Scheme 13).
Ts2O
(i)
87%
BnO OH
11
BnO OTs
25
Pd/C, H2
(ii)
96%
HO OTs
26
Ts2O
(iii)
78%
TsO OTs
20
Reagents:  (i) pyridine, DCM (ii) MeOH (iii) pyridine, DCM
Scheme 13: Reaction scheme of cis-cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) 20.
In the synthesis of cis-3-(benzyloxy)cyclobutyl 4-methylbenzenesulfonate 25, standard tosyla-
tion methods using 4-methylbenzenesulfonyl chloride (TsCl) and triethylamine (TEA) with and
without catalytic amounts of 4-dimethylaminopyridine (DMAP) in dichloromethane (DCM) fol-
lowed by silica chromatography gave low yields (~30%). The reason for this is believed to be
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found in the flipping of the "wing-shaped" conformation of the cyclobutyl ring which makes the
nucleophile attack more difficult. Another explanation for the low yield could be the pathway
proposed in Scheme 14 which was reported by Ding et al. [130] but not further investigated.
BnO OH BnO O
S
O O
TsCl
base
Cl-
BnO Cl
- TsO-
11
Scheme 14: Possible sidereaction of the tosylation of 11 with TsCl.
The alcohol immediately reacts with the TsCl in the presence of the base TEA to give the to-
sylate and chloride ion. The tosyl group can be substituted by the nucleophilic chloride which
could give the byproduct benzyl-trans-3-chlorocyclobutyl ether and, thus, may result in lower
yields of the originally desired product.
When TsCl was used for the synthesis of a similar compound (3-aminocyclobutane-1-carboxy-
lic acid) [131], reaction times over 72 hours were reported to achieve reasonable yields (70-
80%). Switching to p-toluenesulfonic anhydride (Ts2O) and pyridine in DCM led to shorter
reaction times and significantly higher yields (78%).
Following the literature procedure [132], the benzyl protecting group was removed by cat-
alytic hydrogenation using palladium on charcoal under hydrogen atmosphere in MeOH to
give cis-3-hydroxycyclobutyl 4-methylbenzenesulfonate 26 in excellent yield (96%) without fur-
ther purification. Repeating the tosylation with Ts2O gave the desired precursor for indirect
radiolabeling cis-cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) 20 in 78% yield after sil-
ica purification. After the successful precursor synthesis was established, different precursor
preparation and their radiolabeling were evaluated.
3.4.2 Preparation of labeling precursor trans-cyclobutane-1,3-diyl
bis(4-methylbenzenesulfonate) (29)
To investigate whether the cis- or trans-position of the tosyl leaving group has an effect on the
fluorine-18 incorporation, the precursor trans-cyclobutane-1,3-diyl bis(4-methylbenzenesulfo-
nate) 29 was synthesized. The most efficient route to the trans-precursor 29 appeared to be
the Mitsunobu inversion reaction, as this method should introduce the tosyl leaving group and
inverse the stereochemistry in one step if the nucleophile is pyridinium p-tosylate (PPTS). This
method was reported as a high yielding procedure and superior to the TsCl-pyridine reaction
for secondary alcohols [133]. Unfortunately, the yield for this reaction was found to be lower
than those reported when reacting the alcohol 11 with PPTS, diethyl diazocarboxylate (DEAD)
and triphenylphosphine (TPP) in THF. The reaction scheme is shown in Scheme 15.
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Reagents:  (i) DEAD, TPP, THF (ii) EtOH (iii) pyridine, DCM
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(iii)
26%
Scheme 15: Reaction scheme of trans-cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) 29.
The isolated product trans-3-(benzyloxy)cyclobutyl 4-methylbenzenesulfonate 27 was shown
to be a mixture of diastereoisomers in a ratio of approximately 5 parts of the trans- (27) and
1 part of the cis-isomer (25). The separation of the isomers proved to be impossible at this
stage and therefore, the compounds were characterized in the mixture. The 1H NMR is shown
in Figure 29 a and is compared with its already synthesized cis-isomer 25 (Figure 29 b). By
comparing the trans- with the cis-isomer, both isomers showed in the 1H NMR spectra a
difference in the chemical shift of the cyclobutyl protons (Figure 29). The two quintets of the
major trans-isomer 27 appeared at δ ≈ 5.00 ppm (Hx ) and 4.23 ppm (Hy ) while the minor cis-
isomer 25 was at higher field at δ ≈ 4.46 ppm (Hx ) and δ ≈ 3.63 ppm (Hy ). A clear evidence
for the predominantly trans-isomer demonstrated the multiplet at δ ≈ 2.39 ppm of the two CH2
protons (Ha, Hb), whereas in the cis-isomer showed two separated multiplets at δ ≈ 2.61 ppm
(Ha) and δ ≈ 2.16 ppm (Hb).
The next steps were analog to the synthesis of the cis-cyclobutane-1,3-diyl bis(4-methylbenz-
enesulfonate) 20 (see Scheme 13) with palladium on charcoal under hydrogen in EtOH to give
the trans-alcohol 28 in an excellent 99% yield which was used without further purification. The
alcohol 28 was reacted with Ts2O in the presence of pyridine in DCM to give the desired trans-
cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) 29 in 26% yield after silica purification
(separation of isomers). Wiberg et al. [134] reported for trans-isomers higher reactivity which
would give naturally low yields. It is believed that the trans-isomer, catalyzed through the
higher conformation energy, is rearranged into a reactive cyclobutyl cation which could give
side products [135]. This would explain the low yield of 26% compared to the tosylation of the
cis-isomer 26 (78%, see Section 3.4.1).
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Figure 29: 1H NMR spectrum of 3-(benzyloxy)cyclobutyl 4-methylbenzenesulfonate with the tosyl
group in (a) trans- and (b) cis-position (compound 25 synthesis, see Section 3.4.1).
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3.4.3 Syntheses of other bis-cyclobutyl alkyl- (21, 23) and arylsulfonyl precursors (22,
33)
As discussed earlier in the retrosynthetic consideration of the reference compound (Sec-
tion 3.3.2.3), alternative leaving groups for radiolabeling can be used which can have an effect
on the 18F-incorporation and on the conjugation reaction [136]. A simplified route was believed
to be possible to synthesize a wide range of bis-sulfonates as outlined in Scheme 16.
LG LG
6
HO OH
30
HO OBn
11
LG2O Pd/H2
Scheme 16: Proposed retrosynthesis of the preparation of bis-sulfonates 6, where LG = methane-
sulfonate 21, 4-nitrobenzenesulfonate 22, trifluoromethanesulfonate 23 and 2,3-
dibromobenzenesulfonate 33.
The syntheses of the bis-sulfonate were envisaged. Starting from the alcohol cis-3-(benzyl-
oxy)cyclobutanol 11 would give after removal of the benzyl group the intermediate 30 for the
preparation of the bis-sulfonates. Introducing the chosen leaving group methanesulfonate,
trifluoromethanesulfonate, 4-nitrobenzenesulfonate and 3,4-dibromobenzenesulfonate would
yield in the different bis-sulfonates. The preparation of 21 and 23 is shown in Scheme 17.
HO OH
30
RSO2O OSO2R
21 R = methyl
23 R = trifluoromethyl
Reagents: (i) MeOH (ii)DMAP, DCM (iii) pyridine, DCM
(RSO2)2O
(ii) or (iii)
33%
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BnO OH
11
Scheme 17: Syntheses of bis-sulfonates 21 and 23.
The debenzylation reaction of cis-3-(benzy-oxy)cyclobutanol 11 was carried out in MeOH with
hydrogen and palladium on charcoal. Cis-cyclobutane-1,3-diol 30 was isolated in an excellent
97% yield. A dark color after concentration of the product could be observed when perform-
ing the hydrogenation in tetrahydrofuran. The isolated product showed in 1H NMR spectrum
minor unknown impurities which were not further characterized. The next step of the cis-
cyclobutane-1,3-diyl bis(methanesulfonate) 21 synthesis was carried out by adding methane-
sulfonic anhydride (Ms2O) at 0◦C to a solution of 30 and DMAP in DCM [137] to give the
desired product 21 in 33% yield.
A similar reaction using trifluoromethanesulfonic anhydride (Tf2O) and pyridine in DCM at
0◦C [138] gave cis-cyclobutane-1,3-diyl bis(trifluoromethanesulfonate) 23 in 4% yield, which
was shown to be unstable over time as decomposition was observed after 24 hours at -30◦C
(54% purity). The precursor was not pursued further.
In order to synthesize cis-cyclobutane-1,3-diyl bis(4-nitrobenzenesulfonate) 22 similar meth-
ods as above were used. The nosylation of the diol 30, described for secondary alcohols by
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Hoffman and Kim [139], with 4-nitrobenzenesulfonyl chloride (NsCl), DMAP and TEA in DCM
looked straight forward, as shown in Scheme 18.
HO OH
30
Reagents: (i) DMAP, TEA, DCM
NsCl
(i)
NsO ONs
22
Scheme 18: Synthetic attempt of bis-4-nitrobenzenesulfonate 22.
Several attempts failed to give the desired product 22. Therefore, the longer synthesis pathway
via the intermediate cis-3-(benzyloxy)cyclobutanol 11 was tried (Scheme 19).
BnO OH
11
BnO ONs
31
Reagents:  (i) pyridine (ii) MeOH
NsCl
(i)
53%
HO ONs
32
Pd/C, H2
(ii)
Scheme 19: Synthetic attempt of cis-3-hydroxycyclobutyl 4-nitrobenzenesulfonate 32.
The synthesis was carried out by reacting cis-3-(benzyloxy)cyclobutanol 11 with NsCl at 0◦C
in pyridine [140] to give cis-3-(benzyloxy)cyclobutyl 4-nitrobenzenesulfonate 31 in 53% yield.
The next step was the debenzylation by catalytic hydrogenation. Using palladium on char-
coal and hydrogen in MeOH did not result in the desired product 32. The 1H NMR spectrum
showed the disappearance of the benzyl protons and a shift of the aromatic benzenesulfonate
to the higher field. This indicated a reduction of the nitro group to the amine which was also
confirmed by mass spectrometry (244 [M+H]+; calc. 243.3).
Due to the lack of success, the synthesis of the arylsulfonates using the milder base potas-
sium trimethylsilanolate (KOSiMe3) [115] was tried out, pleasingly the desired product 22 was
isolated in 55% yield (Scheme 20).
HO OH
30
RSO2O OSO2R
22 R = 4-nitrophenyl
33 R = 2,3-dibromophenyl
Reagents: (i) KOSiMe3, THF
RSO2OCl
(i)
55%
49%
Scheme 20: Syntheses of the arylsulfonates 22 and 33.
This method using KOSiMe3 provided cis-cyclobutane-1,3-diyl bis(3,4-dibromobenzenesulfo-
nate) 33 in 49% yield after reacting 30 with 3,4-dibromobenzenesulfonyl chloride in THF.
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3.4.4 Synthesis of reference compound trans-3-fluorocyclobutyl
4-methylbenzenesulfonate (34)
Nucleophilic substitution is the typical method of choice to introduce a fluoride atom at a
specific molecule site. Numerous reagents such as potassium fluoride or cesium fluoride are
known for these reactions [124]. The reference compound trans-3-fluorocyclobutyl 4-methyl-
benzenesulfonate 34 was initially believed to be simple to synthesize via fluorination of 20 as
similar methods are reported in literature [125].
TsO OTs
20
TsO F
34
Scheme 21: Direct fluorination approach of 20.
The nucleophilic substitution described by Pan et al. [125] with potassium fluoride (KF) and
2.2.2-cryptand (Kryptofix) seemed to offer an attractive synthesis route. Several attempts us-
ing these fluorination methods including longer heating times and using also cesium fluoride
(CsF) [126] instead of KF were tested but all failed to give the desired product. Using either sil-
ver fluoride (AgF) [141] or tetrabutylammoniumfluoride (TBAF) [142] as an fluorination agent
at room temperature in acetonitrile (ACN) unfortunately did not result in the desired product.
A promising fluorination method published recently by the Chi group [45] using CsF and ter-
tiary alcohol as the solvent should give in general excellent yields where standard methods
were low yielding or did not occur. Refluxing bis-tosylate 20 with CsF in tert-butanol (tBuOH)
for 30 minutes resulted in only traces of compound with a number of impurities which was
observed by 1H- and 19F-NMR.
Kim et al. [124] recently described TBAF to be hygroscopic which could have an influence
on the TBAF reaction and they reported the significantly less hydroscopic fluorination agent
TBAF·(tBuOH)4. This reagent was prepared simply by refluxing TBAF in tBuOH/hexane [124]
and recrystallization at room temperature in 55% yield. The fluorination of the bis-tosylate 20
was tried with the freshly prepared TBAF(tBuOH)4 refluxing in ACN for 1 hour. Unfortunately,
all attempts under a variety of conditions ranging from low to high precursor conditions failed
to give the desired fluorotosylate 34. The different conditions tried are summarized in Table 4.
Table 4: Reaction conditions of fluorination attempt in ACN refluxing at 90◦C for 1 hour using different
ratios of bis-tosylate 8 (Reagent 1) and TBAF(tBuOH)4 (Reagent 2).
Entry Ratio
# Reagent 1 : Reagent 2
1 0.3 : 1
2 0.4 : 1
3 0.5 : 1
4 1.0 : 1
5 2.0 : 1
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Hence, an alternative preparation route of trans-3-fluorocyclobutyl 4-methylbenzenesulfonate
34 had to be found.
The fluorination reaction utilizing the regent DAST via the intermediate 11 was investigated
(Scheme 22).
DAST
(i)
37%
BnO OH
11
BnO F
35
HO F
36
Ts2O
(iii)
14%
(2 steps)
TsO F
34
Reagents:  (i) DCM (ii) MeOH (iii) pyridine
Pd/C, H2
(ii)
not isolated in pure
Scheme 22: Reaction scheme of the reference compound 34 synthesis.
cis-3-(Benzyloxy)cyclobutanol 11 was fluorinated with DAST at 0◦C in DCM and gave the de-
sired trans-(3-fluorocyclobutyl) benzyl ether 35 in 37% yield. Fluorination was also successful
with a mixture of perfluoro-1-butanesulfonyl fluoride and triethylamine trihydrofluoride in pres-
ence of TEA at room temperature in THF albeit in lower yields (25%) than the DAST method.
Removal of the benzyl group using hydrogen and palladium on charcoal in MeOH afforded the
trans-3-fluorocyclobutanol 36, confirmed by 1H NMR. Unfortunately, the fluoroalcohol 36 was
found to be highly volatile and a high quantitiy of product was lost.
Hydrogenation in THF led to a dark color of the evaporated product and 1H NMR analysis
discovered an unknown impurity. In the next step the crude fluorocyclobutyl alcohol 36 was
treated with Ts2O and the product 34 was obtained in 43% yield. The structure of 34 was
confirmed by 1H-, 13C-, 19F-NMR and mass spectrometry analysis (245 [M+H]+; calc. 244.3)
and showed a purity of 92% according to HPLC analysis (Figure 30).
Figure 30: HPLC analysis of the reference compound 34.
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3.5 Organic syntheses of reference compounds L- and D-3FCBT (4, 47)
Reference compounds play an important role in radiopharmacy. The very low concentration
(radiotracer principle: see Section 1.1) of the radiotracer allows only limited detection by e.g.
UV-signal. Therefore, a non-radioactive reference compound had to be synthesized and in-
jected into HPLC to compare the retention time with the radiolabeled sample to identify the
product. Reference compounds are also used to determine the pharmacological properties of
bioactive molecules.
In order to identify the radiolabeled product, the non-radioactive O-(3-fluorocyclobutyl)-L-tyro-
sine (L-3FCBT) 4 and O-(3-fluorocyclobutyl)-D-tyrosine (D-3FCBT) 47 were synthesized.
3.5.1 Synthesis of O-(3-fluorocyclobutyl)-L-tyrosine (4)
A straight forward approach to the reference compound O-(3-fluorocyclobutyl)-L-tyrosine 4
synthesis was originally seen via the alkylation of protected Boc-Tyr-OMe 37 with the trans-
3-fluorocyclobutyl 4-methylbenzenesulfonate 34 (see Section 3.4.4), followed by hydrolysis of
the protecting groups (Scheme 23).
OH
CO2MeBocHN
O
CO2MeBocHN
F
3738
O
CO2HH2N
F
4
O
CO2HBocHN
F
39
TsO
F
34
Scheme 23: Proposed retrosynthesis of O-(3-fluorocyclobutyl)-L-tyrosine 4.
Alkylation of a phenol with a tosylate using crown ether/potassium carbonate or sodium methy-
late are described in literature [113, 143]. Hence, a solution of Boc-Tyr-OMe 37, trans-3-
fluorocyclobutyl 4-methylbenzenesulfonate 34 in dimethylformamide (DMF) in presence of
dibenzo-24-crown-8 ether and cesium carbonate (Cs2CO3) was stirred at room temperature,
however, after 48 hours only starting material was isolated. The alkylation of tyrosine with
bis-cyclobutylsulfonate in presence of sodium methylate was attempted to synthesize the pre-
cursor for indirect radiolabeling and discussed in Section 3.6.1.
After the unsuccessful attempt, the synthesis of the protected reference compound 39 was
behaved possibly via the Mitsunobu reaction followed by the hydrolysis steps to give the ref-
erence compound 4, as shown in Scheme 24.
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Scheme 24: Synthesis attempt of O-(3-fluorocyclobutyl)-L-tyrosine 4.
The volatile alcohol trans-3-fluorocyclobutanol 36 (containing MeOH) was added to a solution
of Boc-Tyr-OMe 37, DEAD and TPP in DMF and stirred at room temperature for 60 hours.
Unfortunately, a product formation was not observed.
A new synthesis strategy had to be devised by using a longer synthesis path via the Mitsunobu
reaction [144] of the phenolic tyrosine and the previous synthesized cyclobutyl alcohol 11.
Mitsunobu reaction and mechanism
The Mitsunobu reaction allows the conversion of primary and secondary alcohols to esters,
phenyl ethers and a number of other compounds and provides a clean inversion of the stere-
ochemistry. In this reaction, the alcohol is the electrophile and the phenol of the tyrosine is
the nucleophile. In general, the nucleophile should ideally have a pKa < 11 [144] which the
phenolic function of tyrosine has (pKPh−OH ∼10.07) [145]. The reagents used are Ph3P, triph-
enylphosphine (in this thesis referred to TPP) and diethyl azodicarboxylate (DEAD), an azo
compound. The reagents needed for the reaction are added at the same time into the reaction
vessel without following a strict addition order.
The first stage of the Mitsunobu reaction is the formation of the phosphonium anion, shown in
Scheme 25.
Ph3P:
EtO2C
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Stage 1 of the Mitsunobu reaction
Scheme 25: Stage 1 of the Mitsunobu reaction.
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This generated anion is basic enough to remove a proton from the alcohol (Scheme 26, stage
2). In stage 3 of the reaction, the new alkoxide ion immediately attacks the positively charged
phosphorus atom displacing a second nitrogen anion stabilized in the same way as the first
(SN2 reaction at phosphorus) as shown in Scheme 26.
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Scheme 26: Stage 2 and 3 of the Mitsunobu reaction.
The in the previous stage formed second basic nitrogen anion removes the proton from the
nucleophile, shown in Scheme 27, stage 4. The next step is the attack of the nucleophile
(anion) to the phosphorus derivative of the alcohol in a normal SN2 reaction at the carbon with
the phosphine oxide (leaving group). At this stage the inversion of the stereochemistry takes
place.
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Scheme 27: Stage 4 and 5 of the Mitsunobu reaction.
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According to the mentioned process above, the Mitsunobu reaction was carried out adding
DEAD to a mixture of Boc-Tyr-OMe 37, the previous synthesized alcohol 11 and TPP in
DMF [146] at room temperature (Scheme 28). The reaction mixture was allow to react for
23 hours at room temperature before extracting with chloroform and water. After silica purifi-
cation, the desired product 40 was isolated in 88% yield. The next step of the synthesis was
the debenzylation of 40 with hydrogen and palladium on charcoal in MeOH which gave after
silica purification the desired methyl N-(tert-butoxycarbonyl)-O-(trans-3-hydroxycyclobutyl)-L-
tyrosine 41 in 94% yield.
O
CO2MeBocHN
OH
41
O
CO2MeBocHN
OBn
OH
CO2MeBocHN
37 40
(i)
88%
Reagents:  (i) DEAD, TPP, DMF (ii) MeOH
Pd/C, H2
(ii)
94%
OHBnO
11
Scheme 28: Preparation of the intermediate methyl N-(tert-butoxycarbonyl)-O-(trans-3-hydroxycyclo-
butyl)-L-tyrosine 41.
The alcohol 41 was then fluorinated by treating with DAST in DCM at 0◦C to give the protected
reference compound 38 in moderate yield (38%) as shown in Scheme 29.
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CO2MeBocHN
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O
CO2MeBocHN
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41 38
Reagents:  (i) DCM (ii) MeOH (iii) DMF
DAST
(i)
38%
LiOH
(ii)
97%
O
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F
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F
4
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(iii)
44%
Scheme 29: Preparation of O-(3-fluorocyclobutyl)-L-tyrosine 4.
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Next was the hydrolysis step of the methyl ester under basic conditions which could lead to
racemization. In order to avoid this problem, the compound 38 was hydrolyzed with lithium
hydroxide (LiOH) in MeOH, as reported by Lampe et al. [147], which afforded the product 39
after extraction with ethyl acetate and saturated sodium chloride solution in an excellent yield
(97%).
The final step in the synthesis was the removal of the Boc group on the NH2-function under
acidic conditions. O-(cis-3-fluorocyclobutyl)-L-tyrosine 39 was treated with trifluoroacetic acid
(TFA) in DCM at room temperature to give 4 in 74% yield. The purification by this method
turned out to be difficult, and using HCl in dioxane proved to be superior due to the the easy
and fast work-up that included evaporation and freeze-drying. The L-reference compound
O-(3-fluorocyclobutyl)-L-tyrosine 4 was isolated in 44% yield. 1H-, 19F-NMR and mass spec-
trometry (254 [M+H]+; calc. 253.3) confirmed the structure of the product. Chiral HPLC anal-
ysis showed the high enantiomeric purity (94% ee) and provided evidence that racemization
occured only to a minor extend due to the LiOH hydrolysis step (Figure 31).
Figure 31: Chiral HPLC analysis of L-reference compound 4.
3.5.2 Synthesis of O-(3-fluorocyclobutyl)-D-tyrosine (47)
In radiolabeling, basic conditions can lead to racemization of the radiolabeled product. There-
fore, the synthesis of the D-isomer of the reference compound O-(3-fluorocyclobutyl)-D-tyro-
sine 47 was required. The strategy was to start with the commercially available Boc-D-Tyr-
OMe 42, followed by the Mitsunobu reaction with the alcohol 11 (see Section 3.5.1) and
debenzylation to give the protected D-alcohol 44 (Scheme 30). The next steps would be the
fluorination of 44 and subsequent hydrolysis step to give the desired D-reference compound
47.
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Scheme 30: Preparation of O-(3-fluorocyclobutyl)-D-tyrosine 47.
The commercially available Boc-D-Tyr-OMe 42 was converted via the Mitsunobu reaction to
43. The reaction was carried out in a 1 g scale of 42 using the alcohol 11 in presence
of DEAD and TPP in DMF followed by extraction with water and chloroform. The prod-
uct was purified by silica chromatography and found to give the product 43 in 72% yield.
The removal of the benzyl group of 43 was carried out by catalytic hydrogenation using
palladium on charcoal and the desired alcohol methyl N-(tert-butoxycarbonyl)-O-(trans-3-
hydroxycyclobutyl)-D-tyrosine 44 was isolated in excellent yield (97%). Methyl N-(tert-butoxy-
carbonyl)-O-(trans-3-hydroxycyclobutyl)-D-tyrosine 44 was then reacted with DAST at 0◦C in
DCM. This resulted after silica purification in formation of methyl N-(tert-butoxycarbonyl)-O-
(trans-3-fluorocyclobutyl)-D-tyrosine 45 in 8% yield. Fluorinations with DAST are known to
give low to moderate yields [126]. The hydrolysis of 45 was successfully achieved using the
same basic conditions as described earlier (Section 3.5.1) to give 46 in 95% yield. The hydro-
lysis of the Boc protecting group was carried out using the more efficient hydrolysis method
with HCl in dioxane to give the desired O-(3-fluorocyclobutyl)-D-tyrosine 47 as a HCl salt in
92% yield. 1H- and 19F-NMR confirmed the structure of the product. Chiral HPLC analy-
sis showed the high enantiomeric purity (92% ee) and provided evidence that racemization
occurs to a minor extend (Figure 32).
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Figure 32: Chiral HPLC analysis of the D-reference compound 47.
3.6 Organic syntheses of precursors for direct radiolabeling
For further biologically evaluation high activity concentrations and high specific activities are
required. This is not achievable with the time-consuming and low yielding two-step radiolabel-
ing method. Therefore, this problem can be eliminated by using a direct radiolabeling method
which allows to produce higher activity concentrations as well as in higher yields and reduces
the preparation time. In addition, a direct labeling method can be easier transferred to an
automated synthesis module. Despite of these advantages, the precursor synthesis can be
very time-consuming due to multistep synthesis routes.
3.6.1 Preparation of methyl N-(tert-butoxycarbonyl)-O-[trans-3-(4-methylbenzene-
sulfonyloxy)cyclobutyl]-L-tyrosine (48)
The syntheses of the precursor and reference compound via an alkylation reaction with the
previous synthesized bis-sulfonate 20 and Boc-Tyr-OMe 37 was seen as being an efficient
and easy route due to the commercial availability and synthesized building block 20. A ret-
rosynthetic route is outlined in Scheme 31.
O
CO2MeBocHN
OTs
OH
CO2MeBocHN
TsO
OTs
2048 37
Scheme 31: Proposed retrosynthesis of the precursor for direct radiolabeling 48.
Previous experiments showed that the alkylation using K2CO3 and crown ether failed so far
(see Section 3.5.1) and therefore, other methods was envisaged. Wester et al. [113] reported
the alkylation of protected tyrosine with 2-fluoroethyl-4-methylbenzenesulfonate and the use
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of methylate (NaOMe) to give the FET reference compound in 54% yield. Using the same con-
ditions, refluxing cis-cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) 20, Boc-Tyr-OMe 37
and sodium NaOMe in ACN for 9 hours failed to give the desired product 48. Only starting
material could be isolated. An alternative synthesis was reported by Zhang et al. [143]. They
used dibenzo-24-crown-8 ether with Cs2CO3 in DMF which gave only starting material when
used this method. This result is consistent with the unsuccessful synthesis of a similar alkyla-
tion reaction in Section 3.5.1 (Scheme 23)
As observed in previous experiments, the nucleophilic substitution reaction of the protected
tyrosine with the cyclic moiety containing the tosyl leaving group does not seem to work, there-
fore, the previous successful Mitsunobu reaction was pursued using as starting material the
protected tyrosine derivate 41 (Scheme 32).
O
CO2MeBocHN
OH
O
CO2MeBocHN
OTs
41 48
Reagents: (i) pyridine, DCM
Ts2O
(i)
78%
Scheme 32: Synthesis of the precursor for direct radiolabeling methyl N-(tert-butoxycarbonyl)-O-
[trans-3-(4-methylbenzenesulfonyloxy)cyclobutyl]-L-tyrosine 48.
The reaction was initially carried out by adding TsCl to a solution of 41, DMAP and TEA in
DCM at 0◦C for 5 hours and gave the desired product 48 in 13% yield. Using Ts2O instead of
TsCl, the desired product 48 was isolated after silica purification in 78% yield. HPLC analysis
showed a purity of > 99% (Figure 33 b). 1H NMR and mass spectrometry (520 [M+H]+; calc.
519.6) confirmed the structure of the product.
3.6.2 Synthesis of methyl N-(tert-butoxycarbonyl)-O-[cis-3-(4-methylbenzenesulfonyl-
oxy)cyclobutyl]-L-tyrosine (49)
To test whether the cis- or trans-position affects the yield in radiolabeling, the synthesis of 49
was carried out via the Mitsunobu reaction (Section 3.5.1) [133] on the alcohol 41 with pyri-
dinium p-tosylate (PPTS), DEAD and TPP in THF at 0◦C for 5 hours. The crude product was
purified by silica chromatography and gave the desired product 49 in 24% yield, as outlined in
Scheme 33.
The 1H NMR spectrum of 49 supported the proposed structure (Figure 34 a). The quintets
of the Hx and Hy proton could be clearly distinguished between the two isomers in 1H NMR
spectrum. The CH protons shifted high field to δ ≈ 4.61 ppm (Hy ) and 4.21 ppm (Hx ). In
addition, the multiplets of the CH2 protons (Ha and Hb) moved further away from each other
which confirmed the cis-configuration of 49. The UV-chromatogram shows the high chemical
purity (> 99%) of the cis-precursor 49 (Figure 33 a).
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Figure 33: UV-chromatogram of the (a) cis-precursor 49 and the (b) trans-precursor 48.
Note: The HPLC gradient is visible due to low amount of compound injected.
O
CO2MeBocHN
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CO2MeBocHN
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Reagents:  (i) DEAD, TPP, THF
PPTS
(i)
24%
Scheme 33: Preparation of trans-precursor 49.
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Figure 34: 1H NMR spectrum of (a) the cis-precursor 49 and (b) the trans-precursor 48.
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3.6.3 Preparation of tert-butoxy N-(tert-butoxycarbonyl)-O-[trans-3-(4-methylbenzene-
sulfonyloxy)cyclobutyl]-L-tyrosine (54)
The methyl group cleavage of the radiolabeled methyl ester [18F]38 requires basic conditions
which is reported to be promoting racemization [148]. In addition, the removal of the Boc group
adds a hydrolysis step to the synthesis which makes the procedure gratuitous longer. Hence,
the methyl protecting group was replaced by an acid labile tert-butyl group which would allow
for an one-step hydrolysis. The synthesis route of 54 is shown in Scheme 34.
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                  (iii) MeOH (iv) pyridine, DCM
(ii)
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Scheme 34: Synthesis of the precursor for direct radiolabeling 54.
The initial reaction was conducted from the commercially available tert-butyl protected tyro-
sine 50 with di-tert-butyldicarbonate (Boc2O) and TEA in DCM at room temperature for 5
hours. [149]. This resulted in formation of Boc-Tyr-OtBu 51. The crude product was washed
with HCl, saturated sodium bicarbonate solution and saturated sodium chloride solution. The
crude product was purified by silica chromatography and gave 51 in 93% yield. The next
step was the Mistunobu reaction (Section 3.5.1) with cis-3-(benzyloxy)cyclobutanol 11. The
reaction was carried out at room temperature by adding the alcohol 11 to a solution of DEAD
and TPP in DMF. The reaction mixture was stirred for 18 hours before the crude product was
extracted with chloroform and water to remove the solvent DMF. The product, tert-butoxy O-
[trans-3-(benzyloxy)cyclobutyl]-N-(tert-butoxycarbonyl)-L-tyrosine 52, was isolated after silica
chromatography in 82% yield. In the next step, the benzyl group was removed using catalytic
hydrogenation with palladium on charcoal in MeOH at ambient pressure. The desired alcohol
53 was received in an 98% yield without further purification. The tosylation of the alcohol 53
with Ts2O [150] provided the direct labeling precursor tert-butoxy N-(tert-butoxycarbonyl)-O-
[trans-3-(4-methylbenzenesulfonyloxy)cyclobutyl]-L-tyrosine 54 after silica purification in 56%
yield.
The successful prepared N-Boc protected precursor 54 was tested further for radiolabeling
and wether racemization can be observed.
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3.6.4 Syntheses of the N-trityl protected precursors
The racemization of N-Boc protected tyrosine amino acids under typically radiolabeling con-
ditions has been reported [151]. Hamacher et al. [152] used therefore the trityl group, a bulky
amino protecting group, to protect the N-function of the tyrosine and found no racemization
during radiolabeling. With this very promising approach the hydrolysis would remain a single-
step procedure (see Section 3.7.2.3).
3.6.4.1 Synthesis of tert-butyl O-(trans-3-(hydroxycyclobutyl)-N-trityl-L-tyrosine (57)
In the synthesis of all trityl precursor for the direct radiolabeling, tert-butyl O-(trans-3-hydroxy-
cyclobutyl)-N-trityl-L-tyrosine 57 represents the intermediate for the synthesis of precursors
with different leaving groups. The first step was the introduction of the trityl group to the O-
protected tyrosine 50 [153], followed by the Mitsunobu reaction with the intermediate 11 and
debenzylation, as outlined in Scheme 35.
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TrtCl
(i)
55%
OH
CO2tBuTrtHN
55
O
CO2tBuTrtHN
56
OBn
(ii)
46%
O
CO2tBuTrtHN
57
OH
O
CO2tBuTrtHN
LG
Pd/C, H2
(iii)
58
OHBnO
11
LG2O
Scheme 35: Proposed synthesis route of the N-trityl sulfonyl precursor (LG = leaving group).
Note: Syntheses of 57 and 58 were not successful.
The tritylation of tert-butyl L-tyrosine 50 using triphenylmethylchloride (TrtCl) in presence of
TEA in DMF gave after silica purification tert-butyl N-L-tyrosine 55 in 55% yield. The next step
was the Mitsunobu reaction of the alcohol 11 with Trt-Tyr-OtBu 55, DEAD and TPP in DMF.
The crude product was extracted with chloroform and water to remove DMF and purified by
silica chromatography. The desired product 56 was isolated in 46% yield. The removal of the
benzyl group of 56 via catalytic hydrogenation proved to be problematic. The isolation of the
desired product failed. A higher hydrogen consumption was observed due to the additional
removal of the trityl group. 1H NMR spectrum showed only traces of the desired product 58
with the main impurity of tert-butyl L-tyrosine 50.
After failing the synthesis of the compound 57, the Mitsunobu reaction of the alcohol 11 in
presence of an unprotected N-function was considered (Scheme 36). In literature, only one
reference could be found which looked very promising [154].
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Reagents:  (i) DEAD, TPP, DMF
O
CO2tBuH2N
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OBn
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CO2tBuH2N
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(i)
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OHBnO
11
Scheme 36: Mitsunobu reaction in presence of a an unprotected N-function to give 59.
The reaction was carried out by adding cis-3-(benzyloxy)cyclobutanol 11 to a solution of tert-
butyl L-tyrosine 50, DEAD and TPP in DMF at room temperature. The 1H NMR spectrum of the
crude residue showed that a mixture of product 59 and triphenylphospine oxide was present
which could not be separated via crystallization, silica chromatography or semi-preparative
HPLC purification.
Another method for the Mitsunobu reaction was described by Tunoori et al. [155] using polymer-
bound triphenylphosphine (TPP-polystyrene) which allows to remove the formed triphenylphos-
phine oxide derivate by filtration. The reaction was carried out on compound 50 via the above
described procedure using TPP-polystyrene to give tert-butyl O-[trans-3-(benzyloxy)cyclobutyl]-
L-tyrosine 59 in 32% yield. 1H- and 13C NMR (HETCOR and COLOC) analysis confirmed the
structure of 59 and were performed by Analytical Department of Bayer HealthCare.
After the successful Mitsunobu reaction in presence of a primary amine the benzyl group had
to be removed by hydrogenation. Numerous catalytic hydrogenation methods were tested, i.e.
different solvents. Unfortunately only starting material was recovered (Scheme 37).
Reagents:  (i) MeOH or THF
O
CO2tBuH2N
60
OH
Pd/C, H2
(i)
O
CO2tBuH2N
59
OBn
Scheme 37: Debenzylation attempt of tert-butyl O-[trans-3-(benzyloxy)cyclobutyl]-L-tyrosine 59.
In literature, evidence was found which could explain the failing of the debenzylationof 59 [156].
The reason for the unsuccessful catalytic hydrogenation is believed to be due to the NH2-group
of the starting material 59 poisoning the palladium catalyst and alters its reactivity toward the
O-benzyl protective group. Even the addition of acetic acid to eliminate the basic effect of the
NH2-group was unsuccessful. Therefore, an alternative route to 57 was required.
Despite to low chance of success, the Mitsunobu reaction of the previous synthesized Trt-
Tyr-OtBu 55 with cis-3-(hydroxycyclobutyl) 4-methylbenzenesulfonate 26 was attempted, as
shown in Scheme 38.
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Reagents:  (i) DEAD or DIAD, TPP, DMF
O
CO2tBuTrtHN
61
OTs
(i)
OH
CO2tBuTrtHN
55
HO
OTs
26
Scheme 38: Synthesis attempt of tert-butyl O-[trans-3-(4-methylbenzenesulfonyloxy)cyclobutyl]-N-
trityl-L-tyrosine 61 by using Mitsunobu reaction.
Unfortunately, the attractive alternative route was unsuccessful and only the starting material
Trt-Tyr-OtBu 55 was recovered after silica purification. It is believed that the tosyl group as
electron withdrawing group (EWG) inactivates the hydroxyl-group of 26 and anticipates the
mitsunobu coupling.
An alternative route to synthesize the desired alcohol 57 was envisaged. Methods are re-
ported in literature for the selective removal of a Boc group in presence of a tert-butyl es-
ter [157]. The first attempt using trifluoroacetic acid (TFA) in DCM was unsuccessful as both
the Boc group and tert-butyl ester were removed (Scheme 39).
O
CO2tBuH2N
60
OH
O
CO2tBuBocHN
53
OH
25% TFA 
in DCM
Scheme 39: Synthesis attempt to remove the Boc protecting group selectively to give 60. The use of
TFA in DCM led to removal of both protecting groups.
Several attempts to remove the Boc protecting group selectively using different TFA conditions
such as altered concentration and lower reaction temperature [158], 2.2.2-trifluoroethanol [159]
or trimethylsilyl trifluoromethanesulfonate/2,6-lutidine [160] failed to give the desired product
60.
The hydrolysis of the Boc group of 53 using p-toluenesulfonic acid monohydrate (PTSA) in
ethyl acetate (EtOAc) at 0◦C for 1 hour [161] was then conducted. The desired product 60
was isolated as its toluenesulfonic salt after silica purification in 52% yield (Scheme 40). Par-
allel to this PTSA reaction, HCl in dioxane was investigated at room temperature for 4 hours.
The desired product 60 was isolated after silica purification as a HCl salt in 56% yield.
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Scheme 40: Selective removal of the N-Boc protecting group to give 60.
The introduction of the trityl group was carried out reacting 60 with TrtCl in presence of TEA to
give tert-butyl O-(trans-3-hydroxycyclobutyl)-N-trityl-L-tyrosine 57 in 62% yield as a crystalline
solid after crystallization in EtOH/ice water (Scheme 41).
Reagents:  (i) TEA, DMF
O
CO2tBuTrtHN
57
OH
TrtCl
(i)
62%
O
CO2tBuH2N
60
OH
Scheme 41: Preparation of tert-butyl O-(trans-3-hydroxycyclobutyl)-N-trityl-L-tyrosine 57.
3.6.4.2 Syntheses of the N-trityl protected precursors with different leaving groups
(61-64)
It is known that a leaving group can have an effect on the 18F-fluorination reaction which has
an impact on the radiochemical yield (see Section 3.4.3) [136]. Therefore, different leaving
groups such as tosylate, mesylate, nosylate and triflate were investigated.
Synthesis of tert-butyl O-[trans-3-(4-methylbenzenesulfonyloxy)cyclobutyl]-N-trityl-L-
tyrosine (61)
The tosyl group is the widely used sulfonate in radiolabeling due to its stability and avail-
ability (see Section 3.3.2.3). Therefore, the tosyl precursor 61 was synthesized by reacting
the already synthesized alcohol 57 with Ts2O in presence of pyridine in DCM at 0◦C for 1
hour followed by an additional hour at room temperature. The crude product was purified by
silica chromatography to give the desired tert-butyl O-(trans-3-(tosylox)cyclobutyl)-N-trityl-L-
tyrosine 61 in 16% yield, as shown in Scheme 42.
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Reagents:  (i) pyridine, DCM
O
CO2tBuTrtHN
57
OH
O
CO2tBuTrtHN
61
OTs
Ts2O
(i)
16%
Scheme 42: Preparation of tert-butyl O-[trans-3-(4-methylbenzenesulfonyloxy)cyclobutyl]-N-trityl-L-
tyrosine 61.
The low yield was due to the difficult separation of the product from byproducts. The byprod-
ucts could not be separated completely from the product by silica purification because of
similar retention times. The UV-chromatogram of the combined product fractions (Figure 35)
showed contamination with byproducts (RT = 4.43 min and 5.43 min). Only semi-preparative
HPLC purification could separate them where considerable product was lost.
Figure 35: HPLC analysis of the precursor for direct radiolabeling 61.
Synthesis of tert-butyl O-[trans-3-(trifluoromethylsulfonyloxy)cyclobutyl]-N-
trityl-L-tyrosine (62)
In order to avoid an elaborated purification of the product, a precursor with an other leav-
ing group than tosylate was chosen. Triflates are known to be the most reactive leaving
group [162] which should result in good fluorine-18 incorporation in the radiolabeling proce-
dure. On the other hand they are known to undergo unwanted reactions or to be unstable.
In synthesizing the triflate precursor 62, Tf2O was reacted in presence of pyridine with the
alcohol 57 in DCM at 0◦C for 1 hour. After evaporation of the solvent, the crude product was
purified by silica chromatography to give the desired product 62 in 27% yield (Scheme 43).
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Reagents:  (i) pyridine, DCM
O
CO2tBuTrtHN
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OTf
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27%
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Scheme 43: Preparation of the triflate precursor 62.
UPLC-MS analysis showed an advancing decomposition of the triflate precursor 62 during
storage at -30◦C (analog Section 3.4.3). Due to the instability, this precursor was not pursued
in radiolabeling experiments.
Synthesis of tert-butyl O-[trans-3-(4-nitrobenzenesulfonyloxy)cyclobutyl]-N-trityl-L-tyro-
sine (63)
The nosylation of the alcohol 57 was carried out reacting NsCl in presence of DIPEA in DCM
at room temperature for 2 hours. The crude product was purified by silica chromatography
and gave the desired product 63 in 27% yield. (Scheme 44).
Reagents:  (i) DIPEA, DCM
O
CO2tBuTrtHN
63
ONs
NsCl
(i)
23%
O
CO2tBuTrtHN
57
OH
Scheme 44: Preparation of the nosylate precursor 63.
Synthesis of tert-butyl O-[trans-3-(methylsulfonyloxy)cyclobutyl]-N-trityl-L-tyrosine (64)
In the synthesis of the tosylate precursor 61, the purification was a major issue. In order to
reduce a complicated purification, the mesylate precursor was prepared by reacting Ms2O
with the alcohol 57 in presence of DIPEA or DMAP (4 eq.) at 0◦C in DCM to give the desired
product 64 after silica purification in 55% yield which could be increased to 72% yield using
more DMAP (5 eq.) (Scheme 45).
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Reagents:  (i) DMAP, DCM
O
CO2tBuTrtHN
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OMs
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O
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OH
Scheme 45: Preparation of mesylate precursor 64.
Summary
The three precursors tosylate 61, nosylate 63 and mesylate 64 were synthesized successfully
and in sufficient amount for radiolabeling tests to evaluate the radiolabeling conditions, 18F-
incorporation and racemization characteristics.
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3.7 Radiosyntheses
3.7.1 Radiosynthesis of n.c.a. [18F]fluorocyclobutyl tyrosine via indirect radiolabeling
The targeting structure [18F]4, as discussed earlier (Section 3.5.1), was chosen as the model
system to test the hypothesis of increasing metabolic stability by introducing a cycloalkyl ring
into the molecule. The radiosynthesis of [18F]4 was initially planned via an indirect route
(Scheme 46) whereby the precursor 20 could be radiolabeled with fluorine-18 to give the 18F-
labeled intermediate prosthetic group [18F]34. Subsequent conjugation of [18F]34 with tyrosine
allows a fast access to the desired radiotracer with this indirect synthesis route.
O
CO2HH2N
18F
[18F]4
TsO 18F TsO OTs
Tyr
[18F]34 20
Scheme 46: Retro synthesis via the indirect approach of targeting structure [18F]4.
3.7.1.1 Radiosynthesis of 18F-labeled cyclobutyl prosthetic group
Optimization of reaction conditions using the precursor cis-cyclobutane-1,3-diyl bis(4-
methylbenzenesulfonate) (20)
The first step in synthesizing [18F]4 using the method via the indirect radiolabeling, was the
radiolabeling of the precursor cis-cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) 20 to
give the prosthetic group trans-3-[18F]fluorocyclobutyl 4-methylbenzenesulfonate [18F]34. No-
carrier-added (n.c.a.) 18F-radiolabeling conditions of the precursor 20 were investigated in
ACN at 105◦C using different basic systems typically used in radiofluorinations [163] to quickly
identify the most promising base for further optimization. The bases tested were potassium
carbonate (K2CO3), cesium carbonate (Cs2CO3), both with the cryptand K2.2.2, and the two
basic phase-transfer-reagents tetrabutylammonium hydroxide (TBAOH) and tetrabutylammo-
nium bicarbonate (TBAHCO3) as shown in Scheme 47).
TsO OTs TsO 18F
20 [18F]34
[18F]F-
(i)
Reagents:  (i) K2.2.2/base or phase-
                       transfer-reagent, ACN
Scheme 47: Optimization of fluorination conditions of the precursor 20.
Procedure: After azeotropically drying of the aqueous [18F]fluoride mixture, the precursor cis-
cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) 20 (3-4 mg) in ACN was added and the
reaction mixture heated at 105◦C for 10 minutes and monitored by radio-HPLC at 5 and 10
minutes. The results of these initial radiofluorinations are illustrated in Figure 36 a. After 5
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minutes, only the reaction in presence of Cs2CO3 showed poor incorporation (< 5%) which did
not change over time, whereas the other three bases showed similar incorporation (~10% at 5
min) which improved over time to 20-25% with K2CO3 and TBAOH. K2CO3 was chosen as the
base to pursue for further optimization due to its use as standard radiofluorination reagent.
Figure 36: Fluorine-18 incorporation of 20 with (a) different bases in ACN at 105◦C and (b) different
solvents at 105◦C using K2CO3 (parallel experiments).
It is known that the solvent can have a high impact on the nucleophilic substitution reaction in
fluorine-18 chemistry [45, 164–166], thus, the radiofluorination of 20 was tested in the follow-
ing solvents: dimethylsulfoxide (DMSO); dimethylformamide (DMF); acetonitrile (ACN); and a
mixture of tert-butanol and acetonitrile (tBuOH/ACN). The reactions were carried out at the
same 105◦C temperature and the fluorine-18 incorporation results are shown in Figure 36 b.
Similar incorporation with all of the tested solvents were found.
Considering these results, the fluorination reaction was tested with the base K2CO3 and the
solvent ACN. In additional experiments it was found that longer reaction times (15 - 20 min)
led to higher 18F-incorporation (50-60% at 15 minutes). Furthermore, increasing the reaction
temperature to 130◦C resulted in ~80% 18F-incorporation.
In the next step the crude trans-3-[18F]fluorocyclobutyl 4-methylbenzenesulfonate [18F]34 had
to be purified to ensure successful alkylation to tyrosine to achieve the desired product [18F]4
in sufficient yields. Initial distillation attempts of [18F]34 using a N2-stream failed. The purifica-
tion by semi-preparative HPLC was envisaged. Pure [18F]34 was achieved but resulted in loss
of activity and in a very time-consuming procedure, therefore, cartridge purification was inves-
tigated. The C18 cartridge purification was performed in three steps: First, the crude [18F]34
was loaded to a Waters C18 light cartridge, second, polar impurities were removed by wash-
ing with water and third, the product was eluted with ACN and surprisingly, the product [18F]34
was given in excellent radiochemical purity (> 95%). In the purification step, activity loss was
observed (sticking to the reaction vial glass walls and washing from the cartridge), however,
the product was isolated in good yields (36%±13, n=15, decay corrected). The radio-HPLC
chromatogram of the purified product [18F]34 in comparison of the non-radioactive reference
34 is shown in Figure 37.
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Figure 37: (a) Radio-chromatogram of the purified [18F]34. (b) Co-elution of the reference compound
34 confirmed the product of the radiolabeling.
Occasionally during this [18F]fluorination reaction, a more polar radioactive side product (RT
≈ 2.55) besides [18F]fluoride was observed in parallel experiments (Figure 38 a, highlighted
in red).
Figure 38: Radio-chromatogram of two reaction mixtures performed parallel showed in (a) the side
product [18F]fluorocyclobutanol and in (b) no side product was observed.
An example of a radiosynthesis without such side product formation is shown in (Figure 38
b). The polar byproduct is believed to be formed due to insufficient drying of the [18F]fluoride,
therefore, traces of water act as nucleophile and replaced the leaving group under the basic
conditions of K2CO3 to give [18F]fluorocyclobutanol. Whether the alcohol or the [18F]fluoro-
cyclobutyl 4-methylbenzenesulfonate is formed first, was not investigated. However, the formed
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[18F]fluorocyclobutanol impurity can easily be removed by the above mentioned C18 cartridge
purification method.
3.7.1.2 Evaluation of different leaving groups
The use of different leaving groups can have a dramatic effect on i) the 18F-incorporation [115,
136] and ii) the subsequent alkylation reaction. The sulfonyl leaving groups investigated were
tosylate, mesylate, nosylate and 3,4-dibromobenzenesulfonate. The triflate was not investi-
gated due to instability (54% after 24 h at -30◦C; discussed in Section 3.4.3). The synthesized
precursors cis-cyclobutane-1,3-diyl bis(methanesulfonate) 21, cis-cyclobutane-1,3-diyl bis(4-
nitrobenzenesulfonate) 22 and cis-cyclobutane-1,3-diyl bis(3,4-dibromobenzenesulfonate) 33
were directly compared agains the cis-cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) 20
as shown in Scheme 48.
20  R = 4-methylphenyl; solvent: ACN
21  R = methyl; solvent: ACN
22  R = 4-nitrophenyl; solvent: DMSO
33  R = 3,4-dibromophenyl; solvent: ACN
Reagents:  (i) K2.2.2/K2CO3, solvent
[18F]F-
(i)
RO2SO OSO2R RO2SO 18F
Scheme 48: Evaluation of the effect in 18F-radiofluorination with different leaving groups.
The precursor (3.6-3.9 mg; 20, 21 or 33) was dissolved in ACN, however, cis-cyclobutane-1,3-
diyl bis(4-nitrobenzenesulfonate) 22 was only partly soluble in ACN, DMSO was used instead.
The different precursors were labeled during the same reaction conditions (despite the solvent
DMSO), e.g. 130◦C for 10 minutes. The results are shown in Figure 39.
The highest fluorine-18 incorporation was obtained with the precursor bis-tosylate 20 (65%)
followed by bis(3,4-dibromobenzenesulfonate) 33 (58%). The precursor bis-mesylate 21 led to
a medium (30%) and bis-nosylate 22 to a low 18F-incorporation (5%). Despite the varying 18F-
incorporation, the conjugation reactions were evaluated for all the trans-3-[18F]fluorocyclobutyl
sulfonates [18F]34, [18F]65, [18F]66 and [18F]67 (see Section 3.7.1.6).
3.7.1.3 Comparison of 18F-incorporation using cis- and trans-cyclobutane-1,3-diyl
bis(4-methylbenzenesulfonate) (20, 29)
1,3-Substituted cyclobutyl rings can be either cis- or trans-isomers. The nucleophilic substi-
tution of an axial leaving group (trans-29) should take place faster than the substitution of an
equatorial leaving group (cis-20). As shown in Figure 40 (top), the attack of the nucleophile
is more hindered by the axial hydrogen (in red) than its cis-isomer (Figure 40, top). Wiberg et
al. [134] found that trans-isomers of cyclobutyl moiety bear a higher energy through the con-
formation and tend to be more reactive (according to Section 3.4.2). Therefore, it is expected
that the trans-isomer 29 shows a higher 18F-incorporation.
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Figure 39: Comparison of 18F-incorporation of with different leaving groups (parallel experiments).
In order to test whether the cis- or trans-orientation has an effect on the fluorine-18 incorpo-
ration, the radiolabeling of the cis- (20) and trans-precursors (29) were investigated using the
same labeling conditions as mentioned above (Scheme 49).
TsO OTs TsO 18F
20 [18F]34
[18F]F-
(i)
Reagents:  (i) K2.2.2/K2CO3, ACN
TsO OTs TsO 18F
29 [18F]68
[18F]F-
(i)
Scheme 49: 18F-Fluorination of cis- (20) and trans-cyclobutane-1,3-diyl bis(4-methylbenzenesulfo-
nate) (29).
In a parallel experiments, using the same precursor amount (3.6 mg) and starting activity
(450 MBq), similar 18F-incorporations were found ([18F]34: 36%, [18F]68: 38%). However, the
precursor 20 (cis) showed a lower UV-impurity profile compared to 29 (trans) as demonstrated
in Figure 40 (bottom).
The expectation of a favored attack to give higher 18F-incorporation could not be observed.
The precursors 20 (cis) and 29 (trans) will be evaluated for their alkylation to tyrosine (see
Section 3.7.1.7).
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Figure 40: Top: The approach of the equatorial leaving group is in 20 (cis) hindered by the hydrogen
in red, whereas the axial leaving group of 29 (trans) is approached less hindered.
Bottom: Radio-HPLC analysis of the products purified by solid-phase-extraction (C18)
cartridge; (left) [18F]34 and (right) [18F]68 (parallel experiments).
3.7.1.4 Conjugation of the prosthetic groups to tyrosine
In order to synthesize the target compound [18F]4, tyrosine was alkylated to the 18F-labeled
prosthetic group (Scheme 50). In this nucleophilic substitution reaction, the active (nucle-
ophilic) phenolate is achieved by using the disodium salt of tyrosine or generated in situ with
sodium hydroxide and tyrosine.
LG 18F Tyr
O
CO2HH2N
18F
[18F]4
Scheme 50: General alkylation reaction of tyrosine with the 18F-labeled intermediate to give the target
compound [18F]4 (LG = leaving group).
The substituent LG represents a leaving group, e.g. 4-methylbenzenesulfonate or methane-
sulfonate. As discussed earlier, leaving groups can not only have an impact on the 18F-
fluorination yield, but also be responsible for an efficient conjugation reaction to tyrosine to
give the target compound [18F]4. In addition, the cis-/trans-position of the leaving group could
also have an influence in the conjugation. These points were evaluated in details.
3 RESULTS AND DISCUSSION 77
3.7.1.5 Radiosynthesis of [18F]4 by alkylation of tyrosine with
trans-[18F]fluorocyclobutyl 4-methylbenzenesulfonate ([18F]34)
As mentioned in the previous section (see Section 3.7.1.1), the best reaction conditions for the
synthesis of trans-3-[18F]fluorocyclobutyl 4-methylbenzenesulfonate [18F]34 have been evalu-
ated. This product was then further reacted with L-tyrosine to form the target molecule [18F]4,
as shown in Scheme 51.
Reagents:  (i) DMSO
TsO 18F
(i)
O
CO2HH2N
18F
[18F]34 [18F]4
O-Na+
CO2-Na+H2N
L-tyrosine disodium
Scheme 51: Alkylation reaction of [18F]34 with tyrosine disodium salt to give targeting structure [18F]4.
Synthesis of L-3[18F]FCBT - Alkylation method I
The synthesis was carried out by eluting trans-3-[18F]fluorocyclobutyl 4-methylbenzenesulfo-
nate [18F]34 from the C18 light cartridge with DMSO and reacting with L-tyrosine disodium salt
(4-5 mg), as this method was successfully used to synthesize [18F]FET [113]. After heating
the reaction mixture to 150◦C, the conversion was followed over 40 minutes by radio-HPLC.
The time dependent course of the alkylation reaction is shown in Figure 41.
Figure 41: Reaction course of alkylation reaction at 150◦C over 40 minutes (n = 3).
This experiment showed an increase of product formation over time reaching after 15 minutes
a maximum of 69% and decreasing after 30 minutes again. In the next step, the alkylation
product was purified by semi-preparative C18 HPLC which provided the desired product [18F]4
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in 4-6% yield (decay corrected). In Figure 42, a radio-HPLC analysis of the intermediate
[18F]34 and the purified product [18F]4 are shown.
Figure 42: Radio-HPLC analysis of (a) the intermediate [18F]34 before conjugation (purified by C18
cartridge) and (b) the alkylation product using tyrosine disodium salt.
Synthesis of L-3[18F]FCBT - Alkylation method II
Parallel to the conjugation with the tyrosine disodium salt, the in situ method was pursued [167,
168]. In this reaction, the activated (nucleophilic) phenolate is generated in situ using tyrosine
and two equivalents of base to give the tyrosine disodium salt, as demonstrated in Scheme 52.
Reagents:  (i) 10% NaOH (aq.), DMSO
TsO 18F
(i)
O
CO2HH2N
18F
[18F]34 [18F]4
OH
CO2HH2N
L-tyrosine
Scheme 52: Alkylation reaction of [18F]34 with tyrosine.
In the first step, [18F]34 was eluted from the C18 cartridge with DMSO, as described in the
conjugation with tyrosine disodium salt. [18F]34 was then reacted with tyrosine (~4-5 mg) in
the presence of two equivalents of 10% sodium hydroxide (NaOH) for 10 minutes at 150◦C,
as previously reported. The alkylation reaction was also conducted in ACN, but no product
formation was observed due to the very low solubility of tyrosine in ACN [169].
After the reaction of [18F]34 was completed, the solvent (ACN) was evaporated, DMSO was
added and transferred to a vial containing L-tyrosine (4-5 mg) and two equivalents of NaOH.
This mixture was reacted to full completion of the alkylation reaction (150◦C for 15 min). The
crude product was purified by semi-preparative C18 HPLC using a gradient of ACN/water with
or without TFA addition. Unfortunately, the product could not be sufficiently separated from
UV impurities, even when using different gradients or flows. Switching to the C18 Synergi
column, a good separation of the product was achieved with 85% water acidified with 1 M HCl
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to pH 2 and 15% ACN and a flow of 3 ml/min (Figure 43). In a typical synthesis made by hand
the product eluted between 18 and 24 minutes from the semi-preparative HPLC column.
Figure 43: Typical semi-preparative HPLC radio-chromatogram of [18F]4.
Choosing HPLC conditions with a product retention time of greater than 25 minutes (by reduc-
tion of ACN ratio or flow) resulted in an increase of lipophilic byproducts which had a dramatic
effect on the radiochemical yield. Moreover, these lipophilic byproducts were never observed
in the analytical HPLC runs. Unfortunately, this phenomenon was not investigated further.
In order to test the tracer [18F]4 in cells or animals, a biocompatible formulation was needed.
This was accomplished by diluting the product with water acidified with 1 M HCl to pH 2,
loaded to a C18 environmental cartridge, washed with water acidified with 1 M HCl to pH 2
and eluted with fractions of 0.5 ml EtOH/water (1:1) to give the product [18F]4 in 8%±5.5 yields
(n=14, decay corrected). Chiral HPLC showed the single L-isomere (Figure 44).
Figure 44: Chiral radio-HPLC analysis of final product [18F]4 showed single L-isomere to be present
(spiked with reference compound 4).
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Synthesis of D-3[18F]FCBT using alkylation method II
The D-isomer of the tracer was synthesized in an analogous manner to the L-isomer, with
D-Tyrosine used as the starting material (Scheme 53).
Reagents:  (i) 10% NaOH (aq.), DMSO
TsO 18F
O
CO2HH2N
18F
[18F]34 [18F]47
(i)
OH
CO2HH2N
D-tyrosine
Scheme 53: Alkylation reaction of [18F]34 with D-tyrosine to give D-3[18F]FCB (alkylation method II).
Using the optimized synthesis conditions of the L-tyrosine, [18F]34 was eluted from the C18
cartridge with ACN and the solvent was evaporated for 10 minutes at 110◦C. The residue was
taken up in DMSO and transferred to a vial containing D-tyrosine (~4-5 mg). This mixture was
reacted in presence of two equivalents of 10% NaOH for 15 minutes at 150◦C. Surprisingly,
only 50% of the intermediate [18F]34 was found to be alkylated to D-tyrosine to give the desired
product [18F]47. The crude product was purified by semi-preparative C18 HPLC using 15%
acetonitrile and 85% water acidified with 1 M HCl to pH 2 with a flow of 3 ml/min. The product
eluted at around 17 minutes. The product fraction was diluted with water acidified with 1 M HCl
to pH 2 and trapped on a C18 Environmental cartridge, washed with water acidified with 1 M
HCl to pH 2. The product was eluted with EtOH to give [18F]47 in 16% yield (decay corrected).
Chiral HPLC showed only the single D-isomere be present (Figure 45).
Figure 45: Chiral radio-HPLC analysis of final product [18F]47 showed single D-isomere to be present
(spiked with reference compound 4).
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3.7.1.6 Evaluation of the alkylation reaction of various trans-3-[18F]fluorocyclobutyl
sulfonates ([18F]34, [18F]65-67) with L-tyrosine
The effect of the leaving group on the alkylation reaction was discuss earlier (Section 3.7.1.2)
and was evaluated with the 18F-radiolabeled sulfonates [18F]65, [18F]66 and [18F]67 in com-
parison to trans-3-[18F]fluorocyclobutyl 4-methylbenzenesulfonate [18F]34 (Scheme 46).
[18F]34  R = 4-methylphenyl
[18F]65  R = methyl
[18F]66  R = 4-nitrophenyl
[18F]67  R = 3,4-dibromophenyl
Reagents:  (i) 10% NaOH (aq.), DMSO
(i)
RSO2O 18F
O
CO2HH2N
18F
[18F]4
OH
CO2HH2N
L-tyrosine
Figure 46: Alkylation reaction of trans-3-[18F]fluorocyclobutyl sulfonates with tyrosine.
The synthesis was carried out by eluting trans-3-[18F]fluorocyclobutyl sulfonate (one of [18F]34,
[18F]65-67, see Section 3.7.1.2) from the C18 cartridge with ACN and reacted with tyrosine
(5-6 mg) in DMSO in presence of two equivalents of 10% NaOH for 10 minutes at 150◦C in
an open vial. The results of the sulfonate alkylation to tyrosine are shown in Figure 47.
Figure 47: Comparison of the alkylation with different leaving groups to tyrosine for 10 minutes at
150◦C in presence of NaOH (parallel experiments).
This parallel experiments showed the best alkylation results using the 4-methylbenzenesulfo-
nate [18F]34 and the 3,4-dibromobenzenesulfonate [18F]67 (69-82%). The methanesulfonate
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[18F]65 gave only low conversion (4%) and the 4-nitrobenzenesulfonate [18F]66 failed to give
product. Interestingly, the same alkylation pattern was found as seen in the fluorination of the
bis-sulfonate precursors (Section 3.7.1.2, Figure 39).
For further optimization of the method for the indirect radiolabeling, the 4-methylbenzenesulfyl
leaving group (precursor 20) was chosen due to the easy availability, high stability and low
costs of the starting materials.
3.7.1.7 Evaluation of the alkylation reaction of cis- ([18F]34) and
trans-[18F]fluorocyclobutyl 4-methylbenzenesulfonate ([18F]68) with L-tyrosine
The cis/trans-position is expected to have an influence on the nucleophilic substitution reaction
(see Section 3.7.1.3), therefore, the alkylation of the [18F]34 and [18F]68 to L-tyrosine was
evaluated, as shown in Scheme 54.
[18F]68
(cis)
Reagents:  (i) NaOH (aq.), DMSO
TsO 18F
O
CO2HH2N
18F
[18F]69
(trans)
TsO 18F
O
CO2HH2N
18F
[18F]34
(trans)
[18F]4 
(cis)
(i)
OH
CO2HH2N
L-tyrosine
(i)
OH
CO2HH2N
L-tyrosine
Scheme 54: Alkylation of [18F]34 and [18F]68 to tyrosine.
The synthesis was tested using the same alkylation conditions as previously, i.e. tyrosine (5
mg) in DMSO in presence of 2 equivalents of NaOH (150◦C for 10 min). The radio-HPLC
chromatogram of the alkylations are shown in Figure 48.
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Figure 48: Radio-HPLC chromatogram of the alkylation to L-tyrosine; with (a) [18F]34 and (b) [18F]68.
The alkylation with the [18F]34 was expected to be better than [18F]68 due to the less hindered
approach of the (activated) phenolate of the tyrosine (similar approach see Section 3.7.1.3).
The results were found to be the same for both isomers (71%). It seems that the bulkier
nucleophile tyrosine is allowed to approaches both the equatorial and axial leaving group in
the same manner and therefore result in similar alkylation kinetics. Both products, [18F]4 and
[18F]69 respectively, were received in 7% yields. Interestingly, this results were congruent with
the fluorination results of the bis-tosylate precursors and indicated that the configuration may
not have any influence on the alkylation reaction.
Summary
In summary, the radiosynthesis of [18F]4 via the indirect labeling method using for the alkyla-
tion tyrosine or tyrosine disodium salt were yielding in 4-12% and had long synthesis times
(>120 min). The desired product [18F]4, starting from 600-900 MBq, was received in very
limited activity amounts (max. 50-70 MBq).
3.7.2 Radiosynthesis of n.c.a. [18F]fluorocyclobutyl tyrosine via direct radiolabeling
The method of indirect radiolabeling proved to be very attractive for fast access to the desired
tracer, but turned out to be time-consuming (> 120 min) and low yielding (4-12%). Regarding
the biological evaluation of the tracer in cells or animals, high specific activities, e.g. receptor
binding studies, and high activity concentration, e.g. animal studies are demanded. A precur-
sor for direct labeling allowing to cope with these problems and in addition, the radiosynthesis
can be easier transferred to automated synthesis module. The general structure of such a
precursor for direct radiolabeling and its radiolabeling procedure is shown in Scheme 55.
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O
CO2HH2N
18F
O
CO2PG2N
H
LG
PG1
[18F]4
PG1 = Amino protecting group
PG2 = Carboxyl protecting group
LG   = Leaving group, sulfonate
O
CO2PG2N
H
18F
PG1
Reagents:  (i) K2.2.2/K2CO3
[18F]F-
(i)
7 [18F]17
H+
Scheme 55: Direct labeling approach to improve synthesis time and yield.
The leaving group (LG) is substituted with [18F]fluoride during the fluorination reaction. The
protecting groups (PG1 and PG2) represent protecting groups which will be removed after the
fluorination reaction to achieve the desired targeting molecule [18F]4. Three important aspects
to the precursor for direct radiolabeling are:
1. Amino protecting group (PG1): The widely used protecting group for amino functions
is the tert-butoxycarbonyl (Boc) and can be removed under mild acidic conditions [170,
171]. Unfortunately, in some examples racemication of the tyrosine derivate could be
observed [151]. The use of the trityl group, a more bulkier protecting group should
reduce racemization.
2. Carboxyl protecting group (PG2): Methyl ester (Me) can be used to protect carboxylic
functions and can be removed under basic conditions which can lead to racemization.
An alternative could be an acidic label protecting group such as the tert-butyl group
(tBu) [171] which can be selectively removed using acidic conditions.
3. Leaving group (LG): Different leaving groups such as tosylate, mesylate, nosylate and
triflate can be used for radiofluorination as discussed earlier (Section 3.3.2.3).
In literature direct radiolabeling of tyrosine derivates using protected precursors have been
described [151, 152, 172, 173]. Since the basic radiolabeling conditions can lead to racem-
ization, the aspect of the protecting groups is important. Also the leaving group can have an
effect on the 18F-incorporation, as mentioned earlier.
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3.7.2.1 Evaluation of the precursor methyl N-(tert-butyloxycarbonyl)-O-trans-3-(4-
methylbenzenesulfonyl)cyclobutyl]-L-tyrosine (48) for direct
radiolabeling
Initially, the 18F-radiofluorination of the precursor methyl N-(tert-butyloxycarbonyl)-O-[trans-
3-(4-methylbenzenesulfonyl)cyclobutyl]-L-tyrosine 48 and subsequent hydrolysis steps were
investigated as shown in Scheme 56.
Reagents:  (i) K2.2.2/K2CO3, ACN
[18F]F-
(i)
O
CO2MeBocHN
18F
48 [18F]38
O
CO2MeBocHN
OTs
O
CO2HH2N
18F
[18F]4
O
CO2HBocHN
18F
[18F]39
1 M NaOH
1 M HCl
Scheme 56: 18F-radiofluorination of the precursor methyl N-(tert-butyloxycarbonyl)-O-[trans-3-(4-
methylbenzenesulfonyl)cyclobutyl]-L-tyrosine 48.
In the initial experiment different reaction solvents were evaluated (DMSO, DMF and ACN).
The radiofluorination was carried out by adding the precursor 48 (~3 mg) in the mentioned
solvent to the dried [18F]fluoride-cryptate complex and reacted in presence of the base K2CO3
at 110◦C. The 18F-incorporation was examined over 40 minutes by radio-HPLC and similar
results for all the solvents were found. A representative example of the reaction course is
shown in Figure 49.
Figure 49: Reaction course (radio-HPLC) of [18F]38 in ACN (110◦C).
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The desired product [18F]38 was formed after 10 minutes with low 18F-incorporation (10%)
and decreased over 30 minutes to 2%. However, HPLC data showed surprisingly an increase
of a more polar radioactive byproduct (Figure 50, RT = 4.636 min) which was identified by
co-injection of the reference compound as [18F]39. This indicated that the basic radiolabel-
ing conditions allow a removal of the methyl ester to form the partly deprotected intermedi-
ate [18F]39. Examples in literature describe the removal of methyl protecting groups using
K2CO3 [174–176]. Longer reaction times over 20 minutes lead to a decomposition of the
partly deprotected [18F]39.
Figure 50: (a) Radio-HPLC chromatogram of 18F-radiolabeled precursor 48 in ACN (110◦C for 20 min)
shows formation of product [18F]38 and partly deprotected product [18F]39 and (b) iden-
tification of the peaks via UV-chromagramm co-injection of reference compound 38 and
39.
The fact, that a two-step deprotection is needed which increases the chance of building more
byproducts and racemization (see next Section 3.7.2.2), led to the conclusion to pursue with
other direct labeling precursors using acid labile protecting groups.
3.7.2.2 Evaluation of the precursor tert-butoxy N-(tert-butoxycarbonyl)-
O-[trans-3-(4-methylbenzenesulfonyl)cyclobutyl]-L-tyrosine (54) for direct
radiolabeling
A single hydrolysis is desirable to reduce synthesis time and possible racemization of the
radiolabeled product due to the basic conditions. The synthesized precursor tert-butoxy
N-(tert-butoxycarbonyl)-O-[trans-3-(4-methylbenzenesulfonyl)cyclobutyl]-L-tyrosinate 54 pos-
sesses two acid labile protecting groups; Boc for the amino- and tert-butyl for the carboxylic
acid function allowing for a single acidic deprotection step to give [18F]4 (Scheme 57).
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Reagents:  (i) K2.2.2/K2CO3, ACN
[18F]F- 
(i)
O
CO2OtBuBocHN
18F
54 [18F]70
O
CO2tBuBocHN
OTs
O
CO2HH2N
18F
[18F]4
1 M HCl
Scheme 57: 18F-radiofluorination of precursor methyl tert-butoxy N-(tert-butoxycarbonyl)-O-[trans-3-
(4-methylbenzenesulfonyl)cyclobutyl]-L-tyrosinate 54 followed by acidic hydrolysis.
In order to investigate the 18F-fluorination yield, general reaction conditions were evaluated.
Similar to previous experiments the bases K2CO3, Cs2CO3, TBAOH and TBAOMs were
tested. The reactions were carried out in ACN at 90◦C. Lower reaction temperature was
chosen to avoid formation of byproducts which was observed in the earlier radiolabeling of 48
at 110◦C. The reaction course is shown in Figure 51.
Figure 51: F-18 incorporation of 54 in acetonitrile using different bases (90◦C, parallel experiments).
After 15 minutes the 18F-incorporation was found to be 4-8% for all tested bases. Only K2CO3
showed an increase to 14% after 30 minutes. With the other bases an 18F-incorporation of
8% was observed after 30 minutes. Longer reaction times (> 30 min) led to decomposition of
the 18F-radiolabeled product and were avoided.
Further optimization studies were carried out in different solvents such as ACN, DMSO and
DMF with K2CO3 at 110◦C. The reaction temperature was increased by 20◦C because previ-
ous experiments showed higher 18F-incorporation at this temperature (110◦C). The reaction
course is shown in Figure 52.
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Figure 52: Optimization of the F-18 incorporation of 54 at 110◦C using different solvents monitored by
radio-HPLC (parallel experiments).
The 18F-incorporations after 15 minutes were similar for all tested solvents (15-19%) at 110◦C
but considerably higher compared to 90◦C in the previous experiment. After 30 minutes the
reaction in ACN showed an increase of the 18F-incorporation to 24% and reached after 45
minutes the value of 29% 18F-incorporation. The radiofluorination reaction in DMSO and
DMF showed a decrease of 18F-incorporation over 45 minutes (15-19%). Further optimization
studies in ACN at 130◦C showed that higher temperature led to higher 18F-incorporation and
in addition, a reaction time of 15 minutes was sufficient to give 18F-incorporation of 43%. This
result was consistent with the high 18F-incorporation observed in the radiosynthesis of trans-
3-[18F]fluorocyclobutyl 4-methylbenzenesulfonate [18F]34 (Section 3.7.1.1).
L-3[18F]FCBT was synthesized by treating the reaction mixture [18F]70 with 1 M HCl (aq.)
in ACN at 110◦C for 10 minutes. After purification of the crude product by semi-preparative
C18 HPLC, the desired product [18F]4 was obtained in low radiochemical yield (4%, decay
corrected) and high radiochemical purity (>99%), as shown in Figure 53.
Figure 53: Radio- and UV-chromatogram of the pure product [18F]4 (RT = 2.58 min).
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These reaction conditions were transferred to the TRACERlab FX F-N module (GE Health-
care, USA) for synthesis automatization. The product [18F]4 was isolated in surprisingly good
yields (27-37%, n=5, decay corrected) and excellent radiochemical purity (> 99%). The au-
tomatization of the synthesis can result in higher yields due to the optimized and standardized
18F-drying process and the temperature consistency of the reactor during the fluorination re-
action.
Unfortunately, the chiral HPLC analysis of the final product revealed racemization of [18F]4.
The chiral radio-HPLC chromatogram showed clearly a racemic mixture of [18F]4 and the two
radioactive compounds were identified by comparison with the non-radioactive compound 4
as shown in Figure 54.
Figure 54: (Top) Chiral radio-HPLC analysis of radiolabeled product [18F]4 and (bottom) co-elution of
the L-reference compound 4 containing 3% of the D-isomer.
Boc-protected tyrosine and other protected amino acids are known to racemize under basic
and sometimes also under acidic conditions [177, 178]. In the majority of cases the typical
radiolabeling procedure is carried out under basic fluorination conditions (e.g. K2CO3) and
elevated temperature which could promote racemization. The following three areas were in-
vestigated to minimize the racemization:
1. Decreasing the base, i.e. reduction from 2.0 eq. to 0.9 eq. base.
2. Using less basic catalyst system, i.e. 18-crown-6 ether/potassium bicarbonate (KHCO3).
3. Use of bulkier protecting groups, i.e. N-trityl instead of N-Boc protecting group.
1. In a typical experiment, the radiosynthesis was carried out using 1.5 - 2 equivalents of the
base K2CO3 and 1 equivalent of precursor. Reducing the base should result in less racemiza-
tion, therefore, the reaction was carried out with 0.9 equivalent of K2CO3. Unfortunately, this
led to lower F-18 incorporation and racemization was observed.
2. A less basic catalyst system to avoid racemization was reported recently in literature [142].
A combination of a mild base (KHCO3) and a neutral phase transfer catalyst (18-crown-6)
instead of K2.2.2/K2CO3 were tested. Radiolabeling of 54 with these conditions (110◦C for 15
min) failed to give the desired product.
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3. Since reduction of the racemization with the above mentioned methods failed, the bulkier
amino protecting group was evaluated.
3.7.2.3 Evaluation of the precursor tert-butyl O-[trans-3-(4-methylbenzenesulfonyl)-
cyclobutyl]-N-trityl-L-tyrosine (61) for direct radiolabeling
To avoid racemization during the fluorination reaction, a precursor with the more bulkier trityl
protecting group was evaluated as there are examples in the literature [152]. The precursor
61 was radiofluorinated followed by the acidic removal of the protecting groups to give the
desired product [18F]4 (Scheme 58).
Reagents:  (i) K2.2.2/K2CO3, ACN
[18F]F-
(i)
O
CO2tBuTrtHN
18F
61 [18F]71
O
CO2tBuTrtHN
OTs
O
CO2HH2N
18F
[18F]4
1 M HCl
Scheme 58: 18F-fluorination of the N-trityl precursor 61 followed by acidic hydrolysis.
The initial fluorination reactions to test if racemization occurs during radiolabeling was per-
formed ’by-hand’. The dried [18F]fluoride-cryptate complex was reacted with the precursor 61
(4 mg) in ACN. After 10 minutes, a 18F-incorporation of 19% was achieved which increased
after 25 minutes to 29%. The next step was the removal of the protecting groups with 1 M HCl
(100◦C for 10 min). The crude product was diluted with water acidified with 1 M HCl to pH 2
and trapped on a C18 environmental cartridge. The product was washed with water acidified
with 1 M HCl to pH 2 to remove polar impurities such as [18F]fluoride and finally, the product
[18F]4 was eluted with a 1:1 mixture of EtOH/water to give the desired product in 14% yield
(decay corrected) and good radiochemical purity (97%). The C18 and chiral HPLC analysis
are shown in Figure 55.
Chiral HPLC analysis showed no racemiziation of the synthesized product as demonstrated
in Figure 56.
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Figure 55: Radio- and UV-chromatograms of the product analysis with co-elution of refence compound
(text highlighted in red).
Figure 56: Chiral radio-HPLC chromatogram of the final product (top) and in comparison the UV-
chromatogram of the reference compound (bottom).
The HPLC analysis of the final product showed small non-radioactive impurities (Figure 55,
UV-trace) which could not be removed by solid-phase-extraction (SPE), especially the lipophi-
lic byproduct and therefore, an additional semi-preparative HPLC was necessary to remove
all impurities.
3.7.2.4 Evaluation of different leaving groups of the direct labeling precursor with trityl
protecting group (61, 63 and 64)
Three precursors with a tosyl- (61), nosyl- (63) and mesyl leaving group (64) were synthesized
to investigate the 18F-incorporation (Scheme 59). As mentioned earlier (see Section 3.6.4.2),
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the triflate precursor was synthesized as well but decomposed on storage (-30◦C for 24 h) and
was not tested.
Reagents:  (i) K2.2.2/K2CO3, ACN
1.  [18F]F-
(i)
2. 1 M HCl
O
CO2HH2N
18F
61  R = 4-methylbenzenesulfonate
63  R = 4-nitrobenzenesulfonate
64  R = methanesulfonate
[18F]4
O
CO2tBuTrtHN
R
Scheme 59: 18F-fluorination of the 4-methylbenzenesulfonate- 61, 4-nitrobenzenesulfonate- 63 and
methanesulfonate precursor 64 followed by acidic hydrolysis.
The precursor (2-2.5 mg, one of 61, 64 or 64) was dissolved in ACN and reacted with dried
[18F]fluoride-cryptate complex in presence of K2CO3 at 120◦C for 20 minutes. The 18F-
incorporations were followed for 30 minutes by radio-HPLC and are shown in Figure 57.
Figure 57: The effect of the leaging group in the F-18 incorporation at 120◦C over 30 minutes (parallel
experiments).
The chosen reaction conditions were best for the tosyl precursor 61. Longer reaction times
and increased temperature led with all precursors to formation of more byproducts. Quan-
titative removal of the protecting groups with 1 M HCl (100◦C for 10 min) gave the desired
product in low yield (6%, decay corrected). During hydrolysis step no racemization occured
which proved the chiral radio-HPLC compared with the L-reference compound 4 shown in
Figure 58.
The decision was made to use the mesylate precursor 64 for the imminent radiosyntheses
since the purification in the organic preparation of 64 is much easier than the synthesis of the
tosylate precursor 61 (see Section 3.6.4.2). Therefore, it was possible to synthesize a larger
amount of the desired precursor in shorter time.
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Figure 58: As a representative example, the chiral radio-HPLC analysis of the final product (top) with
co-elution of L-reference compound (bottom) are shown, starting with the mesylate precur-
sor 64.
3.7.2.5 Synthesis of L-3[18F]FCBT via the precursor tert-butyl
O-[trans-3-(methanesulfonyloxy)cyclobutyl]-N-trityl-L-tyrosine (64) in an
automated synthesizer
For biological evaluation of the tracer in cells an animals, high product activity concentrations
are needed, especially for in vivo metabolism studies. The consequence is to work with more
starting activity which is critical to safety regulations and personal health. To cope with that, the
radiosynthesis was transferred to the Modular-Lab synthesizer (Eckert&Ziegler, Germany) and
to the TRACERlab FX F-N synthesizer (GE Healthcare, USA) for synthesis automatization.
The mesylate precursor 64 and its reaction conditions were evaluated earlier (120◦C for 20
min). A precursor amount of 3-4 mg was considered to be optimal which was evaluated in
initial runs. The reaction was carried out in ACN followed by the removal of the protecting
groups with 1 M HCl (Scheme 60).
Reagents:  (i) K2.2.2/K2CO3, ACN
1.  [18F]F-
2. 1 M HCl
O
CO2HH2N
18F
64 [18F]4
O
CO2tBuTrtHN
OMs
Scheme 60: 18F-radiolabeling of the mesylate precursor 64 followed by acidic hydrolysis.
The dried [18F]fluoride-K2.2.2 complex was reacted with the precursor 64 in ACN at 120◦C for
15 minutes. The reaction mixture was then treated with 1 M HCl (100◦C for 10 minutes). The
crude product was purified by semi-preparative C18 HPLC, eluting with 80% acidified water
(pH 2, HCl)/ 20% acetonitrile and a flow of 4 ml/min.
The collected product fraction was diluted with water acidified with 1 M HCl to pH 2 and trapped
on a C18 environmental cartridge, washed with water acidified with 1 M HCl to pH 2 and
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eluted with a mixture of EtOH/phosphate buffered saline (PBS) to receive the product [18F]4
in an injectable solution in 17-26% radiochemical yields (n=4, decay corrected), excellent
radiochemical purities (> 99%, Figure 59), good specific activity (74-91 GBq/µmol) and no
racemization was observed (Figure 60).
Figure 59: Radiochemical- and UV purity of the formulated product [18F]4.
Figure 60: (a) Chiral radio-HPLC chromatogram of the formulated product [18F]4 with (b) co-elution of
the L-reference compound 4.
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3.8 Physicochemical and biological characterization of 3[18F]FCBT
3.8.1 Determination of the lipophilicity of the non-radioactive L-3FCBT
The lipophilicity is an important factor in the development and evaluation of new PET tracers
and can give biological, relevant information such as solubility, distribution in the body and
the capability of penetrating the cell membrane or blood-brain-barrier (BBB). The lipophilicity
of a compound is the solubility in a organic and aqueous solvent which are immiscible. The
determination of the partition coefficient P is performed typically with octanol and water. P
respectively POW has no dimension and is usually specified logarithmical (log P). Using the
aqueous solvent with a defined pH to determine the lipophilicity of protonated compounds
(usually pH 7.4 for amino acids) the log D is used. Lipophilicity values (log D) below 1 could
indicate a good solubility in vivo with low absorption and brain penetration as well as expected
renal clearance [54]. The lipophilicity for PET tracers are suggested to be log D < 3.5 which
allows good absorped and enough biomembrane- and blood-brain-barrier penetrating charac-
ter [179].
The log P, respectively log D values of the reference compound L-3FCBT and FET were cal-
culated and determined experimentally (Table 5).
Table 5: Calculated and experimental partition coefficient log P and log D of L-3FCBT and FET.
3FCBT FET
Method log P log D* log P log D*
ChemDraw 0.77 - 0.84 -
MarvinSketch 1.19 -1.08 1.12 -1.14
ACD 1.41 -1.9 1.26 -2.2
Experimental◦ - -0.83 - -1.51 [113]
◦ extractive * at pH 7.4
The calculation of the lipophilicity values were performed with commercially available soft-
wares (ChemDraw, version 12, CambridgeSoft; ACD ChemSketch, version 12.0, Advanced
Chemistry Development, Inc.) as well as a web-based program (MarvinSketch, ChemAxon).
The calculated lipophilicity values of L-3FCBT and FET are found to be in the similar range.
The negative log D values of both compounds indicated very hydrophilic character. These
calculated trends were confirmed by the experimental determination of the log D of L-3FCBT
and was found to be -0.83. This analysis was performed by Analytical Services at Bayer
HealthCare. Comparing the experimental value of FET found in literature (-1.51) [113], L-
3FCBT showed a higher lipophilicity. The log D value is clearly below 1 and therefore a very
hydrophilic compound which should not cross the blood-brain-barrier and could show renal
excretion.
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3.8.2 In vitro cell uptake assay of L-3[18F]FCBT
For further evaluation, the time dependent uptake of L-3[18F]FCBT in human lung carcinoma
cell lines (A549 and NCI-H460) and in the human prostate cancer cell lines (DU145) were
tested (Figure 61 a). The uptake of the tracer was measured at selected time points up
to 60 minutes. In addition, a competitive uptake experiment blocking with non-radioactive
FET and non-radioactive L-3FCBT was performed (Figure 61 b). The radiosynthesis of L-
3[18F]FCBT was carried out via the indirect labeling method which gave the product [18F]4
(see Section 3.7.1.5).
Figure 61: (a) Uptake of L-3[18F]FCBT into tumor cells in vitro. (b) Blocking of L-3[18F]FCBT uptake
by adding 1 mM non-radioactive L-3FCBT and non-radioactive FET. Experiments were per-
formed in triplicate.
All cell lines tested showed time dependent uptake of L-3[18F]FCBT into the tumor cells. Hu-
man lung carcinoma cells A549 showed after 10 minutes an uptake of 2.8% (105 cells) and
reached a maximum value of 5.8% after 30 minutes and remained at this value. The human
lung carcinoma cells (NCI-H460) and human prostate tumor cells (DU145) showed an uptake
of 0.7% (105 cells) after 10 minutes and reached a value of 1.7%, respectively 1.5% uptake
after 30 minutes and both increased to a value of 2.1% after 60 minutes. These cells showed
a linear uptake and did not reach a plateau after 60 minutes.
Next, the specificity of L-3[18F]FCBT in human lung carcinoma cell lines (A549 and H460)
and in the human prostate cancer cell lines (DU145) were tested. The competitive uptake
experiment showed that the uptake of L-3[18F]FCBT can be decreased in A549 cell lines by
85% by blocking with non-radioactive FET. Blocking with non-radioactive L-3FCBT showed a
decrease of 91%. The H460 and DU145 cell lines showed for blocking with FET and L-3FCBT
a decrease of 82%. The uptake of the tracer depends on the tracers binding affinity to the
amino acid transporter and the transporter rate. As it is known, four subtypes of large amino
acid transporters (LAT) were discovered (LAT1 to LAT4) with overlapping substrate selectiv-
ity [173]. It is suggested that L-tyrosine derivates are preferred to be transported by LAT1 [98].
Successful blocking of the tracer with FET is a strong evidence for the internalization of L-
3[18F]FCBT by the same transporter.
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3.8.3 Biodistribution in A549 tumor bearing mice
From the in vitro study results, further biological in vivo evaluations were conducted. The in
vivo biodistribution of L-3[18F]FCBT was performed in A549 tumor bearing nude mice to eval-
uate the distribution of the tracer in various organs and tissues at different timepoints (15, 30,
60, 120 and 240 min). This data provided important details about metabolism and biological
behavior of L-3[18F]FCBT in vivo. The radiosynthesis of L-3[18F]FCBT was performed via the
direct labeling method using the mesylate precursor 64 which gave the product [18F]4. The
data of the biodistribution in A549 tumor bearing mice is shown in Table 6.
The data clearly showed an accumulation of L-3[18F]FCBT in the tumor within 15 minutes af-
ter injection (3.3% ID/g). The tracer level was relatively stable up to 60 minutes (2.8% ID/g),
thereafter a decrease was observed after 120 minutes (1.0% ID/g) and after 240 minutes
(0.4% ID/g). The activity concentration in blood showed 15 minutes after injection the highest
value of 5.4% ID/g, decreased steadily to 3.8% ID/g at 30 minutes, then 2.3% ID/g at 60 min-
utes and 0.8% ID/g after 120 minutes which were in the same values found for kidney. The
uptake in the gallbladder showed after 15 minutes a value of 2.0% ID/g which decreased after
30 minutes to 1.7% ID/g and increased to 3.0% ID/g after 60 minutes and remained at this
level to 240 minutes. Liver showed an initial uptake (3.7% ID/g at 15 min) which decreased
over time and did not exceed the activity concentration in blood.
The liver, blood and kidney showed a fast distribution of the tracer, completed within 15 min-
utes after injection followed by a continuous renal clearance (t1/2 ≈ 60 min, Figure 62). The
half-life of the test compound was determined from the concentration-time plot. The clearance
reported for FET was slower (t1/2 ≈ 110 min) [113].
Figure 62: Uptake kinetics of L-3[18F]FCBT in liver, blood and kidney of A549 bearing mice (n=3).
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Table 6: Biodistribution of L-3[18F]FCBT in A549 bearing mice (n=3).
* Tissue aliquots only
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Bone uptake was not significant (1.9% ID/g at 15 min) and remained in the similar range over
240 minutes which indicated the metabolic stability of L-3[18F]FCBT. The pancreas showed a
high activity concentration after 15 minutes of injection (18.3% ID/g) which decreased slowly
over time (30 min: 15.2% ID/g, 60 min: 11.5% ID/g, 120 min: 4.2% ID/g, 240 min: 1.6% ID/g).
The high pancreas uptake in rodents has been observed with the tyrosine derivate [18F]FET,
as described in literature [71, 180], however, Langen et al. [71] reported in whole-body scans
of human only a low pancreas uptake was observed. The reason for these differences re-
mains unclear but it seems to be species specific. The high levels of activity found in urine
strongly suggests an elimination of L-3[18F]FCBT by renal excretion which is also indicated
by the high accumulation in the kidneys after 15 minutes p.i. (5.6% ID/g). 46% of the applied
dose was found in the urine after 60 minutes whereas radioactivity in feces was nonexistent.
Tracer uptake into the brain was low and reached the maximum after 60 minutes (0.5% ID/g),
thereafter a decrease was observed at 120 minutes (0.4% ID/g) and 240 minutes (0.2% ID/g).
For comparison, [18F]FET showed in colon carcinoma-bearing mice brain uptake with a max-
imum at 30 minutes (5.6% ID/g), thereafter the activity concentration decreased [113] which
could be due to the higher lipophilicity of L-3FCBT compared to FET. LAT1 has been shown
to be present at the blood-brain-barrier [181, 182] which allowing large amino acids to pass
the blood-brain-barrier and entering the brain. It is believed that the low brain uptake is due
to a low expression of LAT1 at the blood-brain-barrier and is subject to further investigations.
L-3[18F]FCBT showed similar values as [18F]FET in liver, kidney bone, heart and blood. Inter-
estingly, L-3[18F]FCBT showed lower tracer levels in pancreas, spleen, lung, muscle and skin
as [18F]FET. Only the tumor uptake (colon carcinoma) with [18F]FET (5.6% ID/g at 30 min)
showed higher activity concentration than with L-3[18F]FCBT (3.1% ID/g at 30 min).
The tumor-to-blood ratio has proved useful as an indicator for tracer uptake. With a tumor-to-
blood ration greater than 1 the tumor is differentiated from the background (mainly blood). In
the uptake of L-3[18F]FCBT, the tumor-to-blood radio is increasing for 60 minutes to a maxi-
mum of 1.3 which means an improvement of the background (Figure 63). The tumor-to-muscle
ratio rapidly increased to a maximum of 2.8 (60 min) following a decrease to 2.5 (120 min) and
remaining at this level (240 min).
3.8.4 Animal PET/CT imaging of D- and L-3[18F]FCBT
L-3[18F]FCBT was further investigated in animal PET/CT imaging. The preparation of L-
3[18F]FCBT was performed via the direct labeling method using the tosyl precursor 54 which
was later discovered to be a racemate (D/L-isomer 1:1). The human lung carcinoma cells
(A549) showed a high in vitro uptake and therefore, A549 bearing nude mice were used for
the PET/CT imaging study. The A549 tumor cells were transplanted subcutaneously. In Fig-
ure 64, the PET/CT imaging of two A549 bearing mice with different injection time points are
shown.
In a first PET/CT study, two A549 bearing mice were injected with DL-3[18F]FCBT. In contrast
to human PET imaging, the scan process for animals must involve immobilization achieved
by anesthesia [183]. This may influence the tracer distribution and elimination in vivo as re-
cently reported for [18F]FMT [30]. The first animal (Figure 64 a), which was narcotized before
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Figure 63: Time dependent tumor-to-blood- and tumor-to-muscle ratio of L-3[18F]FCBT in A549 tumor
bearing mice (n=3).
Figure 64: Animal PET/CT image of DL-3[18F]FCBT in A549 bearing nude mouse, (a) mouse 1 (MIP
10-70 min p.i.) and (b) mouse 2 (MIP 60-120 min p.i.).
3 RESULTS AND DISCUSSION 101
DL-3[18F]FCBT injection, showed no tumor accumulation up to 70 minutes of scan time. This
was accounted to be due to the anesthesia before tracer injection. However, high activity
concentrations were observed in heart, kidneys and pancreas. A high urinary excretion was
observed (bladder/urine) which is typical for tyrosine analogs [173].
The second animal (Figure 64 b) was injected 30 minutes before anesthesia. DL-3[18F]FCBT
showed higher accumulation in tumor than surrounding background (60-120 min p.i.). The
tumor uptake was found to be 3.4% ID/g in average. Moreover, high accumulation in pan-
creas and gallbladder as well as renal excretion (bladder/urine) were observed. These re-
sults were consistent with the data found in the biodistribution and are typical for tyrosine
analogs [71, 151].
In several examples of tyrosine derivated PET tracers, a faster elimination of the D-isomer
compared to the L-isomer was found [104] (see Section 3.2). In another animal PET/CT
study, L-3[18F]FCBT and D-3[18F]FCBT were injected in conscious H460 tumor bearing mice
(Figure 65).
Figure 65: Animal PET/CT image in H460 bearing nude mice, (a) mouse 1 injected with L-3[18F]FCBT
(MIP 60 min p.i.) and (b) mouse 3 with D-3[18F]FCBT (MIP 60 min p.i.).
The animal with L-3[18F]FCBT injected showed a high tumor uptake of 4.7% ID/g after 60
minutes p.i. (mouse 1). The activity concentration in the tumor decreased after 90 minutes p.i.
to 2.1% ID/g (mouse 2). However, high activity concentration were observed in gallbladder,
pancreas, bladder and urine (Figure 65 a). These results were consistent with the previous
animal PET/CT study (DL-3[18F]FCBT) and biodistribution using L-3[18F]FCBT.
The animal which was injected with the pure D-isomer showed low accumulation in the tumor
of 1.5% ID/g after 60 minutes (Figure 65 b, mouse 3). This value remained up to 90 minutes at
1.5% ID/g (mouse 4). Moreover, high activity concentration was found in gallbladder, kidneys,
bladder and urine. Surprisingly, the pancreas uptake known to be high for tyrosine analogs
was very low, compared to L-3[18F]FCBT. The D-isomer showed faster clearance since the
human body considers the D-isomer as an unnatural amino acid and eliminates it fast. Both
102 3 RESULTS AND DISCUSSION
findings were described by Tsukada et al. [104]. Surprisingly, D-isomers showed accumulation
of activity in backbone and joints. This result, however, seems to be at odds with previous
findings of the L-isomer’s excellent metabolic stability (biodistribution, in vitro- and in vivo
stability studies) and it was not expected to find less stability for the D-isomer which the animal
PET/CT image demonstrated.
3.8.5 Investigation of the in vitro and in vivo stability
The investigation of the tracer’s stability is a main focus in this work and was evaluated in vitro
using rat hepatocytes, human and rat plasma and phosphate buffer solution as well as in vivo
in mice. The "rat hepatocytes stability analysis" was performed by DMPK (Bayer HealthCare,
Berlin).
3.8.5.1 Determination of in vitro metabolic stability in rat hepatocytes
First, the stability of the non-radioactive reference compound L-3FCBT and non-radioactive
FET were tested in an in vitro experiment using rat hepatocytes. The hepatocytes were iso-
lated from Han Wister rats. The metabolic stability was examined by incubating L-3FCBT and
FET for 2, 8, 16, 30, 45, 60 and 90 minutes and analyzing by HPLC-MS. Both L-3FCBT and
FET showed no metabolic degradation over a period of 90 minutes.
3.8.5.2 Determination of in vitro plasma stability
In the next biological evaluation, the stability of L-3[18F]FCBT and [18F]FET was determined
in plasma. L-3[18F]FCBT and [18F]FET were incubated in human and rat plasma as well as in
phosphate buffer solution for up to 120 minutes and analyzed by radio-HPLC and radio-TLC
at different time points (0, 30, 60, 90, 120 min), as shown in Figure 66 and 67.
Figure 66: In vitro stability of L-3[18F]FCBT in human plasma over 120 minutes; radioactivity signals of
radio-HPLC (left) and radio-TLC (right). Rat data identical - not shown.
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Figure 67: In vitro stability of [18F]FET in human plasma over 120 minutes with an enlarged region of
the main peak with a radio-peak (red arrow). Radioactivity signal of radio-HPLC (left) and
radio-TLC (right). Rat data identical - not shown.
L-3[18F]FCBT and [18F]FET showed high radiochemical purity (> 99.9%) at time point 0 (con-
trol) in human and in rat plasma. L-3[18F]FCBT showed over 120 minutes an excellent stability
(> 99.9%) in human as well as in rat plasma. [18F]FET showed similar stability for 120 minutes.
The compounds were also stable in phosphate buffer solution over 120 minutes. Interestingly,
in [18F]FET, a more polar radio-peak could be observed after 60 minutes in human and rat
plasma (Figure 67). The radioimpurity remained up to 120 minutes at 0.6% which is marginal.
A formation of metabolites would increase the percentage of the polar peak over time which
was not observed. [18F]FET is routinely used in clinic and is known to be metabolically rela-
tively stable in vivo [105]. It is reported that after injecting of [18F]FET into human, the intact
FET to be found is 95% after 5 minutes and about 87% after 2 hours [71, 184].
3.8.5.3 Determination of in vivo stability in mice
Furthermore, the in vivo stability of L-3[18F]FCBT was evaluated. The tracer was intravenously
injected into mice. Blood and urine were taken from the sacrificed animals at time points 5, 15
and 30 minutes, then plasma proteins were precipitated and the supernatant was analyzed by
radio-HPLC and radio-TLC. The results are shown in Table 7.
In radio-HPLC analysis, L-3[18F]FCBT showed in plasma after 5 minutes 98% of intact tracer
which decreased to 95% after 15 minutes and 94% after 30 minutes. The results obtained
with the radio-TLC method were in the similar range as the radio-HPLC method with 93% of
intact tracer after 5 minutes which decreased to 92% over 15 minutes and were found to be
89% after 30 minutes. The two analytical methods (radio-HPLC and -TLC) showed to be con-
sistent and [18F]FCBT can be considered as relatively stable tracer in vivo which showed very
little radiometabolite formation in plasma. Nevertheless, radiometabolites were shown to be
increasing over time, but almost 90% of the parent compound remained intact for 30 minutes.
Due to the a fast renal excretion and low total activity remaining in plasma, longer time points
could not be measured.
The percentage of intact L-3[18F]FCBT in urine were expected to be lower due to further
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Table 7: Radio- HPLC and radio-TLC results of an in vivo stability experiment with L-3[18F]FCBT of
mice. The tracer was injected i.v., the animals were sacrificed after certain time points up to
30 minutes and blood (left) and urine (right) were taken and analyzed (n=3). 0* represents the
control.
Plasma (HPLC)
Time Stability SD
(min) (%) (%)
0* 99.68 0.45
5 98.09 0.02
15 94.63 5.54
30 93.71 7.53
Urine (HPLC)
Time Stability SD
(min) (%) (%)
0* 99.68 0.45
5 77.58 31.71
15 83.64 22.64
30 71.61 17.58
Plasma (TLC)
Time Stability SD
(min) (%) (%)
0* 98.63 0.48
5 92.45 1.47
15 91.83 2.20
30 89.01 4.83
Urine (TLC)
Time Stability SD
(min) (%) (%)
0* 98.64 0.49
5 78.04 5.47
15 48.77 3.57
30 57.44 9.19
metabolism of the tracer during the renal excretion process. Analysis of the urine by radio-
HPLC showed that already after 5 minutes after injection 78% of intact tracer was found which
decreased to 72% after 30 minutes. The analysis using the radio-TLC method showed after 5
minutes 78% of intact tracer in urine which decreased after 15 minutes of injection to around
50% and remained approximately at the same level. Comparing the two methods, the radio-
HPLC showed in general higher stability values with high deviation whereas the radio-TLC
showed lower stability values with low deviation were found. However, the lower urine stability
of the PET tracer is not critical for good PET imaging.
Summary
In summary, in vivo stability in mice of L-3[18F]FCBT showed very little metabolites which is
consistent with the results of the biodistribution and in vitro plasma stability in human and rat
plasma. The lower stability found in urine was expected and not critical for good PET imaging.
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4 Summary and Outlook
Positron emission tomography (PET) is a powerful tool for the early detection of various dis-
eases, using radiolabeled biologically active substances labeled with PET radionuclides e.g.
11C, 18F to non-invasivially visualize a disease progression. These PET tracers are subject to
biotransformation in vivo which can form radioactive metabolites. These radiometabolites are
typically a Cytochrome P450 dealkylation product and can lead to high background in PET
imaging which decreases the accuracy for detection of diseases such as carcinomas. Exam-
ples for in vivo PET tracer metabolism are found in literature [64, 66, 67]. There is a demand
for PET tracers with increased metabolic stability to guarantee good quality of PET images.
The aim of this work was to investigate whether [18F]fluorocyclobutyl rings can be intro-
duced into biolocially active small molecules to increase the metabolic stability of PET trac-
ers whilst maintaining its efficacy. To test this hypothesis, the tyrosine model compound, O-
(3-[18F]fluorocyclobutyl)-L-tyrosine (L-3[18F]FCBT), was chosen to be investigated since the
tyrosine analog [18F]FET is a widely used PET tracer for brain cancer diagnosis in the clin-
ics [71, 185]. The targeting structure [18F]4 (Figure 68) could be synthesized using either an
indirect or a direct labeling methods.
O
CO2HH2N
18F
[18F]4
Figure 68: Targeting structure O-(3-[18F]fluorocyclobutyl)-L-tyrosine (L-3[18F]FCBT).
Both radiolabeling methods offer advantages:
• Indirect method: fast access to desired tracer via intermediate prosthetic group.
• Direct method: higher yields and shorter radiosynthesis time.
Organic syntheses
The building block cis-3-(benzyloxy)cyclobutanol 11 (Scheme 61) was synthesized in a multi-
step synthesis starting from the commercially available epibromohydrin. The first 3 steps are
literature known to give 3-(benzyloxy)cyclobutanone [92, 116–118]. Reduction of this ketone
gave the cis-3-(benzyloxy)cyclobutanol 11 in good yield. The preparation of the precursors
for the indirect labeling method was carried out in three steps using the building block 11
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to give the bis-tosyl precursor 20 in 65% yields (3 steps). Additional precursors with differ-
ent leaving groups (methanesulfonate 21, 4-nitrobenzenesulfonate 22, 2,3-dibromobenzene-
sulfonate 33) were synthesized to investigate whether the leaving group has an effect on the
18F-incorporation and the subsequent alkylation reaction of the 18F-labeled prosthetic cyclic
sulfonates to tyrosine (Scheme 61). The same objective was investigated with the trans-bis-
tosyl precursor 29 (Scheme 61).
20  R = 4-methylphenyl
21  R = methyl
RSO2O OSO2RBnO OH
11
RSO2O OSO2R
22  R = 4-nitrophenyl
33  R = 2,3-dibromophenyl
29  R = 4-methylphenyl
Scheme 61: Syntheses of different precursors for indirect radiolabeling.
In addition, the direct precursors were successfully synthesized via the Mitsunobu reaction of
different protected tyrosine, containing a free phenolic group, with the cyclobutanol building
block 11. Subsequent debenzylation and sulfonation gave the desired precursors 49, 54, 61
and 64 in 4-65% overall yields (Figure 69).
49  PG1 = Boc, PG2 = Me, R = 4-methylphenyl
54  PG1 = Boc, PG2 = tBu, R = 4-methylphenyl
61  PG1 = Trt, PG2 = tBu, R = 4-methylphenyl
64  PG1 = Trt, PG2 = tBu, R = methyl
O
CO2PG2PG1HN
OSO2R
Figure 69: Synthesized precursors for direct radiolabeling.
In the radiolabeling of precursor 49 the cleavage of the methyl ester requires basic conditions
which promotes racemization. In addition, the removal of the N-Boc protecting group adds an
extra hydrolysis step, therefore, the precursor 54 with acid labile protecting groups (Boc and
tBu) was synthesized. Unfortunately, this precursor showed a high degree of racemization
during the radiolabeling reaction. To prevent this racemization a precursor with the bulkier
trityl protecting group on the amino function enabling a single-step hydrolysis was envisaged.
Following the established method via the Mitsunobu reaction using Trt-Tyr-OtBu and the cy-
clobutanol building block 11 gave the desired product but it was not possible to selectively
remove the benzyl group without affecting the trityl group using numerous catalytic hydro-
genation methods. A new approach to synthesize the trityl-precursor 61 was pursued via the
selective removal of the Boc protecting group of the alcohol 53 and subsequent introduction
of the trityl protecting group. This approach was successful and subsequent sulfonation gave
the desired N-trityl precursors (4-methylbenzenesulfonate 61 (16%), 4-nitrobenzenesulfonate
63 (23%) and methanesulfonate 64) (72%)) as shown in Scheme 62.
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O
CO2tBuH2N
OH
53
O
CO2tBuBocHN
OH
60
O
CO2tBuTrtHN
OH
57
O
CO2tBuTrtHN
OSO2R
61   R = 4-methylphenyl
63   R = 4-nitrophenyl
64   R = methyl
HCl in 
dioxane
56%
Ts2O or
NsCl or
Ms2O
16%
23%
72%
TrtCl
62%
Scheme 62: Synthesized precursors for direct radiolabeling.
The reference compound 4 was successfully synthesized in an analogous manner to the direct
precursor syntheses using the Mitsunobu reaction of cis-3-(benzyloxy)cyclobutanol 11 with
the commercially available Boc-Tyr-OMe, followed by removal of the benzyl group, fluorination
using diethylaminosulfur trifluoride (DAST) and then removal of the protecting groups to give
4 in 13% yields (Figure 70). The D-isomer analog 47 was prepared via the same route with
the Boc-D-Tyr-OMe starting material in 5% yield (Figure 70).
O
CO2HH2N
F
O
CO2HH2N
F
4 47
Figure 70: L- 4 and D-3FCBT 47 reference compound.
Radiosyntheses
In order to optimize the no-carrier-added (n.c.a) indirect 18F-radiolabeling of the bis-tosylate 20
different bases (K2CO3, Cs2CO3, TBAOH, TBAHCO3), solvents (ACN, DMF, DMSO, tBuOH/-
ACN) and temperature were tested and found to be best reacting in ACN at 130◦C for 15
minutes to give [18F]34 with high 18F-incorporation (60-80%, n=15). In the next step the crude
[18F]34 had to be purified to ensure successful alkylation of tyrosine to give the desired product
[18F]4. Semi-preparative HPLC provided pure intermediate but simple C18 cartridge purifica-
tion was found to be sufficient in removing unreacted [18F]fluoride and other polar impurities.
The purified intermediate [18F]34 was reacted with tyrosine via an alkylation reaction at 150◦C
(15 min), either using the disodium tyrosine salt method or in situ activation of tyrosine with
sodium hydroxide. The in situ method was found to give better radiochemical yields after
110 4 SUMMARY AND OUTLOOK
HPLC purification and reformulation (6-14%, decay corrected) than the disodium tyrosine salt
method (4-6%, decay corrected). The D-isomer was prepared using an analogous method
using D-tyrosine (150◦C, 15 min) and gave D-3[18F]FCBT in 16% yield (decay corrected) and
high radiochemical purity (> 99%).
Different sulfonates were tested to investigation whether the leaving group had an effect on
the radiofluorination reaction (Scheme 63).
20
21
22 
33
RO2O OSO2R 18F R
[18F]34
[18F]65
[18F]66
[18F]67
R = 4-methylphenyl
R = methyl
R = 4-nitrophenyl
R = 2,3-dibromophenyl
[18F]F-
Scheme 63: Radiofluorination of cyclic bis-sulfonyl precursors.
The bis-tosylate 20 and bis-(3,4-dibenzenesulfonate) 33 showed the best 18F-incorporation
with 65% and 58% respectively, when reacting under the optimized conditions found for 20.
The bis-mesyl precursor 21 led to a 30% incorporation and bis-nosyl precusror led to a 5%
18F-incorporation. Interestingly, the alkylation of the bis-sulfonates to L-tyrosine at 150◦C (15
min) in DMSO followed the same pattern as observed in the fluorination reactions: best con-
version was found with [18F]34 (82%) and [18F]67 (69%) with [18F]65 showing only low con-
version (4%) and [18F]66 gave no conversion. Comparing the 18F-incorporation and alkylation
conversion of 20 (cis) and 29 (trans) showed no significant difference in 18F-incorporation as
well as in the alkylation reactions.
The radiolabeling of 54 via the direct method was investigated and the best conditions were
found with the [18F]fluoride-K2.2.2 complex in presence of K2CO3 at 130◦C (15 min) in ACN
(Scheme 64). After removal of the protecting groups with 1 M hydrochloric acid the desired
product [18F]4 was obtained in 27-37% yields (decay corrected) and excellent radiochemical
purity (> 99%).
Reagents:  (i) K2.2.2/K2CO3, ACN
[18F]F- 
(i)
O
CO2OtBuBocHN
18F
54 [18F]70
O
CO2tBuBocHN
OTs
O
CO2HH2N
18F
[18F]4
1 M HCl
Scheme 64: 18F-fluorination of precursor methyl tert-butoxy N-(tert-butoxycarbonyl)-O-[trans-3-(4-
methylbenzenesulfonyloxy)cyclobutyl]-L-tyrosinate 54 following acidic hydrolysis.
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As mentioned earlier, the radiolabeling of this N-Boc protected precursor 54 for direct labeling
led to racemization; numerous attempts to minimize the racemization failed (e.g. decreasing
the base or using milder bases). Using the trityl-precursor 61 and the same radiolabeling
conditions described for 54, the desired product [18F]4 was isolated and pleasingly showed no
racemization (Scheme 65).
Reagents:  (i) K2.2.2/K2CO3, ACN
[18F]F-
(i)
O
CO2tBuTrtHN
18F
61 [18F]71
O
CO2tBuTrtHN
OTs
O
CO2HH2N
18F
[18F]4
1 M HCl
Scheme 65: 18F-fluorination of the N-trityl precursor 61 followed by acidic hydrolysis.
The radiosynthesis was transferred to an automated synthesizer to allow for large product
batches and for high specific activity or in vivo metabolism studies. The mesyl precursor 64
was chosen because the 18F-fluorination was similar to the tosyl analog 61 but the purification
was simpler and laberious. The fluorination reaction in the automated synthesizer was car-
ried out with the dried [18F]fluoride-K2.2.2 complex and the precursor 64 at 120◦C (15 min)
in ACN. After removing the protecting groups using 1 M HCl at 100◦C (10 min) the desired
product [18F]4 was received in 17-26% radiochemical yields (decay corrected), excellent ra-
diochemical purity (>99%) and good specific activity (74-91 GBq/µmol).
Biological evaluation
The in vitro evaluation of L-3[18F]FCBT was performed by determining the uptake of [18F]4
in human lung carcinoma cell lines (A549 and NCI-H460) and in human prostate cancer cell
lines (DU145). All cell lines demonstrated a time dependent uptake of the tracer, the A549
cell lines showed the highest uptake and reached a plateau of 5.8% after 30 minutes. The
specificity of L-3[18F]FCBT in A549, NCI-H460 and DU145 cells were tested in a competitive
uptake experiment using the non-radioactive L-3FCBT and non-radioactive FET and the up-
take of L-3[18F]FCBT was blocked. This strongly suggests that the transport of L-3[18F]FCBT
into the cell is by the same transporter as FET, namely the large amino acid transporter (LAT).
The tracer L-3[18F]FCBT was further evaluated radiopharmacologically performing a biodistri-
bution in A549 tumor bearing mice which showed a clear tracer accumulation in the tumor over
time. High activity concentration was found in gallbladder, pancreas and bladder which is typ-
ical for tyrosine analogs [71, 113, 151]. The liver, blood and kidneys showed a fast distribution
of the tracer, followed by a continuous renal clearance. Bone uptake was not significant and
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remained in the same range over time, thus, indicating the metabolic stability of L-3[18F]FCBT
to defluorination. The tracer showed similar values as [18F]FET in liver, kidney bone, heart and
blood. Interestingly, L-3[18F]FCBT in comparison with [18F]FET, showed lower tracer levels in
pancreas, spleen, lung and muscle. The tumor-to-blood ratio were found to be 1.3 and 2.8 at
60 minutes p.i., respectively.
In animal-PET/CT imaging of A549 tumor bearing mice showed clearly an uptake of [18F]4
into the tumor (3.4% ID/g) and a high activity concentration in gallbladder, pancreas and blad-
der which confirmed the biodistribution results. In several examples of tyrosine derivated PET
tracers a faster elimination of the D-isomer compared to the L-isomer was found [104]. D-
3[18F]FCBT showed a lower accumulation in the tumor (2.1% ID/g) than the L-3[18F]FCBT
and high activity concentrations in the gallbladder, kidneys, bladder and urine. Interestingly,
the pancreas uptake of the D-isomer was very low in comparison to the L-3[18]FCBT. The D-
isomer also showed a faster clearance than the L-3[18F]FCBT.
The stability of L-3[18F]FCBT in human and rat plasma was tested in vitro. The tracer was
found to be stable in both human and rat plasma over 120 minutes (> 99%). In vivo stability in
mice of L-3[18F]FCBT showed very little metabolites which is consistent with the results of the
biodistribution and in vitro plasma stability in human and rat plasma.
Conclusion
In conclusion, L-3[18F]FCBT showed good tumor uptake in human lung carcinoma cell lines
(A549) and was able to be blocked by both non-radioactive L-3FCBT and non-radioactive FET.
In the biodistribution study (n = 3), the tracer demonstrated tumor uptake and high metabolic
stability due to non accumulation of activity in bone. These results were consistent with the
animal-PET imaging where L-3[18F]FCBT showed good tumor uptake and no accumulation
of activity in the bone. The D-isomer in comparison with the L-isomer was found to give
lower tumor uptake and very low accumulation in the pancreas. The in vitro stability of the
L-3[18F]FCBT in human and rat plasma was excellent over 120 minutes. In vivo stability in
mice showed very little metabolites (< 10% over 30 min) and L-3[18F]FCBT is considered to
be stable in vivo.
These results have shown that the new [18F]fluorocyclobutyl group has the potential for the
preparation of metabolically stable radiotracers and the application looks very promising.
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Outlook - Possible future work on radiofluorinated cyclobutyl derivatives
The results demonstrated that the tyrosine analog L-3[18F]FCBT was taken up and accumu-
lated in the tumor and more important, showed excellent metabolic stability in vitro as well as
in vivo. The results of the blocking study suggested the internalization via the LAT which has to
be further investigated by performing BHC (2-amino-bicyclo-[2,2,1]heptane-2-carboxylic acid)
and sodium dependency tests. Also other cell lines could be tested such as human non-small
cell lung cancer cell lines (PC-3) or human colorectal carcinoma cell lines (SW 707). Fur-
thermore, the influence of the cis- and trans-isomer of 3[18F]FCBT in tumor uptake would be
interesting to investigate.
The next step would be the application of the cyclobutyl prosthetic group to other tracers
known for their metabolic instability. A selection of interesting cyclobutyl analogs of the DAT
radiotracer [18F]FECNT, vesicular acetylcholine transporter ligand [18F]FEOBV or the TSPO
radiotracer [18F]DPA714 are shown in Figure 71.
N
CO2Me
Cl
N
O
HO
N
N N
O
NEt2
O
18F18F
18F
[18F]DPA714 analog[18F]FEOBV analog[18F]FECNT analog
Figure 71: Suggestions for potential tracers with increased metabolic stability.
The 18F-labeled cyclobutyl analogs could be synthesized via the established indirect radio-
labeling method, as demonstrated in an example of DPA714 in Scheme 66. This gives a fast
access to the desired tracer for biological evaluation.
TsO
18F
TsO
OTs
[18F]F-
(i)
DPA714
(phenol)
(ii)
Reagents:  (i) K2.2.2/K2CO3, ACN 
                  (ii) NaOH (aq.), DMSO
N
N N
O
NEt2
O
18F
[18F]DPA714 analog
Scheme 66: Suggested radiosynthesis of cyclobutyl analogs via the indirect radiolabeling approach in
the example of DPA714.
For the phenolic compounds such as FEOBV or DPA714, the syntheses of the corresponding
non-radioactive reference compound and direct labeling precursor could be carried out using
the established synthesis route via the Mitsunobu reaction, as illustrated in Scheme 67.
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O
OH
R
OH
R
O
F
R
O
LG
R
Direct precursor
LG = Leaving group
Mitsunobu
Reference compound
Scheme 67: Suggested synthesis route of the reference compounds and direct labeling precursors.
The syntheses of the FECNT cyclobutyl analog reference compound (see Figure 71) and the
precursor for direct labeling could be carried out via the reductive amination reaction [186]
using a nortropine analog with the protected ketone such as 3-(benzyloxy)cyclobutanone, as
demonstrated in Scheme 68.
R1
NH
R1
R
N
R
OH
O
OPG
PG = Protecting group
R
N
R
F
R
N
R
LG
Reductive
amination
Scheme 68: Suggested synthesis route of the reference compounds and direct labeling precursors.
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5 Experimental
5.1 Material and methods
All solvents and chemicals unless otherwise stated were purchased from Aldrich (Germany),
Fluka (Switzerland), Acros Organics (Belgium), ABCR (Germany) or Merck (Germany) and
used without further purification. The [18F]fluoroethyl-L-tyrosine (FET) reference compound
was purchased from ABX GmbH (Germany). Sep-Pak c© QMA light, Sep-Pak c© C18 light,
Sep-Pak c© C18 Environmental and Sep-Pak c© dry were obtained from Waters (USA). Evap-
oration processes were carried out with the Büchi Rotavapor R-124 using a Büchi Waterbath
B-480. Silica chromatography was performed on Biotage Isolera Flash Purification System
from Biotage R© (Sweden) with corresponding SNAP cartridges (10-340 g silica gel); solvent
gradient were generated automatically, entering Thin-layer chromatography (TLC) values and
were run in general from 5% of the weak solvent to 100% of the strong solvent in 10 column
volumes. TLC was carried out with silica gel plates (TLC Silica gel 60 F254, 20 x 20 mm)
from Merck (Germany) visualized under UV at 254 nm. High performance liquid chromatora-
phy (HPLC) system used an Agilent 1100 and 1200 HPLC system with a binary pump, au-
tosampler and diode array detector (DAD) and an attached gamma-detector (NaI) GABI from
Raytest, using the Agilent ’ChemStation’ software. Semi-preparative Knauer HPLC system
consisted of a Knauer pump, UV detector and an attached gamma-detector (NaI) GABI from
Raytest using the Knauer ’ChromGate’ software. Solvent pH was adjusted with the Knick pH-
meter 766 Calimatic using a Knick SE100N pH/Pt 1000 sensor (pH 0-14). UPLC/MS system
consisted of a Waters ACQUITY UPLCs Column Manager, ACQUITY UPLC PDA (photodiode
array detector) and ACQUITY SQD (MS). Analytical HPLC column ACE C18 (50 x 4.6 mm)
from ACE (Great Britain), the Astec Chirobiotic T Chiral HPLC column (250 x 4.6 mm) from
Sigma-Aldrich (Germany) and the Phenomenex Luna 5 µm C18 100 Å LC Column (250 x
4.6 mm) from Phenomenex (USA). Semi-preparative HPLC column was performed with ACE
C18 (250 x 10 mm) from ACE (Great Britain) and Phenomenex Synergi Hydro-RP 4µ (250
x 10 mm) from Phenomonex (USA). Mass spectra (MS) were obtained on a ZQ 4000 LC
and LCT TOF mass spectrometer from Waters/Micromass (USA) for electrospray ionisation
(ESI) and a DSQ CTC from Thermo Scientific (USA) for chemical ionization (CI) (analyti-
cal department, Bayer HealthCare, Berlin). 1H, 13C and 19F nuclear magnetic resonance
(NMR) spectra were recorded with the Bruker AVANCE-300 and 400 MHz and the Bruker
DRX-600 NMR spectrometer (analytical department, Bayer HealthCare, Berlin). For NMR
measurements substances were dissolved in CDCl3, d6-DMSO or CD3OD and the measured
chemical shifts are specified in δ ppm. The assignments of the NMR signals are performed
by estimation of increments. Dry freezing was performed on LyoVac GT 2E from Finn-Aqua
(Germany). Automated radiosyntheses were performed on GE Healthcare TRACERlabTM FX
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F-N (non-standard-configuration) with semi-preparative HPLC and a UV detector K-2001 from
Knauer and on the Eckert&Ziegler Modular-Lab module with a semi-preparative HPLC and a
UV detector K-2001 from Knauer. [18F]fluoride was received from the cyclotron of Helmholtz-
Zentrum Dresden-Rossendorf, Klinik und Poliklinik für Nuklearmedizin in Leipzig (Germany),
Charité Berlin in Berlin (Germany) or Eckert & Ziegler in Adlershof in Berlin (Germany). The
radio-TLC phosphorimager screens were read out with Storm 825 from GE Healthcare (USA)
and the software ’ImageQuant 5.2’. The Countess Automated Cell Counter from Invitrogen
(USA) was used for cell counting. The in vitro biosamples were shaken at a designated tem-
perature with the Thermomixer Comfort from Eppendorf (Germany) and precipitation were
performed using the Biofuge primo R centrifuge from Heraeus (USA). Radioactive biosam-
ples were measured with the Automated Gamma Counter 1480 Wizard 3" from Perkin Elmer
(USA). PET/CT images were acquired with the Siemens Inveon Preclinical PET/CT (integrated
version) and the software ’Inveon Acquisition Workplace’ and ’Inveon Research Workplace’
from Siemens (Germany).
5.1.1 Radioananalytical methods
Identification of the products and determination of the radiochemical yields (RCY) both ra-
dio high performance liquid chromatography (radio-HPLC) and radio thin layer chromatogra-
phy (radio- TLC) were performed. All 18F-labelled compounds were identified by their non-
radioactive reference compounds via comparison of the retention times (UV-signals to radio-
active signals). Retention time difference of 0.2 minutes had to be considered due to the
HPLC setup.
Radio-HPLC
All radio-HPLC analysis were performed on the system described in Section 5.1 with a ACE
3 C18 (50 x 4.6 mm) column using a gradient system starting from 95% water+0.1% TFA/5%
ACN+0.1% TFA and reaching 95% ACN in 7 minutes with a flow of 2 ml/min. Reaction control
was performed taking an aliquot of the reaction mixture to give approximately 1-2 MBq of ac-
tivity and diluted in water (100 µl) and injected into the radio-HPLC. The product was identified
by comparing the retention times of the reference compound (± 0.2 mins).
Chiral radio-HPLC: Chiral HPLC was performed on a Astec Chirobiotic T Chiral HPLC col-
umn (250 x 4.6 mm) using isocratic solvent 70% EtOH/ 30% water with a flow of 1 ml/min.
An aliquot of the product (1-2 MBq) was diluted in water (100 µl) and injected into the HPLC
system.
Specific activity: In order to determine the specific activity a calibration curve with the non-
radioactive L-3FCBT 4 was prepared with a concentration range of 5 µg/ml to 40 µg/ml (Fig-
ure 72). Injection of a high amount of radiolabeled tracer (∼ 50 µl) gave the integrated UV
signal (mAUs) and therefore the corresponding concentration of non-radioactive product in
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the sample. With the known activity (measured) and the concentration of non-radioactive
L-3FCBT in the sample, the specific activity could be calculated.
Figure 72: Integral of the UV signal as a function of the concentration of 4 (n=2).
Radio-TLC
Radio-TLC was performed on silica gel plates (TLC Silica gel 60 F254, 20 x 20 mm) from Merck
(Germany) with the solvent mixture of Butanol/AcOH/H2O 12:3:5. After TLC development of
about 1 hour the radio-TLC was exposed to a phosphor screens on measured with the STORM
825 from GE Healthcare (USA). The same method was used for in vitro and in vivo stability
studies.
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5.2 Organic syntheses
5.2.1 Syntheses of precursors for indirect labeling and reference compound
2-Benzyloxy-1,3-dibromopropane (9)
O
Br
Br
The mixture of epibromohydrin (20 g; 146 mmol), benzyl bromide (25 g; 146 mmol) in pres-
ence of mercury (I) chloride (26 mg: 0.06 mmol) was reacted at 160◦C for 8 hours, according
to Avram et al. [116]. The product was distilled at 220◦C and 0.06 mbar to give the pure prod-
uct 9 as an oil.
Yield: 16.19 g (39%).
1H NMR (400 MHz, CDCl3): δ ppm 3.521- 3.58 (m, 4H, CH2) 3.74 - 3.18 (m, 1H, CH) 4.64 (d,
2H, CH2) 7.26 - 7.42 (m, 5H, CHarom).
1-Methylsulfinyl-1-methylsulfonyl-3-benzyloxycyclobutane (24)
O
S
S
O
A solution of methyl methylthiomethyl sulfoxide (1.02 g; 8.23 mmol) in dry THF (10 ml) un-
der argon was cooled to -70◦C before 2.5 M n-BuLi (3.4 ml;8.50 mmol) was added in slow
rate [117]. To this mixture 2-benzyloxy-1,3-dibromopropane 9 (1.08 g; 3.55 mmol) was added
slowly (15 mins) and was stirred for 2 hours at -70◦C. The reaction mixture was allowed to
reach room temperature overnight. Brine (20 ml) was added and extracted with EtOAc (2x
20 ml). The extracts were combined, dried with Na2SO4 and the solvent was evaporated in
vacuo to give the crude product in a yellow oil. Silica purification eluting with EtOAc/hexane
(3:7) gave the product 24 as a pale yellow oil. TLC (EtOAc, Rf ∼ 0.36).
Yield: 0.38 g (40%).
ESI-MS: m/e 293 (M+Na)+
1H NMR (400 MHz, CDCl3): δ ppm 2.08 (d, 3H, CH3) 2.40 (s, 2H, CH) 2.51 (s, 2H, CH) 2.98
- 3.05 (m, 1H, CH) 4.08 - 4.19 (m, 0.5H, CH) 4.29 - 4.32 (m, 0.5H, CH) 4.42 (d, 2.1H, CH2)
7.24 - 7.33 (m, 5H, CHarom).
3-(Benzyloxy)cyclobutanone (10)
O O
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To a solution of 24 (0.34 g; 1.26 mmol) in THF (10 ml) at 0◦C was added 6 M HCl (12ml) in
such a rate that the temperature did not exceed 10◦C and the reaction mixture was allowed
to warm to room temperature overnight. Water (20 ml) water was added and the mixture was
extracted with Et2O (20 ml). The organic layer was washed with brine (15 ml), dried with
Na2SO4 and evaporated in vacuo to give the crude product as yellow oil. The residue was
purified by silica chromatography eluting with DCM to give the pale yellow product 10.
Yield: 0.05 g (23%).
ESI-MS: m/e 177 (M+H)+.
1H NMR (400 MHz, CDCl3): δ ppm 3.13 - 3.19 (m, 4H, CH) 4.31 - 4.37 (m, CH) 4.50 (s, CH2)
7.25 - 7.4 (m, 5H, CHarom).
cis-3-(Benzyloxy)cyclobutanol (11)
O OH
To an ice-cooled solution of 3-(benzyloxy)cyclobutanone 10 (10.4 g; 59.0 mmol) [92, 118] in
ethanol (100 ml) was added sodium borohydride (2.45 g; 64.9 mmol) in portions. The mixture
was stirred at 0◦C for 3 hours and monitored by TLC (EtOAc/hexane 1:1). The pale yellow
mixture was filtered over Celite, evaporated to dryness, re-dissolved in methanol with gas evo-
lution, neutralized with 3 M HCl and evaporated in vacuo. To the boronic salt was added water
(80 ml) and extracted with diethyl ether (80 ml). The combined organic phases were dried
with anhydrous Na2SO4, filtered and evaporated in vacuo. The crude product was purified
by silica chromatography with a gradient of ethyl acetate and hexane. Product fractions were
combined and evaporated to give 11 as a clear colorless oil. TLC (EtOAc/hexane 1:1, Rf ∼
0.28).
Yield: 8.97 g (86%).
ESI-MS: m/e 179 (M+H)+.
1H NMR (400 MHz, CDCl3): δ ppm 1.87 (d, J=6.32 Hz, OH) 1.90 - 2.00 (m, 2H, CH) 2.68 -
2.79 (m, 2H, CH) 3.64 (quin, J=6.95 Hz, 1H, CH) 3.92 (sxt, J=6.97 Hz, 1H, CH) 4.43 (s, 2H,
CH2) 7.28 - 7.40 (m, 5H, CHarom).
13C NMR (101 MHz, CDCl3): δ ppm 39.62 (CH2) 41.42 (CH2) 59.77 (CH) 64.40 (CH) 70.40
(CH2) 127.73 (CH) 127.85 (CH) 127.92 (CH) 128.45 (CH) 138.11 (C).
cis-3-(Benzyloxy)cyclobutyl 4-methylbenzenesulfonate (25)
O O S
O
O
A solution of cis-3-(benzyloxy)cyclobutane-1-ol 11 (1.10 g; 6.2 mmol) in DCM (40 ml) was
cooled to 0◦C and pyridine (1.0 ml; 12.3 mmol) was added followed by addition of Ts2O (3.02
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g; 9.3 mmol) under nitrogen. The mixture was stirred at 0◦C for 5 hours and an additional 24
hours at 23◦C. The mixture was concentrated in vacuo, suspended in Et2O (50 ml) washed
with 1M HCl, saturated NaHCO3 solution and brine. The organic layer was dried over Na2SO4
and evaporated in vacuo. The resulting yellow oil was purified by silica chromatography, eluting
with a gradient of EtOAc/hexane to afford a clear pale yellow oil of 25. TLC (EtOAc/hexane
1:2, Rf ∼ 0.43).
Yield: 1.87 g (87%).
ESI-MS: m/e 355 (M+Na)+.
1H NMR (600 MHz, CDCl3): δ ppm 2.11 - 2.23 (m, 2H, CH) 2.45 (s, 3H, CH3) 2.58 - 2.65 (m,
2H, CH) 3.63 (quin, J=6.95 Hz, 1H, CH) 4.37 (s, 2H, CH2) 4.46 (quin, J=7.26 Hz, 1H, CH)
7.28 - 7.37 (m, 7H, CHarom) 7.78 (d, J=8.34 Hz, 2H, CHarom).
13C NMR (101 MHz, CDCl3): δ ppm 21.70 (CH3), 37.58 (CH2), 38.91 (CH2), 64.84 (CH),
67.28 (CH), 70.62 (CH2), 127.83 (CH), 127.89 (CH), 128.49 (CH), 129.85 (CH), 129.89 (C),
133.94 (C), 137.60 (C), 144.85 (C).
cis-3-Hydroxycyclobutyl 4-methylbenzenesulfonate (26)
HO O S
O
O
A solution of cis-3-(benzyloxy)cyclobutyl 4-methylbenzenesulfonate 25 (1.8 g; 5.42 mmol) in
absolute EtOH (35 ml) was stirred at room temperature with palladium on charchoal 10%
(1.02 g; 0.96 mmol) and a positive pressure of hydrogen (balloon) for 4 hours. After reaction
completion, the catalyst was removed by filtration over Celite and evaporation in vacuo to give
the 26 as an yellow oil. TLC (EtOAc/hexane 1:2, Rf ∼ 0.11).
Yield: 1.3 g (96%)
1H NMR (300 MHz, CDCl3): δ ppm 1.73 (br. s., OH) 2.06 - 2.19 (m, 2H, CH) 2.46 (s, 3H, CH3)
2.64 - 2.78 (m, 2H, CH) 3.92 (quin, J=7.02 Hz, 1H, CH) 4.42 (quin, J=7.06 Hz, 1H, CH) 7.35
(d, J=7.91 Hz, 2H, CHarom) 7.79 (d, J=8.10 Hz, 2H, CHarom).
cis-Cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) (20)
O O S
O
O
S
O
O
A solution of cis-3-hydroxycyclobutyl 4-methylbenzenesulfonate 26 (4.29 g; 17.7 mmol) in
DCM was cooled to 0◦C. Pyridine (2.9 ml) was added, followed by the addition of Ts2O (8.67 g;
26.6 mmol). The mixture was stirred over the weekend at 25◦C. The mixture was concentrated
to dryness and re-suspended in Et2O (750 ml). The suspension was washed with 0.5 M
HCl, saturated NaHCO3 solution and brine. The mixture was dried over Na2SO4, filtered and
evaporated in vacuo. The crude product was purified by silica chromatography eluting with
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EtOAc/heptane (1:6) to give pure 20 as a white solid.
Yield: 5.35 g (64%).
CI-MS: m/e 396 (M)+.
1H NMR (600 MHz, CDCl3): δ ppm 2.29 - 2.37 (m, 2H, CH) 2.45 (s, 6H, CH3) 2.60 - 2.68 (m,
2H, CH) 4.40 (quin, 2H, CH) 7.33 (d, 4H, CHarom) 7.71 - 7.75 (m, 4H, CHarom).
13C NMR (151 MHz, CDCl3): δ ppm 21.7 (CH3) 39.1 (CH2) 66.2 (CH) 127.8 (CH) 130.0 (CH)
133.4 (C) 145.2 (C).
trans-3-(Benzyloxy)cyclobutyl 4-methylbenzenesulfonate (27)
O O S
O
O
To a solution of cis-3-(benzyloxy)cyclobutanol 11 (0.34 g; 1.91 mmol) and TPP (1.02 g; 3.82
mmol) in dry THF (6 ml) at 0◦C was added PPTS (0.98 g; 3.82 mmol) and DEAD (601 ul;
3.82 mmol) and stirred at 0◦C for 1 hour before the the mixture was allowed to reach room
temperature. The light yellow solution was diluted with EtOAc, washed with saturated NaHCO3
and brine. The organic layer was dried with Na2SO4 and evaporated in vacuo. The residue
was purified by silica chromatography, eluting with a gradient of EtOAc/hexane to give the
product as clear colorless oil. TLC (EtOAc/hexane 1:1, Rf ∼ 0.55).
Yield: 0.14 g (20%).
ESI-MS: no corresponding mass found.
1H NMR 300 MHz, CDCl3): δ ppm 2.30 - 2.44 (m, 2H, CH) 2.46 (s, 3H, CH3) 4.18 - 4.29 (m,
1H, CH) 4.37 (s, 2H, CH) 5.00 (quin, J=6.03 Hz, 1H, CH) 7.28 - 7.41 (m, 6H, CHarom) 7.78 (d,
J=8.29 Hz, 2H, CHarom).
trans-3-Hydroxycyclobutyl 4-methylbenzenesulfonate (28)
HO O S
O
O
A solution of trans-3-(benzyloxy)cyclobutyl 4-methylbenzenesulfonate 27 (129 mg; 0.39 mmol)
in EtOH (10 ml) was stirred at room temperature with 10% palladium on charchoal (106 mg;
0.1 mmol) and a positive pressure of hydrogen (balloon) for 3 hours. The catalyst was removed
by filtration over Celite and the solvent was evaporated in vacuo to give 28 as a yellow oil. TLC
(DCM/hexane 9:1, Rf ∼ 0.63).
Yield: 95 mg (99%).
ESI-MS: m/e 260 (M+18).
1H NMR 400 MHz, CDCl3): δ ppm 1.70 (d, J=3.96 Hz, 1H, OH) 2.27 (m, 2H, CH) 2.46 (s, 3H,
CH3) 2.40 - 2.56 (m, 2H, CH) 4.55 (tq, J=7.19, 3.87 Hz, 1H, CH) 5.03 (tt, J=7.06, 4.80 Hz, 1H,
CH) 7.35 (d, J=8.10 Hz, 2H, CHarom) 7.79 (d, J=8.29 Hz, 2H, CHarom).
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trans-Cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) (29)
O O S
O
O
S
O
O
To a solution of trans-3-hydroxycyclobutyl 4-methylbenzenesulfonate 28 (96 mg; 0.40 mmol)
in anhydrous DCM (5 ml) was added pyridine (64.1 µl; 0.79 mmol) and Ts2O (104 mg; 0.59
mmol). The mixture was allowed to warm to room temperature overnight. The mixture was
concentrated in vacuo and re-suspended in Et2O (10 ml) and washed with 0.5 M HCl (2x 5 ml),
saturated NaHCO3 solution (5 ml) and brine (5 ml). The organic layer was dried over Na2SO4
and evaporated in vacuo to give the crude 11 as a yellow oil. The residue was purified by
silica chromatography, eluting with a gradient of ethyl acetate/hexane to give the desired 29
as a white solid. TLC (EtOAc/hexane 1:1, Rf ∼ 0.32).
Yield: 41 mg (26%).
ESI-MS: m/e 397 (M+H)+.
1H NMR 300 MHz, CDCl3): δ ppm 2.46 (s, 6H, CH3) 2.50 (t, J=5.84 Hz, 4H, CH) 4.94 (quin,
J=5.84 Hz, 2H, CH) 7.35 (d, J=8.10 Hz, 4H, CHarom) 7.75 (d, J=8.29 Hz, 4H, CHarom).
cis-Cyclobutane-1,3-diol (30)
HO OH
A solution of cis-3-(benzyloxy)cyclobutane-1-ol 11 (1.01 g; 5.70 mmol) in MeOH (50 ml) was
stirred with 10% palladium on charcoal (1.21 g; 1.14 mmol) under a positive pressure of
hydrogen at room temperature for 1 hour. The catalyst was removed by filtration and the
solvent was evaporated in vacuo to give 30 as a clear colorless oil. TLC (DCM/MeOH 9:1,
Rf ∼ 0.21; stained with KMNO4).
Yield: 0.49 g (96%).
ESI-MS: m/e 89 (M+H)+.
1H NMR (400 MHz, CDCl3): δ ppm 1.66 (br, s, 2H, OH) 1.83 - 1.96 (m, 2H, CH) 2.80 (dtd, 2H,
CH) 3.91 (sxt, J=6.82 Hz, 2H, CH).
cis-Cyclobutane-1,3-diyl bis(methanesulfonate) (21)
O O SS
O
O O
O
To an ice-cooled solution of cis-cyclobutyl-1,3-diol 30 (34 mg; 0.39 mmol) in DCM (5 ml)
were added methansulfonic anhydride (235 mg; 0.1.35 mmol) and 4-dimethylaminopyridine
(189 mg; 1.54 mmol). The mixture was allowed to warm to room temperature and stirred
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for 48 hours under nitrogen. To the reaction mixture was added HCl 0.5% (5 ml, v/v) and
diluted with water (10 ml) and the separated aqueous layer was extracted with Et2O (2 x 20
ml). The combined organic layers were washed with saturated NaHCO3, brine, dried over
Na2SO4, filtered and concentrated in vacuo to give 21 as a white solid. TLC (DCM/MeOH 9:1,
Rf ∼ 0.64; stained with KMNO4). Due to the low product amount no mass spectrometry was
performed.
Yield: 31 mg (33%).
1H NMR (300 MHz, CDCl3): δ ppm 2.62 - 2.75 (m, 2H, CH) 3.04 (s, 6H, CH3) 3.06 - 3.16 (m,
2H, CH) 4.72 (quin, J=7.02 Hz, 2H, CH).
cis-Cyclobutane-1,3-diyl bis(trifluoromethanesulfonate) (23)
O O SS
O
O O
OF
F
F
F
F
F
To an ice-cooled solution of cis-cyclobutyl-1,3-diol 30 (30 mg; 0.34 mmol) in DCM (5 ml) were
added pyridine (27 µl; 0.34 mmol) and trifluormethanesulfonic anhydride (127 µl; 0.75 mmol)
and stirred for 30 minutes under nitrogen. The mixture was concentrated in vacuo. The black
residue was mixed with EtOAc/hexane 1:2 (15 ml), the precipitation was filtered off and the
filtrate was evaporated in vacuo. The residue was purified by silica chromatography, eluting
with a gradient of EtOAc/hexane to give 23 as an yellow oil. TLC (EtOAc/hexane 1:1, Rf ∼
0.77). The product showed decomposition after 24 hours at -30◦C. Due to the instability and
the small amount isolated no mass spectrometry was performed.
Yield: 9 mg (4%).
1H NMR (400 MHz, CDCl3): δ ppm 2.86 - 2.95 (m, 2H, CH) 3.23 (m, 2H, CH) 4.94 (quin,
J=6.88 Hz, 2H, CH).
cis-Cyclobutane-1,3-diyl bis(4-nitrobenzenesulfonate) (22)
O O SS
O
O O
O
O2N NO2
To an ice-cooled solution of cis-cyclobutyl-1,3-diol 30 (101.3 mg; 1.15 mmol) in dry THF (2
ml) was added 4-nitrobenzenesulfonyl chloride (650 mg; 2.87 mmol) dissolved in dry THF (2
ml) followed by KOSiMe3 (820 mg; 5.75 mmol) in portions over 30 minutes. The resulting
slurry was stirred for 4 hours at 0◦C. The slurry was poured onto ice-cold water (30 ml) and
extracted with DCM. The organic layer was washed with ice-cold water to remove a white
solid, dried with Na2SO4, filtered and evaporated in vacuo. The residue was purified by silica
chromatography, eluting with a gradient of EtOAc/hexane to give 22 as pale yellow crystals.
TLC (EtOAc/hexane 1:1, Rf ∼ 0.51).
Yield: 289 mg (55%).
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CI-MS: m/e 476 (M+18)+.
1H NMR (300 MHz, DMSO-D6): δ ppm 2.20 - 2.36 (m, 2H, CH) 2.57 - 2.70 (m, 2H, CH) 4.57
(quin, J=6.88 Hz, 2H, CH) 8.11 - 8.20 (m, 4H, CHarom) 8.37 - 8.50 (m, 4H, CHarom).
cis-Cyclobutane-1,3-diyl bis(3,4-dibromobenzenesulfonate) (33)
O O SS
O
O O
O
Br Br
Br Br
To an ice cold solution of cis-cyclobutyl-1,3-diol 30 (101.3 mg; 1.15 mmol) in dry THF (2
ml) was added 4-nitrobenzenesulfonyl chloride (650 mg; 2.87 mmol) dissolved in dry THF (2
ml) followed by KOSiMe3 (820 mg; 5.75 mmol) in portions over 30 minutes. The resulting
slurry was stirred for 4 hours at 0◦C. The slurry was poured onto ice-cold water (30 ml) and
extracted with DCM. The organic layer was washed with ice-cold water to remove a white
solid, dried with Na2SO4, filtered and evaporated in vacuo. The residue was purified by silica
chromatography, eluting with a gradient of EtOAc/hexane to give 33 as pale yellow crystals.
TLC (DCM/hexane 8:2, Rf ∼ 0.22).
Yield: 289 mg (55%).
ESI-MS: m/e 467 (M+18)+.
1H NMR (300 MHz, DMSO-D6): δ ppm 2.20 - 2.36 (m, 2H, CH) 2.57 - 2.70 (m, 2H, CH) 4.57
(quin, J=6.88 Hz, 2H, CH) 8.11 - 8.20 (m, 4H, CHarom) 8.37 - 8.50 (m, 4H, CHarom).
trans-3-(Fluorocyclobutyl) benzyl ether (35)
O F
To an ice-cooled solution of cis-3-(benzyloxy)cyclobutane-1-ol 11 (0.9 g; 5.54 mmol) in dry
DCM (25 ml) was added DAST (0.86 ml; 6.54 mmol). The mixture was stirred for 2 hours
at 0◦C under nitrogen and was allowed to warm to room temperature overnight. The yellow-
brown reaction mixture was washed with water (20 ml), the organic layer was separated and
the aqueous layer was extracted with DCM (2 x 20 ml). The organic layers were combined,
dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica
chromatography with a gradient of EtOAc/hexane to give pure 35 as a clear colorless oil. TLC
(EtOAc/hexane 1:2, Rf ∼ 0.67).
Yield: 306 mg (37%).
ESI-MS: m/e 254 (M+H)+.
1H NMR (300 MHz, CDCl3): δ ppm 2.34 - 2.63 (m, 4H, CH) 4.31 - 4.41 (m, 1H, CH) 4.43 (s,
1H, CH) 5.14 - 5.19 (m, 0.5H, CH-F) 5.28 - 5.38 (m, 0.5H, CH-F) 7.28 - 7.58 (m, 5H, CHarom).
19F NMR (400 MHz, CDCl3): δ ppm -176.4.
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trans-3-Fluorocyclobutyl 4-methylbenzenesulfonate (34)
O FS
O
O
A solution of trans-3-(fluorocyclobutyl) benzyl ether 35 (152 mg; 0.84 mmol) in MeOH (10 ml)
was stirred with 10% palladium on charcoal (140 mg) and with a positive pressure of hydro-
gen at room temperature. The mixture was filtered and the solvent was partly evaporated in
vacuo (40◦C/100mbar, volatile!) to give 36. TLC (EtOAc/hexane 1:2, Rf ∼ 0.26; stained with
KMNO4). 1H NMR (400 MHz, CDCl3): δ ppm 2.22 - 2.39 (m, 2H, CH) 2.48 - 2.63 (m, 2H,
CH) 3.50 (s, 1H, CH) 4.59 - 4.72 (m, 1H, CH) 5.15 - 5.39 (m, 1H, CH); 19F NMR (376 MHz,
CDCl3): δ ppm -178.3.
A solution of trans-3-fluorocyclobutane-1-ol 36 (50 mg; 0.56 mmol) in dry DCM (5 ml) was
cooled to 0◦C and pyridine (82µl; 1.0 mmol) was added, followed by Ts2O (201 mg; 0.62
mmol). The mixture was stirred for 5 hours at 0◦C under nitrogen and was allowed to warm
to room temperature overnight. The yellow solution was concentrated in vacuo. The resulting
residue was dissolved in HCl 0.5 M (5 ml), extracted with Et2O (10 ml) and the organic layer
was washed with NaHCO3 and brine. The mixture was dried with Na2SO4, filtered and evap-
orated in vacuo. The crude oil was purified by silica chromatography, eluting with a gradient
of EtOAc/hexane to give 34 as a clear colorless oil. TLC (EtOAc/hexane 1:2, Rf ∼ 0.52).
Yield: 59 mg (14%, over 2 steps).
ESI-MS: m/e 245 (M+H)+.
1H NMR (400 MHz, CDCl3): δ ppm 2.47 (s, CH3) 2.48 - 2.62 (m, 4H, CH) 5.01 - 5.33 (m, 2H,
CH) 7.36 (d, J=8.10 Hz, 2H, CHarom) 7.79 (d, J=8.29 Hz, 2H, CHarom).
13C NMR (100 MHz, CDCl3): δ ppm 21.7 (CH3) 38.8 (CH2) 72.3 (CH) 85.7 (CH) 127.9 (CH)
129.9 (CH) 133.5 (C) 145.05 (C).
19F NMR (376 MHz, CDCl3): δ ppm -178.8.
5.2.2 Synthesis of reference compounds O-(cis-3-fluorocyclobutyl)-DL-tyrosine
Methyl O-[trans-3-(benzyloxy)cyclobutyl]-N-(tert-butoxycarbonyl)-L-tyrosine (40)
O
N
H
O
O
O
O
O
To a solution of Boc-Tyr-OMe (1.02 g; 3.35 mmol) and cis-3-(benzyloxy)cyclobutanol 11 (1.33
g; 7.37 mmol) in dry DMF (25 ml) was added DEAD (1.20 ml; 7.37 mmol). The yellow solution
was stirred under nitrogen and TPP (1.98 g; 7.37 mmol) was added. The mixture was stirred
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at room temperature for 23 hours and evaporated in vacuo. The crude oil was dissolved in
CHCl3 (50 ml) and washed with water (3 x 30 ml) to remove DMF. The organic layer was dried
with anhydrous Na2SO4, filtered and concentrated in vacuo to give a brown oil. The crude
product was purified by silica chromatography, eluting with a gradient of EtOAc/hexane to give
the desired product 40 as a clear colorless oil. TLC (EtOAc/hexane 1:2, Rf ∼ 0.46).
Yield: 1.35 g (88%).
CI-MS: m/e 356 (M-Boc)+.
1H NMR (400 MHz, CDCl3): δ ppm 1.43 (s, 9H, CH3) 2.38 - 2.56 (m, 2H, CH) 2.94 - 3.11 (m,
2H, CH) 3.72 (s, 3H, CH3) 4.30 - 4.39 (m, 1H, CH) 4.46 (s, 2H, CH2) 4.50 - 4.60 (m, 1H, CH)
4.78 - 4.88 (m, 1H, CH) 4.90 - 5.00 (m, 1H, NH) 6.71 (d, 2H, CHarom) 7.02 (d, 2H, CHarom)
7.29 - 7.42 (m, 5H, CHarom).
Methyl N-(tert-butoxycarbonyl)-O-(trans-3-hydroxycyclobutyl)-L-tyrosine (41)
O
N
H
OH
O
O
O
O
A solution of methyl O-[trans-3-(benzyloxy)cyclobutyl]-N-(tert-butoxycarbonyl)-L-tyrosine 40
(1.35 g; 2.96 mmol) in MeOH (20 ml) was stirred with 10% palladium on charcoal (500 mg,
50% wet). The mixture was stirred under a positive pressure (ambient) of hydrogen at room
temperature for 2 hours. The mixture was filtered and the solvent evaporated in vacuo. The
crude oil was dissolved in DCM, filtered through Celite, washed with DCM and evaporated in
vacuo to give the desired product 41 as a clear colorless oil. TLC (EtOAc, Rf ∼ 0.54).
Yield: 1.02 g (94%).
ESI-MS: m/e 366 (M+H)+.
1H NMR (400 MHz, CDCl3): δ ppm 1.42 (s, 9H, CH3) 1.80 (br. s., 1H, OH) 2.34 - 2.59 (m, 2H,
CH) 3.02 (m, 2H, CH) 3.72 (s, 3H, CH3) 4.47 - 4.59 (m, 1H, CH) 4.60 - 4.70 (m, 1H, CH) 4.79
- 4.90 (m, 1H, CH) 4.96 (d, J=7.91 Hz, 1H, NH) 6.71 (d, 2H, CHarom) 7.02 (d, 2H, CHarom).
Methyl N-(tert-butoxycarbonyl)-O-(cis-3-fluorocyclobutyl)-L-tyrosine (38)
O
N
H
F
O
O
O
O
5 EXPERIMENTAL 129
To an ice-cooled solution of methyl N-(tert-butoxycarbonyl)-O-(trans-3-hydroxycyclobutyl)-L-
tyrosine 41 (658 mg; 1.80 mmol) in dry DCM (25 ml) was added DAST (358 µl; 2.70 mmol).
The mixture was stirred at 0◦C for 3 hours and was allowed to reach room temperature
overnight. The crude product was purified by column chromatography with a gradient of
EtOAc/hexane to give the desired product 38 as white crystals. TLC (EtOAc/hexane 1:2,
Rf ∼ 0.62).
Yield: 257 mg (38%).
ESI-MS: m/e 368 (M+H)+.
1H NMR (300 MHz, CDCl3): δ ppm 1.42 (s, 9H, CH3) 2.36 - 2.53 (m, 2H, CH) 2.95 - 3.08 (m,
2H, CH) 3.72 (s, CH3) 4.17 - 4.27 (m, 1H, CH) 4.50 - 4.60 (m, 1H, CH) 4.81 (quin, 0.5H, CH-F)
4.94 (quin, 0.5H, CH-F) 4.96 (d, J=7.91 Hz, 1H, NH) 6.73 (d, J=8.59 Hz, 2H, CHarom) 7.03 (d,
J=8.59 Hz, 2H, CHarom).
19F NMR (376 MHz, CDCl3): δ ppm -169.3.
N-(tert-Butoxycarbonyl)-O-(cis-3-fluorocyclobutyl)-L-tyrosine (39)
O
N
H
F
O
OH
O
O
To a solution of methyl N-(tert-butoxycarbonyl)-O-(cis-3-fluorocyclobutyl)-L-tyrosine 38 (85
mg; 23 µmol) in MeOH (3.5 ml) was added 1 M LiOH (650 µl; 65 µmol). The clear mix-
ture was stirred for 6 hours at room temperature. After TLC showed full conversion, the pH
of the mixture was adjusted to pH 5 with 1 M HCl and evaporated in vacuo. The resulting
oil was dissolved in EtOAC, washed with brine and evaporated to dryness, was re-dissolved
in EtOAc, dried over Na2SO4, filtered and evaporated to give the 39 as a white solid. TLC
(EtOAc/hexane 1:1, Rf ∼ 0, spot at start).
Yield: 80 mg (97%).
ESI-MS: m/e 354 (M+H)+.
1H NMR (400 MHz, CDCl3): δ ppm 1.41 (m, 9H, 3 CH3) 2.33 - 2.51 (m, 2H, CH) 2.75 (d,
1H, CH) 2.90 (dd, 2H, CH) 3.12 (d, 2H, CH) 4.16 - 4.27 (m, 1H, CH) 4.52 (d, J=5.56Hz, 1H,
CH) 4.76 (quin, 0.5H, CH-F) 4.90 (quin, 0.6H, CH-F) 4.98 (d, J=7.58 Hz, 1H, NH) 6.05 (br. s.,
COOH) 6.74 (d, J=8.34 Hz, 2H, CHarom) 7.09 (d, J=8.34 Hz, 2H, CHarom).
19F NMR (376 MHz, CDCl3): δ ppm -169.2.
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O-(cis-3-Fluorocyclobutyl)-L-tyrosine hydrochloride salt (4)
O
+H3N
F
O
OH
Cl-
A solution of 39 (79 mg; 0.22 mmol) in DMF (0.6 ml) was treated with 4 M HCl in dioxane
(0.5 ml; 2.24 mmol) for 1 hour at room temperature. The mixture was evaporated in vacuo,
re-suspended in EtOH/water (1:1) and extracted with a small amount of DCM. The aqueous
phase was evaporated to remove EtOH and gave after freeze-drying the desired product 4 as
a white solid. TLC (DCM/MeOH 9:1, Rf ∼ 0, spot at start).
Yield: 25 mg (44%).
ESI-MS: m/e 254 (M+H)+.
HPLC: ratio D/L 3% : 97%.
1H NMR (300 MHz, CD3OD): δ ppm 2.19 - 2.36 (m, 2H, CH) 2.95 - 3.12 (m, 2H, CH) 3.24 -
4.16 (m, 1H, CH) 4.27 - 4.37 (m, 1H, CH) 4.84 (quin, 1H, CH-F) 4.92 (quin, 1H, CH-F) 6.85
(d, 2H, CHarom) 7.20 (d, 2H, CHarom).
13C NMR (151 MHz, CDCl3): δ ppm 36.74 (CH2) 40.3 (CH2) 40.5 (CH2) 55.8 (CH) 63.6 (CH)
63.8 (CH) 81.0 (CH) 82.4 (CH) 116.6 (CH) 128.1 (C) 131.7 (CH) 158.3 (C) 171.8 (C).
19F NMR (376 MHz, CD3OD): δ ppm -179.5.
Methyl O-[trans-3-(benzyloxy)cyclobutyl]-N-(tert-butoxycarbonyl)-D-tyrosine (43)
O
N
H
O
O
O
O
O
To a solution of Boc-D-Tyr-OMe (1.16 g; 3.81 mmol) and cis-3-(benzyloxy)cyclobutanol 11
(1.51 g; 8.39 mmol) in dry DMF (25 ml) were added DEAD (1.36 ml; 8.39 mmol) and TPP
(2.2 g; 8.39 mmol). The mixture was stirred for 18 hours under nitrogen at room temperature.
The reaction mixture was evaporated in vacuo and dissolved in CHCl3 (50 ml) and washed
with water (3 x 30 ml) to remove DMF. The organic layer was dried with anhydrous Na2SO4,
filtered, concentrated in vacuo and purified by silica chromatography, eluting with a gradient of
EtOAc/hexane to give the product 43 as a colorless clear oil. TLC (EtOAc/hexane 1:2, Rf ∼
0.39).
Yield: 1.29 g (72%).
ESI-MS: m/e 456 (M+H)+.
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1H NMR (300 MHz, CDCl3): δ ppm 1.43 (s, 9H, CH3) 2.37 - 2.58 (m, 4H, CH) 2.92 - 3.11 (m,
3H, CH3) 3.72 (s, 3H, CH3) 4.30 - 4.39 (m, 1H, CH) 4.46 (s, 2H, CH2) 4.54 (m, J=7.16 Hz,
1H, CH) 4.79 - 4.88 (m, 1H, CH) 4.96 (d, J=7.91 Hz, 1H, NH) 6.71 (d, J=8.48 Hz, 2H, CHarom)
7.02 (d, J=8.48 Hz, 2H, CHarom) 7.28 - 7.41 (m, 5H, CHarom).
Methyl N-(tert-butoxycarbonyl)-O-(trans-3-hydroxycyclobutyl)-D-tyrosine (44)
O
N
H
OH
O
O
O
O
A solution of methyl O-[trans-3-(benzyloxy)cyclobutyl]-N-(tert-butoxycarbonyl)-D-tyrosine 43
(1.35 g; 2.96 mmol) in MeOH (20 ml) was stirred with 10% palladium on charcoal (500 mg,
50% wet) at roomt temperature under a positive pressure (ambient) of hydrogen for 1 hour.
The mixture was filtered and the solvent evaporated in vacuo. The crude oil was dissolved in
DCM, filtered through Celite, washed with DCM and evaporated in vacuo to give the desired
product 44 as a colorless clear oil. TLC (DCM/MeOH 9:1, Rf ∼ 0.59).
Yield: 1.52 g (97%).
ESI-MS: m/e 366 (M+H)+.
1H NMR (300 MHz, CDCl3): δ ppm 1.42 (s, 9H, CH3) 1.63 (br. s., 1H, OH) 2.34 - 2.57 (m,
4H, CH) 2.93 - 3.11 (m, 2H, CH2) 3.72 (s, 3H, CH3) 4.48 - 4.59 (m, 1H, CH) 4.59 - 4.70 (m,
1H, CH) 4.80 - 4.89 (m, 1H, CH) 4.97 (d, J=8.10 Hz, 1H, NH) 6.71 (d, J=8.67 Hz, 2H, CHarom)
7.02 (d, J=8.48 Hz, 2H, CHarom).
Methyl N-(tert-butoxycarbonyl)-O-(cis-3-fluorocyclobutyl)-D-tyrosine (45)
O
N
H
F
O
O
O
O
To an ice-cooled solution of methyl N-(tert-butoxycarbonyl)-O-(trans-3-hydroxycyclobutyl)-D-
tyrosine 44 (1.52 mg; 4.16 mmol) in dry DCM (25 ml) was added DAST (0.83 ml; 6.27 mmol).
The mixture was stirred at 0◦C for 3 hours and was allowed to reach room temperature
overnight. The crude product was purified by column chromatography with a gradient of
EtOAc/hexane to give the desired product 45 as white crystals. TLC (ethyl acetate/hexane
1:2, Rf ∼ 0.62).
Yield: 147 mg (8%).
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ESI-MS: m/e 368 (M+H)+.
1H NMR (300 MHz, CDCl3): δ ppm 1.43 (s, 9H, CH3) 2.37 - 2.52 (m, 4H, CH) 2.94 - 3.10
(m, 2H, CH2) 3.72 (s, 3H, CH3) 4.17 - 4.26 (m, 1H, CH) 4.51 - 4.59 (m, 1H, CH) 4.72 - 4.93
(m, 1H, CH) 4.94 - 4.99 (m, 1H, NH) 6.73 (d, J=8.59 Hz, 2H, CHarom) 7.03 (d, J=8.34 Hz, 2H,
CHarom).
19F NMR (376 MHz, CDCl3): δ ppm -169.3.
N-(tert-Butoxycarbonyl)-O-(cis-3-fluorocyclobutyl)-D-tyrosine (46)
O
N
H
F
O
OH
O
O
To a solution of methyl N-(tert-butoxycarbonyl)-O-(cis-3-fluorocyclobutyl)-D-tyrosine 45 (21
mg; 56 µmol) in MeOH (1 ml) at 0◦C was added 1 M LiOH (200 µl; 200 µmol). The clear
solution was stirred overnight at room temperature. After TLC showed full conversion, the
mixture was adjusted to pH 5 with 1 M HCl (250 µl) and evaporated in vacuo. The resulting
oil was dissolved in EtOAC, washed with brine, dried with Na2SO4, filtered and evaporated to
give the product 46 as a white solid. TLC (EtOAc/hexane 1:1, Rf ∼ 0, spot at start). Due to
the low product amount no mass spectrometry was performed.
Yield: 19 mg (95%).
1H NMR (300 MHz, CD3OD): δ ppm 1.38 (s, 9H, CH3) 2.17 - 2.37 (m, 2H, CH) 2.76 - 2.88 (m,
1H, CH) 2.93 - 3.04 (m, 1H, CH) 3.04 - 3.12 (m, 1H, CH) 4.28 (d, J=4.04 Hz, 2H, CH2) 4.71 -
4.81 (m, 1H, NH) 6.76 (d, J=8.59 Hz, 2H, CHarom) 7.13 (d, J=8.59 Hz, 2H, CHarom).
19F NMR (376 MHz, CD3OD): δ ppm -170.5.
O-(cis-3-Fluorocyclobutyl)-D-tyrosine hydrochloride salt (47)
O
+H3N
F
O
OH
Cl-
A solution of 46 (17 mg; 48 µmol) in THF (0.5 ml) was treated with 4 M HCl in dioxane (0.14
ml; 0.57 mmol) for 1 hour at room temperature. The mixture was evaporated in vacuo. Due to
only 50% conversation according to 1H NMR, the residue was dissolved in DMF (0.5 ml) and
treated with additional 4 M HCl in dioxane (0.25 ml) for 1 hour at room temperature. After full
conversion, the reaction mixture was evaporated in vacuo to give the desired product 47 as a
white solid. TLC (DCM/MeOH 9:1, Rf ∼ 0, spot at start).
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Yield: 14 mg (92%).
ESI-MS: m/e 254 (M+H)+.
1H NMR (400 MHz, CD3OD): δ ppm 2.17 - 2.36 (m, 2H, CH) 2.94 - 3.15 (m, 2H, CH) 3.19 -
3.28 (m, 1H, CH) 4.17 (dd, J= 7.58, 5.31 Hz, 1H, CH) 4.32 (m, 1H, CH) 4.77 (quin, J=6.57 Hz,
1H, CH) 6.85 (d, J=8.59 Hz, 2H, CHarom) 7.20 (d, J=8.59 Hz, 2H, CHarom).
19F NMR (376 MHz, CD3OD): δ ppm -170.5.
5.2.3 Syntheses of precursors for direct labeling
Methyl N-(tert-butoxycarbonyl)-O-[trans-3-(4-methylbenzenesulfonyloxy)cyclobutyl]-L-
tyrosine (48)
O
N
H
O
S
O O
O
O
O
O
To an ice-cooled solution of methyl N-(tert-butoxycarbonyl)-O-(trans-3-hydroxycyclobutyl)-L-
tyrosine 41 (145 mg; 0.40 mmol) and pyridine (64.3 µl; 0.80 mmol) in dry DCM (16 ml) was
added Ts2O (194.7 mg; 0.60 mmol) and stirred for 5 hours at 0◦C and was allowed to reach
room temperature overnight. After full conversion, the mixture was evaporated in vacuo and
the residue was purified by silica chromatography, eluting with a gradient of EtOAc/hexane to
give the product 48 as a clear colorless oil. TLC (EtOAc/hexane 1:1, Rf ∼ 0.58).
Yield: 162 mg (78%).
ESI-MS: m/e 520 (M+H)+.
1H NMR (300 MHz, CDCl3): δ ppm 1.42 (s, 9H, CH3) 2.46 (s, 3H, CH3) 2.44 - 2.54 (m, 2H,
CH) 2.62 (m, 2H, CH) 3.01 (qd, J=13.85, 5.94 Hz, 2H, CH2) 3.71 (s, 3H, CH3) 4.49 - 4.58 (m,
1H, CH) 4.79 (tt, J=6.92, 3.44 Hz, 1H, CH) 4.94 (d, J=8.34 Hz, 1H, NH) 5.00 - 5.09 (m, 1H,
CH) 6.64 (d, J=8.59 Hz, 2H, CHarom) 7.00 (d, J=8.34 Hz, 2H, CHarom) 7.36 (d, J=8.34 Hz, 2H,
CHarom) 7.80 (d, J=8.08 Hz, 2H, CHarom).
Methyl N-(tert-butoxycarbonyl)-O-[cis-3-(4-methylbenzenesulfonyloxy)cyclobutyl]-L-
tyrosine (49)
O
N
H
O
S
O O
O
O
O
O
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To an ice-cooled solution of methyl N-(tert-butoxycarbonyl)-O-(trans-3-hydroxycyclobutyl)-L-
tyrosine 42 (100 mg; 0.27 mmol), PPTS (137 mg; 0.54 mmol) and TPP (142 mg; 0.54 mmol)
in dry THF (2 ml) was added DEAD (86 µl; 0.54 mmol) and stirred for 10 minutes at 0◦C
before the ice bath was removed and was allowed to reach room temperature overnight. The
suspension was diluted with EtOAc and washed with saturated NaHCO3 and brine. The
organic layer was dried with Na2SO4, filtered and evaporated in vacuo. The yellow residue
was purified by silica chromatography, eluting with a gradient of EtOHAc/hexane to give the
desired product 49 as a clear colorless oil. TLC (EtOAc/hexane 2:1, Rf ∼ 0.59).
Yield: 34 mg (24%).
1H NMR (300 MHz, CDCl3): δ ppm 1.41 (s, 9H, CH3) 2.34 (dtd, 2H, CH) 2.46 (s, 3H, CH3)
2.85 (dtd, 2H, CH) 2.91 - 3.10 (m, 2H, CH2) 3.70 (s, 3H, CH3) 4.21 (quin, J=6.78 Hz, 1H, CH)
4.58 (d, J=7.16 Hz, 1H, CH) 4.95 (d, J=7.54 Hz, 1H, NH) 6.65 (d, J=8.67 Hz, 2H, CHarom) 7.00
(d, J=8.29 Hz, 2H, CHarom) 7.35 (d, J=7.91 Hz, 2H, CHarom) 7.80 (d, J= 8.29 Hz, 2H, CHarom).
tert-Butyl N-(tert-butoxycarbonyl)-L-tyrosine (51)
OH
N
H
O
O
O
O
To a solution of L-tyrosine tert-butyl ester (3.0 g; 12.64 mmol) in DCM (45 ml) and DMF (6 ml)
in presence of TEA (1.76 ml; 12.64 mmol) was added Boc2O (2.9 ml; 12.64 mmol) and stirred
under nitrogen for 5 hours at room temperature. The yellowish solution was washed with 1
M HCl (3 x 20 ml), saturated NaHCO3 solution (20 ml) and brine (20 ml), dried with Na2SO4,
filtered and evaporated in vacuo. The crude product was purified by silica chromatography
with a gradient of EtOAc/hexane to give the desired product 51 as a white solid after foaming
at high-vacuum. TLC (EtOAc, Rf ∼ 0.66).
Yield: 4.02 g (93%).
ESI-MS: m/e 338 (M+H)+.
1H NMR (300 MHz, CDCl3): δ ppm 1.39 - 1.47 (m, 18H, CH3) 2.99 (d, J=5.27 Hz, 2H, CH2)
4.41 (m, J=8.10 Hz, 1H, CH) 4.94 (s, OH) 4.99 (d, J=7.35 Hz, 1H, NH) 6.75 (d, J=8.29 Hz,
2H, CHarom) 7.02 (d, J=8.28 Hz, 2H, CHarom).
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tert-Butyl O-[trans-3-(benzyloxy)cyclobutyl]-N-(tert-butoxycarbonyl)-L-tyrosine (52)
O
N
H
O
O
O
O
O
A mixture of tert-butyl N-(tert-butoxycarbonyl)-L-tyrosine 51 (1.05 g; 3.11 mmol), cis-3-(benzyl-
oxy)cyclobutanol 11 (1.22 g; 6.85 mmol) and TPP (1.80; 6.85 mmol) in dry DMF (25 ml) was
reacted with DIAD (1.35 ml; 6.85 mmol) for 18 hours under nitrogen at room temperature and
in the absence of light. The yellow solution was evaporated in vacuo, dissolved in CHCl3 (100
ml) and washed with water (3x 40ml) to remove DMF. The organic phase was dried with an-
hydrous Na2SO4, filtered and evaporated in vacuo. The crude product was purified by silica
chromatography, eluting with a gradient of EtOAc/hexane to give the product 52 as a clear
colorless oil. TLC (EtOAc/hexane 1:2, Rf ∼ 0.57).
Yield: 1.30 g (82%).
ESI-MS: m/e 498 (M+H)+.
1H NMR (400 MHz, CDCl3): δ ppm 1.42 (d, J=6.82 Hz, 18H, CH3) 2.39 - 2.55 (m, 4H, CH)
2.95 - 3.03 (m, 2H, CH2) 4.31 - 4.37 (m, 1H, CH) 4.38 - 4.44 (m, 1H, CH) 4.46 (s, 2H, CH2)
4.80 - 4.88 (m, 1H, CH) 4.96 (d, J=8.08 Hz, 1H, NH) 6.72 (d, 2H, CHarom) 7.05 (s, 2H, CHarom)
7.28 - 7.38 (m, 5H, CHarom).
tert-Butyl O-(trans-3-hydroxycyclobutyl)-N-(tert-butoxycarbonyl)-L-tyrosine (53)
O
N
H
OH
O
O
O
O
A solution of tert-butoxy O-[trans-3-(benzyloxy)cyclobutyl]-N-(tert-butoxycarbonyl)-L-tyrosine
52 (1.3 g; 2.61 mmol) in MeOH (30 ml) was stirred with 10% palladium on charcoal (560 mg,
50% wet) under a positive pressure (ambient) of hydrogen at room temperature. The mixture
was filtered and the solvent evaporated in vacuo to give 53 as a clear colorless oil. TLC
(EtOAc, Rf ∼ 0.58).
Yield: 1.06 g (98%).
ESI-MS: m/e 408 (M+H)+.
1H NMR (300 MHz, CDCl3): δ ppm 1.42 (d, J=4.71 Hz, 18H, CH3) 1.88 (d, J=4.33 Hz, 1H,
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OH) 2.33 - 2.57 (m, 4H, CH) 2.99 (d, J=5.84 Hz, 2H, CH2) 4.35 - 4.46 (m, 1H, CH) 4.58 - 4.70
(m, 1H, CH) 4.80 - 4.90 (m, 1H, CH) 4.99 (d, 1H, NH) 6.71 (d, J=8.67 Hz, 2H, CHarom) 7.07
(d, J=8.48 Hz, 2H, CHarom).
tert-Butoxy N-(tert-butoxycarbonyl)-O-[trans-3-(4-methylbenzenesulfonyloxy)cyclo-
butyl]-L-tyrosine (54)
O
N
H
O
O
O
O
O
S
O O
The alcohol 53 (0.21 g; 0.49 mmol) dissolved in dry DCM was cooled to 0◦C before pyridine
(79.1 µl; 0.98 mmol) and Ts2O (0.24 g; 0.73 mmol) dissolved in DCM (2 ml) were added.
Reaction mixture was stirred under nitrogen for 3 hours at 0◦C followed by 3 hours at room
temperature. After full conversion (TLC), to the reaction mixture 1 M HCl (2 ml) were added,
the organic phase was separated, washed with saturated NaHCO3, dried with Na2SO4, filtered
and concentrated in vacuo and purified by silica chromatography, eluting with a gradient of
EtOAc/hexane to give the desired product 54 as a white solid after foaming at high-vacuum.
TLC (EtOAc/hexane 1:1, Rf ∼ 0.63).
Yield: 0.16 g (56%).
ESI-MS: m/e 562 (M+H)+.
1H NMR (300 MHz, CDCl3): δ ppm 1.42 (d, J=4.14 Hz, 18H, CH3) 2.46 (s, 3H, CH3) 2.49 -
2.69 (m, 4H, CH) 2.98 (d, J=4.71 Hz, 2H, CH2) 4.39 (d, J=7.35 Hz, 1H, CH) 4.79 (tt, J=6.95,
3.70 Hz, 1H, CH) 4.95 (d, J=8.48 Hz, 1H, NH) 5.01 - 5.11 (m, 1H, CH) 6.64 (d, J=8.67 Hz, 2H,
CHarom) 7.05 (d, J=8.48 Hz, 2H, CHarom) 7.36 (d, J=8.29 Hz, 2H, CHarom) 7.80 (d, J=8.29 Hz,
2H, CHarom).
tert-Butyl O-[trans-3-(benzyloxy)cyclobutyl]-L-tyrosine (59)
O
H2N
O
O
O
To a solution of L-tyrosine tert-butyl ester (0.73 g; 3.08 mmol), 11 (0.60 g; 3.39 mmol) and
TPP polystyrene-bound (2.14 g; 2.36 mmol) in dry DCM (17ml) was added DEAD (534 µl; 3.39
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mmol) and stirred under nitrogen at room temperature for 20 hours. The resin was filtered off
with Celite, washed with DCM and purified by silica chromatography, eluting with a gradient
of EtOAc/hexane to give the desired product 59 as a clear colorless oil. TLC (EtOAc, Rf ∼
0.35).
Yield: 0.39 g (32%).
ESI-MS: m/e 389 (M+H)+.
1H NMR (300 MHz, CDCl3): δ ppm 1.44 (s, 9H, CH3) 2.38 - 2.57 (m, 4H, CH) 2.73 - 2.83 (m,
1H, CH) 2.92 - 3.02 (m, 1H, CH) 3.53 - 3.60 (m, 1H, CH) 4.29 - 4.39 (m, 1H, CH) 4.45 (s,
2H, CH2) 4.79 - 4.89 (m, 1H, NH) 6.72 (d, J=8.48 Hz, 2H, CHarom) 7.11 (d, J=8.48 Hz, 2H,
CHarom) 7.29 - 7.41 (m, 5H, CHarom).
tert-Butyl O-[trans-3-hydroxycyclobutyl]-L-tyrosine (60)
O
H2N
OH
O
O
Method 1: To a solution of 53 (52 mg; 0.13 mmol) in dry ethyl acetate (0.95 ml) was slowly
added p-toluenesulfonic acid monohydrate (24 mg; 0.3 mmol) in absolut ethanol (0.25 ml) at
0◦C. The cooling bath was removed and the mixture was allow to reach room temperature
overnight. The mixture was concentrated in vacuo and purified by silica chromatography, elut-
ing with a gradient of DCM/MeOH to give the desired product 60 as a white crystalline solid
(toluenesulfonic salt). TLC (DCM/MeOH 9:1, Rf ∼ 0.29).
Yield: 32 mg (52%).
ESI-MS: m/e 308 (M+H)+.
1H NMR (300 MHz, CD3OD): δ ppm 1.40 (s, 9H, CH3) 2.30 - 2.45 (m, 4H, CH) 2.93 (m, 2H,
CH2) 3.64 - 3.70 (m, 1H, CH) 4.44 - 4.54 (m, 1H, CH) 4.75 - 4.84 (m, 1H, CH) 6.75 (d, J=8.59
Hz, 2H, CHarom) 7.12 (d, J=8.84 Hz, 2H, CHarom) 7.23 (d, J=7.83 Hz, 2H, CHarom) 7.71 (d,
J=8.08 Hz, 2H, CHarom).
Method 2: To a solution of 53 (1.06 g; 2.60 mmol) in dry THF (15 ml) was slowly added
4 M HCl in 1,4-dioxane (6.5 ml; 26 mmol) at room temperature. The solution was stirred for 4
hours and additional 4 M HCl in dioxane (3.2 ml; 12.7 mmol) was added and stirred overnight.
The mixture was concentrated in vacuo and purified by silica chromatography, eluting with a
gradient of DCM/MeOH to give the desired product 60 as a crystalline solid. TLC (DCM/MeOH
9:1, Rf ∼ 0.42).
Yield: 0.54 g (56%).
ESI-MS: m/e 308 (M+H)+.
1H NMR (300 MHz, CD3OD): δ ppm 1.40 (s, 9H, CH3) 2.30 - 2.47 (m, 4H, CH) 2.89 - 2.94 (m,
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2H, CH2) 3.63 - 3.71 (m, 1H, CH) 4.43 - 4.53 (m, 1H, CH) 4.78 - 4.86 (m, 1H, CH) 6.75 (d,
J=8.48 Hz, 2H, CHarom) 7.12 (d, J=8.67 Hz, 2H, CHarom).
tert-Butyl O-(trans-3-hydroxycyclobutyl)-N-trityl-L-tyrosine (57)
O
N
H
OH
O
O
To a solution of 60 (200 mg; 0.65 mmol) and TEA (0.18 µl; 1.29 mmol) in DMF (3.5 ml) was
added TrtCl (149 mg; 0.53 mmol) and stirred under nitrogen overnight at room temperature.
The reaction mixture was concentrated in vacuo and purified by silica chromatography, eluting
with a gradient of EtOAc/hexane to give the desired product 57 as a clear colorless oil. TLC
(EtOAc, Rf ∼ 0.61).
Yield: 0.22 g (62%).
ESI-MS: m/e 550 (M+H)+.
1H NMR (300 MHz, CDCl3): δ ppm 1.07 (s, 9H, CH3) 1.74 (d, J=4.29 Hz, 1H, OH) 2.36 - 2.55
(m, 4H, CH) 2.58 (d, J=9.35 Hz, 1H, CH) 2.72 - 2.86 (m, 2H, CH2) 3.47 (dt, J=9.28, 6.60 Hz,
1H, CH) 4.65 (tq, J=6.93, 4.56 Hz, 1H, CH) 4.84 - 4.91 (m, 1H, CH) 6.71 (d, J=8.59 Hz, 2H,
CHarom) 7.11 (d, J=8.34 Hz, 2H, CHarom) 7.15 (t, J=7.10 Hz, 3H, CHarom) 7.19 - 7.26 (m, 6H,
CHarom) 7.45 (d, J=7.33 Hz, 6H, CHarom).
tert-Butyl O-[trans-3-(4-methylbenzenesulfonyloxy)cyclobutyl]-N-trityl-L-tyrosine (61)
O
N
H
O
O
O
S
O O
To an ice-cooled solution of 57 (60 mg; 0.11 mmol) in dry DCM (3 ml) was added pyridine
(17.7 µl; 0.22 mmol) and Ts2O (53 mg; 0.16 mmol) in dry DCM (1 ml). The reaction mix-
ture was stirred for 1 hour at 0◦C under nitrogen followed by 1 hour at room temperature.
Additional 7 mg of Ts2O and 2.5 ul of pyridine were added and stirred for 2 hours at room
temperature. To the mixture was added 1M HCl and water. The organic layer was separated,
washed with saturated NaHCO3, dried with Na2SO4, filtered and concentrated in vacuo. The
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residue dissolved in ACN (2 ml) and water was added (50 ml). The suspension was subject
thy dry freezing. The crude product was purified by semi-preparative HPLC using an ACE
C18 5µ column (250 x 10 mm) with a gradient of water/ACN (5% ACN to 50% in 20 mins) to
give after dry freezing the product 61 as a white solid. TLC (EtOAc, Rf ∼ 0.68).
Yield: 13 mg (16%).
ESI-MS: m/e 704 (M+H)+.
1H NMR (600 MHz, CDCl3): δ ppm 1.02 - 1.08 (m, 9H, CH3), 2.44 (s, 3H, CH3), 2.45 - 2.52
(m, 2H, CH), 2.55 (d, 1H, NH), 2.58 - 2.65 (m, 2H, CH), 2.71 - 2.76 (m, 1H, CH), 2.77 - 2.82
(m, 1H, CH), 3.41 - 3.48 (m, 1H, CH), 4.79 (tt, 1h, CH), 5.05 (tt, 1H, CH), 6.63 (d, 2H, CHarom),
7.08 (d, 2H, CHarom), 7.12 - 7.16 (m, 3H, CHarom), 7.18 - 7.23 (m, 6H, CHarom), 7.34 (d, 2H,
CHarom), 7.40 - 7.45 (m, 6H, CHarom), 7.79 (d, 2H, CHarom).
13C NMR (151 MHz, CDCl3): δ ppm 21.7 (CH3) 27.9 (CH3) 37.7 (CH2) 41.2 (CH2) 58.0 (CH)
71.2 (C) 80.4 (C) 114.4 (CH) 114.4 (CH) 127.8 (CH) 127.9 (CH) 128.8 (CH) 129.9 (CH) 130.4
(C) 131.1 (CH) 133.6 (C) 144.9 (C) 146.3 (C) 155.7 (C) 173.61 (C).
tert-Butyl O-[trans-3-(trifluoromethylsulfonyloxy)cyclobutyl]-N-trityl-L-tyrosine (62)
O
N
H
O
O
O
S
O O
F
F
F
To a solution of 57 (50 mg; 0.09 mmol) and pyridine (18 µl; 0.22 mmol) in dry DCM (4 ml)
at 0◦C was added Tf2O (41 µl; 0.24 mmol) and stirred under nitrogen at 0◦C for 1 hour.
The reaction mixture was carefully evaporated in vacuo and purified by silica chromatography,
eluting with a gradient of EtOAc/hexane to give the desired product 63 as an white solid. TLC
(EtOAc/hexane 1:1, Rf ∼ 0.72). Due to the the compound’s instability no further analytics
were performed.
Yield: 20 mg (26%).
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tert-Butyl O-[trans-3-(4-nitrobenzenesulfonyloxy)cyclobutyl]-N-trityl-L-tyrosine (63)
O
N
H
O
O
O
S
O O
NO2
To a solution of 57 (62 mg; 0.11 mmol) and DIPEA (82 µl; 0.46 mmol) in dry DCM (2 ml) was
added NsCl (31 mg; 0.14 mmol) and stirred under nitrogen for 2 hours at room temperature.
The reaction mixture was evaporated in vacuo and purified by silica chromatography, eluting
with a gradient of EtOAc/hexane to give the desired product 63 as an yellowish oil. TLC
(EtOAc/hexane 1:1, Rf ∼ 0.65). Due to the low product amount no mass spectrometry was
performed.
Yield: 19 mg (23%).
1H NMR (300 MHz, CDCl3): δ ppm 1.01 - 1.14 (m, 9H, CH3) 2.49 - 2.74 (m, 4H, CH) 2.75
- 2.89 (m, 2H, CH2) 3.46 (t, J=6.12 Hz, 1H, CH) 4.84 (tt, J=6.71, 3.46 Hz, 1H, CH) 5.03 -
5.25 (m, 1H, CH) 6.65 (s, 2H, CHarom) 7.07 - 7.26 (m, 11H, CHarom) 7.44 (d, J=7.35 Hz, 6H,
CHarom) 8.12 (d, J=8.85 Hz, 2H, CHarom) 8.41 (d, J=8.85 Hz, 2H, CHarom).
tert-Butyl O-[trans-3-(methylsulfonyloxy)cyclobutyl]-N-trityl-L-tyrosine (64)
O
N
H
O
O
O
S
O O
To a solution of 57 (109 mg; 0.20 mmol) and DMAP (120 mg; 0.99 mmol) in DCM (5 ml)
at 0◦C was added Ms2O (122 mg; 0.69 mmol) and stirred under nitrogen for 6 hours at 0◦C.
After full conversion (TLC), the reaction mixture was evaporated in vacuo and purified by silica
chromatography, eluting with a gradient of EtOAc/hexane to give the desired product 64 as a
white solid after foaming at high-vacuum. TLC (EtOAc/hexane 1:1, Rf ∼ 0.51).
Yield: 89 mg (72%).
ESI-MS: m/e 628 (M+H)+.
1H NMR (400 MHz, CDCl3): δ ppm 1.07 (s, 9H, CH3) 2.58 (d, J=9.60 Hz, 1H, CH) 2.64 - 2.73
(m, 2H, CH2) 2.73 - 2.78 (m, 2H, CH2) 2.78 - 2.86 (m, 2H, CH2) 3.03 (s, 3H, CH3) 3.46 (m,
J=15.16 Hz, 1H, CH) 3.48 (d, J=15.20 Hz, 1H, CH) 4.90 (tt, J= 6.98, 3.63 Hz, 1H, CH) 5.25
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- 5.33 (m, 1H, CH) 6.70 (d, J=8.59 Hz, 2H, CHarom) 7.14 (dd, J=17.68, 7.83 Hz, 5H, CHarom)
7.19 - 7.26 (m, 6H, CHarom) 7.45 (d, J=7.58 Hz, 6H, CHarom).
13C NMR (151 MHz, CDCl3): δ ppm 27.9 (CH3) 38.0 (CH2) 38.2 (CH3) 41.2 (CH2) 58.0 (CH)
68.1 (CH) 71.2 (C) 72.9 (CH) 80.4 (C) 114.5 (CH) 126.3 (CH) 127.8 (CH) 128.8 (CH) 130.5
(C) 131.2 (CH) 146.3 (C) 155.7 (C) 173.6 (C).
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5.3 Radiosyntheses
5.3.1 Production of no-carrier-added (n.c.a.) [18F]fluoride
The no-carrier-added (n.c.a.) [18F]fluoride was produced routinely via bombardment of en-
riched [18O]water target with a proton beam using 18O(p,n)18F nuclear reaction and was re-
ceived from either the cyclotron of Helmholtz Zentrum Dresden-Rossendorf in Dresden (Ger-
many), Klinik und Poliklinik für Nuklearmedizin in Leipzig (Germany), Charité Berlin in Berlin
(Germany) or Eckert & Ziegler in Adlershof in Berlin (Germany). The n.c.a. [18F]fluoride
was separated from the 18O-enriched water by an anion exchange resin, typically a QMA
cartridge [35].
5.3.2 Preparation of the n.c.a. [18F]fluoride-cryptate complex
General procedure: The [18F]fluoride was eluted from a QMA cartridge (preconditioned with
5 ml 0.5 M K2CO3, washed with 10 ml water) with a mixture of Kryptofix R© 2.2.2 (5 mg; 13
µmol) and K2CO3 (1 mg; 15 µmol) in acetonitrile (0.95 ml) and water (0.05 ml) into a 5 ml
Wheaton glass V-vial (Wheaton Science Products, Millville, USA) equipped with a small mag-
netic stirring bar and a silicon septum seal lid. The solvents were evaporated and the residue
dried at 110◦C under a light nitrogen-stream, more anhydrous acetonitrile was added, and the
drying process was repeated. The resulting dry [18F]fluoride-cryptate complex was used in
the further nucleophilic 18F-labelling reaction.
Evaluation procedure: Only in the evaluation of radiosynthesis conditions in addition to the
procedure above different bases for eluting the [18F]fluoride from the QMA cartridge were
used. The [18F]fluoride was eluted from a QMA cartridge (preconditioned with 5 ml 0.5 M
K2CO3, washed with 10 ml water) with a mixture of Kryptofix R© 2.2.2 (5 mg; 13 µmol) and
Cs2CO3 (2.3 mg; 7 µmol) in ACN (0.95 ml) + water (0.05 ml) or Kryptofix R© 2.2.2 (5 mg; 13
µmol) and 10ul of 40% tetrabutylammonium hydroxid-solution in 90ul water + 900ul ACN or
Kryptofix R© 2.2.2 (5 mg; 13 µmol) and 74.5 mg (22 µmol) of tetrabutylammonium methanesul-
fonate in 1 ml MeOH (0.2 M) into a 5 ml Wheaton glass V-vial equipped with a small magnetic
stirring bar and a silicon septum seal lid. The solvents were evaporated and the residue dried
at 110◦C under a light nitrogen-stream, more anhydrous acetonitrile was added, and the dry-
ing process was repeated. The resulting dry [18F]fluoride-cryptate complex was used in the
further nucleophilic 18F-labelling reaction.
5.3.3 Radiosynthesis of n.c.a. O-(cis-3-[18F]fluorocyclobutyl)-L-tyrosine ([18F]4) via
indirect radiolabeling
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5.3.3.1 Preparation of trans-3-[18F]fluorocyclobutyl 4-methylbenzenesulfonate
([18F]34)
18F O
S
O
O
The precursor cis-cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) 20 (5 mg; 13 µmol) in
anhydrous ACN (0.5 ml) was added to the reaction vial containing the dry [18F]fluoride-cryptate
complex (1251 MBq) and the reaction was stirred at 130◦C for 15 minutes in a sealed vial.
The crude product was purified by passing through a Waters C18 light cartridge (equilibrated
with 5 ml EtOH followed by 5 ml water and air), washing with water (5 ml) and eluted with
ACN (0.8 ml) and the solvent was evaporated at 110◦C with a nitrogen stream. The reaction
mixture and isolated product were analyzed by radio-TLC and radio-HPLC. The radiochemical
yield was 56% (decay corrected) and the radiochemical purity was greater than 99%.
5.3.3.2 Alkylation of [18F]34 with L-tyrosine disodium salt (method I)
O
CO2HH2N
18F
A solution of trans-3-[18F]fluorocyclobutyl 4-methylbenzenesulfonate [18F]34 in DMSO (1 ml)
was added to L-tyrosine disodium salt (7 mg; 31 µmol) [113]. The reaction mixture was stirred
at 150◦C for 15 minutes and quenched by the addition of water (4 ml). The product was
purified by semi-preparative HPLC (ACE 5µm C18, 250x10 mm; isocratic ACN/water 45:55,
flow: 4 ml/min). The product peak was collected, diluted with water acidified by addition of 1 M
HCl to pH 2 (25 ml) and and trapped on a Waters C18 Environmental cartridge (preconditioned
with 10 ml EtOH, 10 ml with 1 M HCl acidified water (pH 2) and cartridge was dried by passing
20 ml air through). The cartridge was washed with water acidified with 1 M HCl to pH 2 and the
product was eluted with EtOH (1 ml). The resulting product was analyzed by radio-HPLC and
confirmed by co-injection. Starting from 652 MBq [18F]fluoride, 5 MBq (6%, decay corrected)
of the desired product [18F]4 was obtained within 151 minutes. The product was analyzed by
radio-HPLC and radio-TLC.
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5.3.3.3 Alkylation of [18F]34 with L-tyrosine (method II)
O
CO2HH2N
18F
The trans-3-[18F]fluorocyclobutyl 4-methylbenzenesulfonate [18F]34 was diluted with DMSO (1
ml) and added to L-tyrosine (~5 mg; 28 µmol) and aqueous 10% NaOH (2 eq., 22.1 µl). The
reaction was heated at 150◦C for 10 minutes and quenched by addition of water acidified with
1 M HCl to pH 2 (4 ml). The crude product was purified by HPLC (Synergi Hydro RP 4µ 250
x 10mm; 15% acetonitrile in water acidified with 1 M HCl to pH2; flow 3 ml/min). The product
peak was collected, diluted with water acidified with 1 M HCl to pH 2 (25 ml) and trapped on
a Waters C18 Environmental cartridge (preconditioned with 10 ml EtOH, 10 ml acidified water
and the cartridge dried by passing 20 ml air through). The cartridge was washed with water
acidified with 1 M HCl to pH 2 (5 ml) and the product was eluted with fractions (0.5ml) of 1:1
mixture of EtOH and PBS (total volume: 1.5 ml). Starting from 881 MBq [18F]fluoride, 44 MBq
(12%, decay corrected) of the desired product [18F]4 was obtained within 144 minutes. The
product was analyzed by radio-HPLC and radio-TLC.
5.3.3.4 Alkylation of [18F]34 with D-tyrosine (method II)
O
CO2HH2N
18F
The dry trans-3-[18F]fluorocyclobutyl 4-methylbenzenesulfonate [18F]34 was diluted with DMSO
(1 ml) and added to D-tyrosine (~4.5 mg; 25 µmol) and aqueous 10% NaOH (2 eq., 19.9 µl).
The reaction was heated at 150◦C for 15 minutes and quenched by addition of water acidified
with HCl to pH 2 (4 ml). The crude product was purified by HPLC (Synergi Hydro RP 4µ 250
x 10mm; 15% acetonitrile in water acidified with 1 M HCl to pH 2; flow 3 ml/min). The product
peak was collected, diluted with water acidified with 1 M HCl to pH 2 (25 ml) and trapped on
a Waters C18 Environmental cartridge (preconditioned with 10 ml EtOH, 10 ml acidified water
and the cartridge dried by passing 20 ml air through). The cartridge was washed with water
acidified with 1 M HCl to pH 2 (5 ml) and the product was eluted with EtOH (2 ml). The ethanol
volume was reduced to 0.2 ml by evaporation at 120◦C with a nitrogen stream. Starting from
901 MBq [18F]fluoride, 67 MBq (16%, decay corrected) of the desired product [18F]47 was
obtained within 104 minutes. The product was analyzed by radio-HPLC and radio-TLC.
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5.3.3.5 Evaluation of the leaving groups effect on 18F-incorporation and the alkylation
reaction of cis-3-[18F]fluorocyclobutyl sulfonates to L-tyrosine
18F O
[18F]34  R = 4-methylphenyl
[18F]65  R = methyl
[18F]66  R = 4-nitrophenyl
[18F]67  R = 3,4-dibromophenyl
S
O
O
R
General method for fluorination: The precursors 20, 21, 22 and 33 (amount see below)
were dissolved in the solvent stated below (0.5 ml) and was added to a vial containing dried
[18F]fluoride-cryptate complex (approx. 270 MBq).
Precursor [mg] [µmol] Solvent
20 3.9 10 ACN
21 3.6 12 ACN
22 4.3 9 DMSO
33 3.8 8 ACN
The reaction was carried out at 130◦ for 15 minutes in a sealed vial, then cooled to room
temperature. The crude product quenched by addition of water (3 ml) and purified by passing
through a Waters C18 light cartridge (equilibrated with 5 ml EtOH followed by 5 ml water),
washing with water (3 ml) and eluted with ACN (0.8 ml) into a vial containing tyrosine (5 mg;
29 µmol) in DMSO (0.5 ml) and aqueous 10% NaOH (2 eq., 22.µl). The mixture was heated
in with a needle equipped vial for ACN evaporation at 150◦C for 15 minutes and analyzed by
radio-HPLC to determine the conversion of product [18F]4.
5.3.3.6 Preparation of cis-3-[18F]fluorocyclobutyl tosylate ([18F]68) with alkylation to
L-tyrosine
18F O
S
O
O
O
CO2HH2N
18F
The cis-3-[18F]fluorocyclobutyl 4-methylbenzenesulfonate [18F]68 was prepared analogue de-
scribed in Section 5.3.3.1. The alkylation reaction was performed similar to the alkylation
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reaction described below. In the synthesis of cis-3-[18F]fluorocyclobutyl 4-methylbenzene-
sulfonate [18F]68, the precursor trans-cyclobutane-1,3-diyl bis(4-methylbenzenesulfonate) 29
(3.5 mg; 9 µmol) was dissolved in anhydrous ACN (0.5 ml) and was added to a vial containing
dry n.c.a. [18F]fluoride-cryptate complex (450 MBq). The reaction was carried out at 130◦C
for 10 minutes in a sealed vial. To the reaction mixture was added water (3 ml) and then
trapped on a Waters C18 light cartridge (equilibrated with 5 ml EtOH followed by 5 ml water,
air), washed with water (5 ml) and eluted with ACN (0.8 ml) into a vial containing tyrosine (5
mg; 29 µmol) in DMSO (0.5 ml) and aqueous 10% NaOH (2 eq., 22.µl). The mixture was
heated in a vial with a vent needle equipped for ACN evaporation at 150◦C for 15 minutes and
analyzed by radio-HPLC to determine the conversion of product [18F]69.
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5.3.4 Radiosynthesis of n.c.a. O-(cis-3-[18F]fluorocyclobutyl)-L-tyrosine ([18F]4) via
direct radiolabeling
5.3.4.1 Evaluation of methyl
N-(tert-butoxycarbonyl)-O-[trans-3-(4-methylbenzenesulfonyloxy)cyclo-
butyl]-L-tyrosine (48)
O
N
H
O
O
O
O
O
H2N
18F
O
OH
OTs
The precursor methyl N-(tert-butyloxacarbonyl)-O-[trans-3(4-methylbenzenesulfonyloxy)cyclobutyl]-
L-tyrosine 48 (3 mg; 6 µmol) in anhydrous ACN (0.5 ml) was added to reactor containing the
dry [18F]fluoride-cryptate complex (600 MBq) and the reaction was stirred at 105◦C for 20
minutes. The product was analyzed by radio-HPLC. The intermediate was not further investi-
gated.
5.3.4.2 Evaluation of tert-butyloxy
N-(tert-butoxycarbonyl)-O-[trans-3-(4-methylbenzenesulfonyloxy)cyclo-
butyl]-L-tyrosine (54)
O
N
H
O
O
O
O
O
H2N
18F
O
OH
OTs
The ’by-hand’ optimized synthesis was performed in the automated synthesizer GE Tracer-
lab FX F-N (GE Healthcare, US). The precursor textittert-butyloxy N-(tert-butoxycarbonyl)-O-
[trans-3-(4-methylbenzenesulfonyloxy)cyclobutyl]-L-tyrosine 54 (5 mg; 9 µmol) in anhydrous
ACN (0.5 ml) was added to reactor containing the dry [18F]fluoride-cryptate complex (3400
MBq) and the reaction was stirred at 130◦C for 15 minutes. To the reaction mixture 1 M HCl
(1 ml) was added and heated at 100◦C for 10 minutes. To the reaction mixture water acidified
with HCl to pH 2 was added and purified by HPLC (Synergi Hydro RP 4µ 250 x 10mm; 28%
acetonitrile in acidified water (pH2); flow 3 ml/min). The product peak was collected (retention
time ~7.3 mins), diluted with acidified water (35 ml, pH 2) and trapped on a Waters C18 Envi-
ronmental cartridge (preconditioned with 10 ml EtOH, 10 ml acidified water and air dried). The
cartridge was washed with acidified water (5 ml, pH 2) and the product was eluted with EtOH
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(2 ml). Starting from 15 GBq [18F]fluoride, 3.4 GBq (37%, decay corrected) of the desired
product [18F]4 was obtained within 66 minutes. The product was analyzed by radio-HPLC.
5.3.4.3 Evaluation of the direct labeling precursor tertbutyl
O-[trans-3-(4-methylbenzenesulfonyloxy)cyclobutyl]-N-trityl-L-tyrosine (61)
O
N
H
O
O
OTs
O
H2N
18F
O
OH
The synthesis was performed ’by-hand’. The precursor 61 (4 mg; 6 µmol) in anhydrous ACN
(0.5 ml) was added to reactor containing the dry [18F]fluoride-cryptate complex (750 MBq) and
the reaction was stirred at 130◦C for 25 minutes. To the reaction mixture 1 M HCl (1 ml) was
added and heated at 100◦C for 10 minutes and cooled to 50◦C before water acidified with HCl
to pH 2 (3.5 ml) was added. The crude product was purified by HPLC (Synergi Hydro RP 4µ
250 x 10mm; 28% acetonitrile in water acidified with 1 M HCl to pH 2; flow 3 ml/min). The
product peak was collected (retention time ~22 mins), diluted with water acidified with 1 M HCl
to pH 2 (10 ml) and trapped on a Waters C18 Environmental cartridge (preconditioned with
10 ml EtOH, 10 ml acidified water and cartridge was dried by passing 20 ml air through). The
cartridge was washed with water acidified with 1 M HCl to pH 2 (5 ml) and the product was
eluted with EtOH/water 1:1 (2 ml) to give the desired product [18F]4 in a radiochemical yield
of 14% (decay corrected). The product was analyzed by radio-HPLC.
5.3.4.4 Preparation of L-[18F]FCBT using trityl-precursor (64) in an automated
synthesizer
O
H2N
18F
O
OH
O
N
H
O
O
OMs
The automated synthesis was performed on the Modular Lab module (Eckert/Ziegler, Ger-
many). The precursor 64 (~3 mg; 5 µmol) in anhydrous ACN (0.8 ml) was added to reactor
containing the dry [18F]fluoride-cryptate complex (21.7 GBq) and the reaction was stirred at
120◦C for 15 minutes. To the reaction mixture 1 M HCl (1 ml) was added and heated at 100◦C
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for 10 minutes. The reaction mixture was diluted with water acidified by HCl to pH 2 (3.5 ml)
and purified by HPLC (Synergi Hydro RP 4µ 250 x 10mm; 20% acetonitrile in acidified water
(pH2); flow 4 ml/min). The product peak was collected (retention time ~25 mins), diluted with
acidified water (30 ml, pH 2) and trapped on a Waters C18 Environmental cartridge (precon-
ditioned with 10 ml EtOH, 10 ml acidified water and air dried). The cartridge was washed with
acidified water (5 ml, pH 2) and the product was eluted with a mixture of EtOH/PBS 1:1 (2 ml).
Starting from 21.7 GBq [18F]fluoride, 2.9 GBq (36%, decay corrected) of the desired product
[18F]4 was obtained within 102 minutes. The product was analyzed by radio-HPLC.
5.3.5 Preparation of O-(3-[18F]fluoroethyl)-L-tyrosine ([18F]FET)
FET was synthesized via a two-step reaction. In the first step, 2-bromoethyl 4-nitrobenzene-
sulfonate (10 mg; 49 µmol) in o-dichlorobenzene (0.5 ml) was reacted with the dry [18F]fluoride-
cryptate complex (mentioned above) for 10 minutes at 120◦C in a sealed 5 ml Wheaton
glass V-vial followed by distillation of the product 1-bromo-2-[18F]fluoroethane at 120◦C for
about 20 minutes into a receiver vial containing DMSO (0.5 ml) [187]. The 2-bromoethyl 4-
nitrobenzenesulfonate was synthesized according to literature using 4-nitrobenzenesulfonyl
chloride in presence of 1,2,2,6,6-pentamethylpiperidine [188]. L-Tyrosine (5 mg; 28 µmol)
dissolved in anhydrous DMSO (0.2 ml) and 2 M NaOH (27.6 µl; 55 µmol) were added to the
receiver vial and heated at 120◦C for 15 minutes in a sealed vial. The reaction mixture was di-
luted with water (4 ml) and purified by semi-preparative HPLC (ACE 5 C18, 250 x 4.6mm; 15%
acetonitrile+0.1% TFA in water+0.1% TFA; flow 3 ml/min). The product peak (retention time
15 mins) was collected, diluted with water acidified with 1 M HCl to pH 2 (35 ml) and trapped
on a Waters C18 plus cartridge (equilibrated with 5 ml ethanol, 10 ml acidified water and the
cartridge dried by passing 20 ml air through). The cartridge was washed with water acidified
with 1 M HCl to pH 2 (5 ml) and the product was eluted with fractions (0.5ml) of 1:1 mixture of
ethanol and water acidified with 1 M HCl to pH 2. Starting from 2889 MBq [18F]fluoride, 136
MBq (12%, decay corrected) of the desired product was obtained in excellent radiochemical
purity (>99%) and within 160 minutes.
5.4 Physicochemical and biological characterization
5.4.1 Determination of the lipophilicity of the non-radioactive L-3FCBT
The experiment was carried out by Analytical Services of Bayer HealthCare. The log D assay
was performed manually in two single vials. L-3FCBT ( 0.1 mg) was dissolved in octanol
and 10 mM phosphate buffer pH 7.4 with the help of sonication (3 mins). The sample was
equilibrated by shaking for 4 min at a constant temperature (20◦C). Phases were separated
by centrifugation at 10 min (20◦C, 3000 rpm). The sample was analyzed by HPLC with UV
detector at 254 nm and quantified by area integration.
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5.4.2 In vitro cell uptake assay of L-3[18F]FCBT
The A549 and DU145 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and the NCI-DU460 were cultured in DMEM/F-
12 (1:1) supplemented with 10% FBS. The cells were seeded 1-2 days prior to the assay and
grown in until sub-confluency in 48 well plates. Prior to the assay, the cell culture medium
was removed and the cells were washed with 500 µl phosphate buffered saline (PBS) + 0.1%
Bovine serum albumin (BSA). After adding 250 µl of the L-3[18F]FCBT in 8% EtOH in PBS (0.2
MBq), the cells were incubated at 37◦C in a humidified atmosphere containing 5% CO2 for 10,
20, 30 and 60 minutes. For investigation of transporter characteristics and competitions, the
cells were coincubated with non-radioactive FET (1 mM) and non-radioactive L-3FCBT (1 mM)
for 30 minutes to monitor radioactivity uptake. To stop tracer uptake after the time point, the
incubation buffer was removed, the cells were washed with 500 µl PBS and lysed with 500 µl
1 M NaOH. Subsequently, the amount of radioactivity in the cell lysate was determined in the
Automated Gamma Counter (Perkin Elmer).
Aliquots of the applied tracer amount were measured in a gamma counter to determine the
total amount in counts per minute (cpm) together with the samples to correct for radioactiv-
ity decay. Cell numbers per well were determined after detaching cells by trypsinization in
3 wells prior to start of the assay and counted with the Automated Cell Counter (Invitrogen).
The mean of cells was calculated. To compare tracer uptake between different studies the cell
number was normalized to 100’000 cells. The assay was performed in triplicates.
5.4.3 Biodistribution in A549 tumor bearing mice
Biodistribution and excretion were performed in A549 lung tumor bearing nude NMRI nu/nu
mice (22-30 g, n= 3 per time point). Each mouse (conscious) was injected (i.v. tail vein)
with L-3[18F]FCBT (158 KBq) in 100 µl 7% EtOH in 0.9% NaCl. The animals were sacrified
under isoflurane anesthesia at the specified time points and blood samples, tumor and tis-
sues removed and were weighted. The radioactivity of blood, tumor and various tissues were
measured using the gamma counter.
5.4.4 PET/CT imaging of L-3[18F]FCBT
PET imaging studies were performed on a Siemens Inveon Preclinical PET/CT, which has an
imaging field of view of 12.5 cm. The A549 tumor bearing mice were injected i.v. (tail vein)
with 7-10 MBq of L-3[18F]FCBT in PBS. Data acquisition was performed under isoflurane
anesthesia (2.5%, 0.5 l/min oxygen) and began following the intravenous injection. Mice were
visually monitored for breathing and a heating pad was used to maintain body temperature
throughout the entire procedure. Images were acquired with ’Inveon Acquisition Workplace’
(IAW) and region of interest (ROI) analysis was performed using ’Inveon Research Workplace’
(IRW).
5 EXPERIMENTAL 151
5.4.5 Determination of in vitro metabolic stability in rat hepatocytes
Hepatocytes from Han Wistar rats were isolated via a 2-step perfusion method. After per-
fusion, the liver was carefully removed from the rat: the liver capsule was opened and the
hepatocytes were gently shaken out into a Petri dish with ice-cold Williams’ Medium E (WME).
The resulting cell suspension was filtered through sterile gaze in falcon tubes (50 ml) and cen-
trifuged at 50 x g for 3 minutes at room temperature. The cell pellet was resuspended in WME
(30 ml) and centrifuged through a Percoll R© gradient for 2 times at 100 x g. The hepatocytes
were washed again with WME and resuspended in medium containing 5% FCS. Cell viability
was determined by trypan blue exclusion.
For the metabolic stability assay liver cells were distributed in WME containing 5% FCS to
glass vials at a density of 0.5 x 106 vital cells/ml. The test compound was added to a fi-
nal concentration of 1 µM. During incubation, the hepatocyte suspensions were continuously
shaken and aliquots were taken at 2, 8, 16, 30, 45 and 60 minutes, to which equal volumes of
cold MeOH were immediately added. Samples were frozen at -20◦C over night, subsequently
centrifuged for 15 minutes at 3000 rpm and the supernatant was analyzed with an Agilent
1200 HPLC-system with LCMS/MS detection.
5.4.6 Determination of in vitro plasma stability
This investigation determines the stability of test L-3[18F]FCBT and [18F]FET in plasma of dif-
ferent species. The tracers were incubated in plasma of human and rats for different time
points (0, 30, 60, 90 and 120 mins) at a concentration of 22 MBq/ml. Samples were precip-
itated with MeOH and subsequently centrifuged for 15 minutes at 3000 rpm and the super-
natant was analyzed with an Agilent 1200 HPLC-system with a Raytest radio-detection with
the column Phenomenex Luna 5 µm C18 100 Å LC Column (250 x 4.6 mm) with a gradient
of 5-95% ACN in water in 10 minutes and a flow of 1 ml/min and by TLC using the solvent
Butanol/AcOH/H2O 12:3:5 for developing the TLC plate. The stability of the test compound
was quantified by comparison of the remaining amount at the different time points with the
amount of the 0 minute sample (control) and is expressed in % of initial concentration.
5.4.7 Determination of in vivo stability in mice
The extent of in vivo degradation of L-3[18F]FCBT were investigated at 5, 15 and 30 min postin-
jection (p.i.) and analyzed by radio-HPLC and radio-TLC on blood and urine samples. The
mice (9 mice, n = 3 per time point) were injected (i.v. tail vein) 37-51 MBq of L-3[18F]FCBT di-
luted in PBS. The animals were sacrified and blood and urine samples were taken, the plasma
proteins were precipitated with MeOH and immediately centrifuged at 3000 rpm. Determina-
tion of metabolites was carried out using the supernatant solution of blood and urine with the
HPLC conditions using Phenomenex Luna 5 µm C18 100 Å LC Column (250 x 4.6 mm) with
a gradient of 5-95% ACN in water in 10 minutes and a flow of 1 ml/min and by TLC using the
solvent Butanol/AcOH/H2O 12:3:5 for developing the TLC plate.
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A List of Abbreviation
5-HT 5-hydroxytryptamine
3[18F]FCBT 3-[18F]fluorocyclobutyl tyrosine
Ac acetyl
ACN acetonitrile
AcOH acetic acid
arom aromatic
BHC 2-amino-bicyclo-[2,2,1]heptane-2-carboxylic acid
Bn benzyl
Boc tert-butoxycarbonyl
bp boiling point
Bq Becquerel (1 Bq = 1 s−1)
BSA Bovine Serum Albumin
n-BuLi n-butyllithium
br broad
c.a. carrier-added
COLOC Correlation through Long-Range Coupling, NMR
cpm counts per minute
Cs2CO3 cesium carbonate
d doublet
DAD diode array detector
DAT dopamine transporter
DAST diethylaminosulfur trifluoride
DCM dichloromethane
DEAD diethyl azodicarboxylate
DIPEA N,N-diisopropylethylamine
DMAP 4-dimethylaminopyridine
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DMF dimethylformamide
DMSO dimethylsulfoxide
ETA endothelin type A receptor
e.q. equivalent
ESI electrospray ionization
Et2O diethyl ether
EtOAc ethyl acetate
EtOH ethanol
EWG electron-withdrawing group
FCBT Fluorocyclobutyl tyrosine
FBS Fetal Bovine Serum
FCS Fetal Calf Serum
HCl hydrochloric acid
HETCOR Heteronuclear Shift Correlation, also known as HETERO-
COSY, NMR
HPLC high performance liquid chromatography
HSD hydroxysteroid dehydrogenase
ID/g injected dose per gramm
i.v. intravenous
K2.2.2 Kryptofix R© 222
K2CO3 potassium carbonate
KHCO3 potassium bicarbonate
KMnO4 potassium permanganate
KOSiMe3 potassium trimethylsilanolate
LAT large amino acid transporter
LG leaving group
LiAlH4 lithium aluminum hydroxide
LiOH lithium hydroxide
m multiplet
MeOH methanol
MIP maximum intensity projection
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mM millimolar
Ms mesyl, methanesulfonyl
MS mass spectrometry
Ms2O methanesulfonic anhydride
n numbers of experiment of carbon atoms
NaBH4 sodium borohydride
nAChR nicotinic acetylcholine receptors
NaCl sodium chloride
NaOH sodium hydroxide
NaOMe sodium methylate
n.c.a. no-carrier-added
NK1 neurokinin 1
NMR nuclear magnetic resonance
NOE Nuclear Overhauser Effect
Ns nosyl, 4-nitrobenzenesulfonyl
NsCl 4-nitrobenzenesulfonyl chloride
p para
p.i. post injection
PBS phosphate buffered saline
Pd/C palladium on charcoal
Ph3P see TPP
PPTS pyridium p-tosylate
PTSA p-toluenesulfonic acid
R rest
Rf retention factor in thin layer chromatography
rpm rounds per minute
quin quintet
RT retention time
s singulet
SD standard deviation
172 A LIST OF ABBREVIATION
SPE solid phase extraction
t triplet
t1/2 half-life time
TBAF tetrabutylammoniumfluoride
TBAOH tetrabutylammonium hydroxide
TBAOMs tetrabutylammonium methanesulfonate
tBu tert-butyl
tBuOH tert-butanol
TEA triethylamine
Tf triflate, trifluoromethanesulfonyl
Tf2O trifluoromethanesulfonic anhydride
TFA trifluoroacetic acid
THF tetrahydrofuran
TLC thin layer chromatography
TPP triphenylphospine, Ph3P
Trt trityl, triphenylmethyl
TrtCl tritylchloride, triphenylmethylchloride
Ts tosyl, 4-methylbenzenesulfonyl
Ts2O p-toluenesulfonic anhydride
TsCl 4-methylbenzenesulfonyl chloride, p-toluenesulfonyl chloride
TSPO translocator protein, former benzodiazepine receptor (PBR)
UPLC ultra performance liquid chromatography
UV ultra violet
v volume (liquids)
WME Williams’ Medium E
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